


**CUMULATIVE
SUPPLEMENT 6
JUNE 2015**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs**

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Cumulative Supplement 6

June 2015

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

CUMULATIVE SUPPLEMENT 6
June 2015

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME <u>(FORMER ABBREVIATED NAME)</u>	NEW APPLICANT NAME <u>(NEW ABBREVIATED NAME)</u>
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically

equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic

Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2014</u>	<u>MAR 2015</u>	<u>JUN 2015</u>	<u>SEPT 2015</u>	<u>DEC 2015</u>
DRUG PRODUCTS LISTED	16150	16352	16543		
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)	2586 (15.6%)		
MULTISOURCE	13578 (84.1%)	13744 (84.1%)	13957 (84.4%)		
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)	13832 (83.6%)		
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)	125 (0.8%)		
EXCEPTIONS ¹	77 (0.5%)	75 (0.5%)	75 (0.5%)		
NEW MOLECULAR ENTITIES APPROVED	13	22	12		
NUMBER OF APPLICANTS	927	935	957		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.

CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN

SOLUTION;IV (INFUSION)
OFIRMEV

>D>	+	CADENCE PHARMS	1000MG/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Jun CAHN
>A>	+	MALLINCKRODT IP	1000MG/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Jun CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL
FIORICET

@	ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616	001	Nov 09, 1984	Feb CAHN
---	---------------------	-----------------	---------	-----	--------------	----------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
FIORICET W/ CODEINE

AB	+	ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Jan CAHN
----	---	---------------------	----------------------	---------	-----	--------------	----------

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		SUN PHARM INDS LTD	300MG;30MG	A085868	001		Apr CAHN
AA			300MG;60MG	A087083	001		Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	+	MIKART	325MG;2.5MG	A040846	001	Jun 09, 2010	Feb CTEC
	@	SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007	Apr CAHN
		NORCO					
AA		ACTAVIS LABS FL INC	325MG;2.5MG	A040148	004	Jul 07, 2014	Feb NEWA
AA			325MG;5MG	A040148	005	Jul 07, 2014	Feb NEWA

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL
DIAMOX

>D>	AB	+	DURAMED PHARMS BARR	500MG	N012945	001		Jun CAHN
>A>	AB	+	TEVA BRANDED PHARM	500MG	N012945	001		Jun CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS
ACETYLCYSTEINE

AP		AKORN INC	6GM/30ML (200MG/ML)	A203173	001	Mar 24, 2015	Mar NEWA
>A>	AP	MYLAN INSTITUTIONAL	6GM/30ML (200MG/ML)	A203624	001	Jun 19, 2015	Jun NEWA

ACITRETIN

CAPSULE;ORAL
ACITRETIN

AB		SIGMAPHARM LABS LLC	10MG	A204633	001	May 22, 2015	May NEWA
AB			17.5MG	A204633	002	May 22, 2015	May NEWA
AB			22.5MG	A204633	003	May 22, 2015	May NEWA
AB			25MG	A204633	004	May 22, 2015	May NEWA

ACLIDINIUM BROMIDE

POWDER, METERED;INHALATION
TUDORZA PRESSAIR

+	ASTRAZENECA PHARMS	0.375MG/INH	N202450	001	Jul 23, 2012	Apr CAHN
---	--------------------	-------------	---------	-----	--------------	----------

ACYCLOVIR

TABLET;ORAL
ACYCLOVIR

AB		SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Apr CAHN
AB			800MG	A074980	002	Sep 30, 1998	Apr CAHN

ADENOSINE

INJECTABLE;INJECTION
ADENOSINE

>A>	AP		EUROHLTH INTL SARL	3MG/ML	A076500	001	Jun 16, 2004	Jun CAHN
>D>	AP		HIKMA MAPLE	3MG/ML	A076500	001	Jun 16, 2004	Jun CAHN
	AP		MYLAN PHARMS INC	3MG/ML	A078686	001	May 13, 2009	Apr CAHN
		@	WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009	May DISC

ALBENDAZOLE

>A>	TABLET, CHEWABLE;ORAL							
>A>	ALBENZA							
>A>	+ AMEDRA PHARMS LLC	200MG	N207844	001	Jun 11, 2015	Jun	NEWA	

ALBUTEROL SULFATE

	POWDER, METERED;INHALATION							
	PROAIR RESPICLICK							
	+ TEVA BRANDED PHARM	EQ 0.090MG BASE/INH	N205636	001	Mar 31, 2015	Mar	NEWA	
	SYRUP;ORAL							
	ALBUTEROL SULFATE							
AA	G AND W LABS INC	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Apr	CAHN	

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

	AEROSOL, METERED;INHALATION							
	COMBIVENT							
	@ BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996	May	DISC	

ALFUZOSIN HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL							
	ALFUZOSIN HYDROCHLORIDE							
	@ WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Feb	DISC	
	UROXATRAL							
>A> AB	+ CONCORDIA PHARMS INC	10MG	N021287	001	Jun 12, 2003	Jun	CAHN	
>D> AB	+ COVIS PHARMA SARL	10MG	N021287	001	Jun 12, 2003	Jun	CAHN	

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

	TABLET;ORAL							
	TEKAMLO							
	@ NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010	May	DISC	
	@	EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010	May	DISC	
	@	EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010	May	DISC	
	@	EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010	May	DISC	

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

	TABLET;ORAL							
	AMTURNIDE							
	@ NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045	001	Dec 21, 2010	May	DISC	
	@	EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045	002	Dec 21, 2010	May	DISC	
	@	EQ 300MG BASE;EQ 5MG BASE;25MG	N200045	003	Dec 21, 2010	May	DISC	
	@	EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045	004	Dec 21, 2010	May	DISC	
	@	EQ 300MG BASE;EQ 10MG BASE;25MG	N200045	005	Dec 21, 2010	May	DISC	

ALMOTRIPTAN MALATE

	TABLET;ORAL							
>A>	ALMOTRIPTAN MALATE							
>A> AB	TEVA PHARMS USA	EQ 6.25MG BASE	A078027	001	Jul 07, 2015	Jun	NEWA	
>A> AB		EQ 12.5MG BASE	A078027	002	Jul 07, 2015	Jun	NEWA	
	AXERT							
>D>	JANSSEN PHARMS	EQ 6.25MG BASE	N021001	001	May 07, 2001	Jun	CFTG	
>A> AB		EQ 6.25MG BASE	N021001	001	May 07, 2001	Jun	CFTG	
>D>	+	EQ 12.5MG BASE	N021001	002	May 07, 2001	Jun	CFTG	
>A> AB	+	EQ 12.5MG BASE	N021001	002	May 07, 2001	Jun	CFTG	

ALOSETRON HYDROCHLORIDE

	TABLET;ORAL							
	ALOSETRON HYDROCHLORIDE							
AB	ROXANE	EQ 0.5MG BASE	A200652	001	May 04, 2015	Apr	NEWA	
AB		EQ 1MG BASE	A200652	002	May 04, 2015	Apr	NEWA	
	LOTRONEX							
AB	PROMETHEUS LABS	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Apr	CFTG	
AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Apr	CFTG	

ALPRAZOLAM

	TABLET;ORAL							
	ALPRAZOLAM							
AB	NATCO PHARMA LTD	0.25MG	A200739	001	Apr 15, 2015	Mar	NEWA	
AB		0.5MG	A200739	002	Apr 15, 2015	Mar	NEWA	
AB		1MG	A200739	003	Apr 15, 2015	Mar	NEWA	
AB		2MG	A200739	004	Apr 15, 2015	Mar	NEWA	

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL					
AMANTADINE HYDROCHLORIDE					
AB	BANNER LIFE SCIENCES	100MG	A078720	001	May 29, 2008 Jan CAHN
SYRUP;ORAL					
AMANTADINE HYDROCHLORIDE					
	@ G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990 May CAHN

AMIKACIN SULFATE

INJECTABLE;INJECTION					
AMIKACIN SULFATE					
	@ IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995 Mar CAHN
	@	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995 Mar CAHN

AMINO ACIDS

INJECTABLE;INJECTION					
BRANCHAMIN 4% IN PLASTIC CONTAINER					
	@ BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984 Feb DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION					
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER					
	@ BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177	001	Oct 23, 1995 Feb DISC

AMINOCAPROIC ACID

SYRUP;ORAL					
AMINOCAPROIC ACID					
AA	VERSAPHARM INC	1.25GM/5ML	A074759	001	Sep 02, 1998 May CAHN
TABLET;ORAL					
AMINOCAPROIC					
AB	VERSAPHARM INC	500MG	A075602	001	May 24, 2001 May CAHN

AMLODIPINE BESYLATE

TABLET;ORAL					
AMLODIPINE BESYLATE					
AB	CHINA RESOURCES	EQ 5MG BASE	A090752	001	Apr 15, 2011 Mar CAHN
AB		EQ 10MG BASE	A090752	002	Apr 15, 2011 Mar CAHN
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007 Apr CAHN
AB		EQ 5MG BASE	A077974	002	Jul 09, 2007 Apr CAHN
AB		EQ 10MG BASE	A077974	003	Jul 09, 2007 Apr CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL					
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE					
AB	LUPIN LTD	5MG;12.5MG;160MG	A200797	001	Jun 03, 2015 May NEWA
AB		5MG;25MG;160MG	A200797	002	Jun 03, 2015 May NEWA
AB		10MG;12.5MG;160MG	A200797	003	Jun 03, 2015 May NEWA
AB		10MG;25MG;160MG	A200797	004	Jun 03, 2015 May NEWA
AB		10MG;25MG;320MG	A200797	005	Jun 03, 2015 May NEWA
AB	PAR PHARM	5MG;12.5MG;160MG	A201087	001	Jun 01, 2015 May NEWA
AB		5MG;25MG;160MG	A201087	002	Jun 01, 2015 May NEWA
AB		10MG;12.5MG;160MG	A201087	003	Jun 01, 2015 May NEWA
AB		10MG;25MG;160MG	A201087	004	Jun 01, 2015 May NEWA
AB		10MG;25MG;320MG	A201087	005	Jun 01, 2015 May NEWA
AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012 May CAIN
AB		5MG;25MG;160MG	A200435	002	Sep 25, 2012 May CAIN
AB		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012 May CAIN
AB		10MG;25MG;160MG	A200435	003	Sep 25, 2012 May CAIN
AB		10MG;25MG;320MG	A200435	004	Sep 25, 2012 May CAIN
AB	TORRENT PHARMS LTD	5MG;12.5MG;160MG	A201593	001	Jun 04, 2015 May NEWA
AB		5MG;25MG;160MG	A201593	002	Jun 04, 2015 May NEWA
AB		10MG;12.5MG;160MG	A201593	003	Jun 04, 2015 May NEWA
AB		10MG;25MG;160MG	A201593	004	Jun 04, 2015 May NEWA
AB		10MG;25MG;320MG	A201593	005	Jun 04, 2015 May NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Jan NEWA
		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Jan NEWA
+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Jan NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;160MG	A202713	001	Apr 03, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202713	003	Apr 03, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202713	002	Apr 03, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202713	004	Apr 03, 2015	Mar NEWA
AB	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Mar NEWA
AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Mar NEWA
AB	MYLAN PHARMS INC	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Apr CAHN
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Apr CAHN
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Apr CAHN
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Apr CAHN
AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A202829	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202829	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202829	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A204352	001	May 01, 2015	Apr NEWA
>A>	CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015	Jun NEWA
AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Apr NEWA
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan NEWA
AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr NEWA

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Apr CAHN
AB		500MG	A065016	002	Apr 08, 1999	Apr CAHN

FOR SUSPENSION; ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD

@

200MG/5ML

400MG/5ML

A065113 001 Nov 29, 2002 Apr CAHN

A065113 002 Nov 29, 2002 Apr CAHN

TABLET; ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Apr CAHN
AB		875MG	A065059	002	Nov 24, 2000	Apr CAHN

TABLET, CHEWABLE; ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Apr CAHN
	@	200MG	A065060	001	Nov 29, 2000	Apr CAHN
AB		250MG	A065021	002	Dec 23, 1999	Apr CAHN
	@	400MG	A065060	002	Nov 29, 2000	Apr CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Apr CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Apr CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Apr CAHN

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	@ SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr CAHN
AB		875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Apr CAHN

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Apr CAHN
AB		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Apr CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	COREPHARMA	1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May NEWA

AMPHETAMINE SULFATE

TABLET; ORAL

EVEKEO

	ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Mar CTNA
+		10MG	A200166	002	Aug 09, 2012	Mar CTNA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION; ORAL

PROBAMPACIN

	@ G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		Apr CAHN
--	--------------------	---------------------------	---------	-----	--	----------

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

	@ KREMERS URBAN PHARMS	1MG	A091331	001	Jan 05, 2011	Mar CAHN
--	------------------------	-----	---------	-----	--------------	----------

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Apr CDFR
----	--------------------	------------------------	---------	-----	--------------	----------

INJECTABLE; IV (INFUSION)

ARGATROBAN

AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Mar NEWA
----	--------------------	------------------------	---------	-----	--------------	----------

ARIPIPRAZOLE

TABLET; ORAL

ABILIFY

AB	OTSUKA	2MG	N021436	006	Nov 15, 2002	Apr CFTG
AB	+	5MG	N021436	005	Nov 15, 2002	Apr CFTG
AB	+	10MG	N021436	001	Nov 15, 2002	Apr CFTG
AB		15MG	N021436	002	Nov 15, 2002	Apr CFTG
AB		20MG	N021436	003	Nov 15, 2002	Apr CFTG
AB		30MG	N021436	004	Nov 15, 2002	Apr CFTG

ARIPIPRAZOLE

AB	ALEMBIC PHARMS LTD	2MG	A202101	001	Apr 28, 2015	Apr NEWA
AB		5MG	A202101	002	Apr 28, 2015	Apr NEWA
AB		10MG	A202101	003	Apr 28, 2015	Apr NEWA
AB		15MG	A202101	004	Apr 28, 2015	Apr NEWA
AB		20MG	A202101	005	Apr 28, 2015	Apr NEWA
AB		30MG	A202101	006	Apr 28, 2015	Apr NEWA
AB	HETERO LABS LTD V	2MG	A205064	001	Apr 28, 2015	Apr NEWA
AB		5MG	A205064	002	Apr 28, 2015	Apr NEWA
AB		10MG	A205064	003	Apr 28, 2015	Apr NEWA
AB		15MG	A205064	004	Apr 28, 2015	Apr NEWA
AB		20MG	A205064	005	Apr 28, 2015	Apr NEWA
AB		30MG	A205064	006	Apr 28, 2015	Apr NEWA
AB	TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015	Apr NEWA
AB		5MG	A078607	002	Apr 28, 2015	Apr NEWA
AB		10MG	A078608	001	Apr 28, 2015	Apr NEWA

TABLET;ORAL
ARIPIPIRAZOLE

AB		15MG	A078708	001	Apr 28, 2015	Apr NEWA
AB		20MG	A078708	002	Apr 28, 2015	Apr NEWA
AB		30MG	A078708	003	Apr 28, 2015	Apr NEWA
AB	TORRENT PHARMS LTD	2MG	A201519	001	Apr 28, 2015	Apr NEWA
AB		10MG	A201519	003	Apr 28, 2015	Apr NEWA
AB		5MG	A201519	002	Apr 28, 2015	Apr NEWA
AB		15MG	A201519	004	Apr 28, 2015	Apr NEWA
AB		20MG	A201519	005	Apr 28, 2015	Apr NEWA
AB		30MG	A201519	006	Apr 28, 2015	Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
ABILIFY

AB	+ OTSUKA	10MG	N021729	002	Jun 07, 2006	Apr CFTG
AB		15MG	N021729	003	Jun 07, 2006	Apr CFTG
ARIPIPIRAZOLE						
AB	ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	Apr NEWA
AB		15MG	A202102	002	Apr 28, 2015	Apr NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION
M.V.I.-12 LYOPHILIZED

>D>	@ ASTRAZENECA	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jun CAHN
>A>	@ IGI LABS INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jun CAHN

ASENAPINE MALEATE

TABLET;SUBLINGUAL
SAPHRIS

>D>	FOREST LABS INC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jun CAHN
>D>	+	EQ 10MG BASE	N022117	002	Aug 13, 2009	Jun CAHN
>A>	FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jun CAHN
>A>	+	EQ 10MG BASE	N022117	002	Aug 13, 2009	Jun CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
FIORINAL

AA	+ ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Jan CAHN
TABLET;ORAL FIORINAL						
	@ ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
FIORINAL W/CODEINE

AB	+ ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Jan CAHN
----	-----------------------	----------------------	---------	-----	--------------	----------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL
NORGESIC

	@ MEDICIS	385MG;30MG;25MG	N013416	003	Oct 27, 1982	Mar DISC
NORGESIC FORTE						
	@ MEDICIS	770MG;60MG;50MG	N013416	004	Oct 27, 1982	Mar DISC
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE						
	SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996	Mar CTEC
+		770MG;60MG;50MG	A074654	002	Dec 31, 1996	Mar CTEC

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL
OXYCODONE AND ASPIRIN

AA	ACTAVIS LABS FL INC	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar CAHN
----	---------------------	----------------	---------	-----	--------------	----------

ATAZANAVIR SULFATE; COBICISTAT

TABLET; ORAL

EVOTAZ

+ BRISTOL MYERS SQUIBB EQ 300MG BASE;150MG

N206353 001 Jan 29, 2015 Jan NEWA

ATENOLOL

TABLET; ORAL

ATENOLOL

>D>	AB	DAVA PHARMS INC	25MG	A074099	001	Apr 28, 1992	Jun DISC
>A>		@	25MG	A074099	001	Apr 28, 1992	Jun DISC
		TENORMIN					
	AB	ALVOGEN IPCO SARL	25MG	N018240	004	Apr 09, 1990	Feb CAHN
	AB		50MG	N018240	001		Feb CAHN
	AB	+	100MG	N018240	002		Feb CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

TENORETIC 100

AB	+	ALVOGEN IPCO SARL	100MG;25MG	N018760	001	Jun 08, 1984	Feb CAHN
		TENORETIC 50					
AB		ALVOGEN IPCO SARL	50MG;25MG	N018760	002	Jun 08, 1984	Feb CAHN

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB		KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar CAHN
AB			EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar CAHN
AB			EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar CAHN
AB			EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar CAHN
AB		SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr CAHN
AB			EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr CAHN
AB			EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr CAHN
AB			EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

@ MERCK SHARP DOHME

@

@

@

EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May DISC
EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May DISC
EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May DISC
EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB		GLENMARK GENERICS	62.5MG;25MG	A091211	002	Apr 06, 2015	Mar NEWA
----	--	-------------------	-------------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP		AUROBINDO PHARMA LTD	10MG/ML	A206011	001	Apr 08, 2015	Mar NEWA
		ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP		AUROBINDO PHARMA LTD	10MG/ML	A206010	001	Apr 08, 2015	Mar NEWA

ATROPINE SULFATE

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

+ AKORN 1%

N206289 001 Jul 18, 2014 May CRLD

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+ SEBELA IRELAND LTD 0.025MG;1MG

N017744 002 Feb CAHN

MOTOFEN HALF-STRENGTH

@ SEBELA IRELAND LTD 0.025MG;0.5MG

N017744 001 Feb CAHN

AVIBACTAM SODIUM; CEFTAZIDIMEPOWDER; IV (INFUSION)
AVYCAZ

+ CEREXA INC EQ 0.5GM BASE; 2GM/VIAL N206494 001 Feb 25, 2015 Feb NEWA

AZITHROMYCINFOR SUSPENSION; ORAL
AZITHROMYCINAB LUPIN LTD EQ 100MG BASE/5ML A065488 001 May 15, 2015 May NEWA
AB EQ 200MG BASE/5ML A065488 002 May 15, 2015 May NEWAINJECTABLE; INJECTION
AZITHROMYCIN

>A> AP AUROBINDO PHARMA LTD EQ 500MG BASE/VIAL A203294 001 Jun 19, 2015 Jun NEWA

TABLET; ORAL

AB AZITHROMYCIN LUPIN LTD EQ 250MG BASE A065398 001 May 15, 2015 May NEWA
AB EQ 500MG BASE A065399 001 May 15, 2015 May NEWA
AB EQ 600MG BASE A065400 001 May 15, 2015 May NEWABENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB AMNEAL PHARMS LLC 5MG A076820 001 Feb 03, 2006 Jan CAHN
AB 10MG A076820 002 Feb 03, 2006 Jan CAHN
AB 20MG A076820 003 Feb 03, 2006 Jan CAHN
AB 40MG A076820 004 Feb 03, 2006 Jan CAHN
AB SUN PHARM INDS LTD 5MG A076344 001 Feb 11, 2004 Apr CAHN
AB 10MG A076344 002 Feb 11, 2004 Apr CAHN
AB 20MG A076344 003 Feb 11, 2004 Apr CAHN
AB 40MG A076344 004 Feb 11, 2004 Apr CAHNBENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB SUN PHARM INDS LTD 5MG; 6.25MG A077483 001 Sep 08, 2005 Apr CAHN
AB 10MG; 12.5MG A077483 002 Sep 08, 2005 Apr CAHN
AB 20MG; 12.5MG A077483 003 Sep 08, 2005 Apr CAHN
AB 20MG; 25MG A077483 004 Sep 08, 2005 Apr CAHNBENZONATATE

CAPSULE; ORAL

BENZONATATE

AA APOTEX INC 100MG A091310 001 Jan 16, 2015 Jan NEWA
AA 200MG A091310 002 Jan 16, 2015 Jan NEWA
AA BANNER LIFE SCIENCES 100MG A081297 001 Jan 29, 1993 Jan CAHN
AA 200MG A081297 002 Oct 30, 2007 Jan CAHNBENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

>D> + DOW PHARM 2.5%; EQ 1.2% BASE N050819 001 Oct 23, 2008 Jun CFTG

>A> AB + 2.5%; EQ 1.2% BASE N050819 001 Oct 23, 2008 Jun CFTG

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>A> AB ACTAVIS LABS UT INC 2.5%; EQ 1.2% BASE A205128 001 Jun 19, 2015 Jun NEWA

ONEXTON

+ DOW PHARM 3.75%; EQ 1.2% BASE N050819 002 Nov 24, 2014 Jan CRLD

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

>D> AA KVK TECH 50MG A090968 001 Jul 20, 2010 Jun CRLD

>A> AA + 50MG A090968 001 Jul 20, 2010 Jun CRLD

>D> DIDREX

>D> AA + PHARMACIA AND UPJOHN 50MG N012427 002 Jun DISC

>D> AA + 50MG N012427 002 Jun DISC

>A> @ 50MG N012427 002 Jun DISC

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA	NUVO PHARM INC	0.5MG	A204713	001	Apr 14, 2015	Mar	NEWA
AA		1MG	A204713	002	Apr 14, 2015	Mar	NEWA
AA		2MG	A204713	003	Apr 14, 2015	Mar	NEWA

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	G AND W LABS INC	EQ 0.05% BASE	A071467	001	Aug 10, 1987	Apr	CAHN
	@	EQ 0.05% BASE	A071882	001	Jun 06, 1988	Apr	CAHN

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETA-VAL

AB	G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Apr	CAHN
----	------------------	--------------	---------	-----	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Mar	CAHN
AA		10MG	A091256	002	May 04, 2010	Mar	CAHN
AA		25MG	A091256	003	May 04, 2010	Mar	CAHN
AA		50MG	A091256	004	May 04, 2010	Mar	CAHN
AA	LANNETT HOLDINGS INC	5MG	A040703	001	Mar 27, 2008	Feb	CMFD
AA		50MG	A040677	001	Mar 27, 2008	Feb	CMFD
	DUVOID						
AA	WELLSPRING PHARM	10MG	A086262	001		Jan	CMFD
AA		25MG	A086263	001		May	CMFD
AA		50MG	A085882	003		May	CMFD

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

>D>	@ BANNER LIFE SCIENCES	75MG	A203174	001	Aug 12, 2014	Jun	CMFD
>A>	AB	75MG	A203174	001	Aug 12, 2014	Jun	CMFD
	@	75MG	A203174	001	Aug 12, 2014	Jan	CAHN
	TARGETIN						
>D>	+ VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Jun	CTEC
>A>	AB	75MG	N021055	001	Dec 29, 1999	Jun	CTEC

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	APOTEX INC	50MG	A200274	001	May 21, 2015	May	NEWA
AB	STASON PHARMS	50MG	A091011	001	Jun 10, 2015	May	NEWA

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

AT	ALCON RES LTD	0.03%	A202565	001	May 05, 2015	Apr	NEWA
AT	+ LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Apr	CTEC
	+	0.03%	A203991	001	Feb 20, 2015	Mar	CTEC
AT	+	0.03%	A203991	001	Feb 20, 2015	Feb	NEWA

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

ANGIOMAX

>D>	+ MEDICINES CO	250MG/VIAL	N020873	001	Dec 15, 2000	Jun	CFTG
>A>	AP	250MG/VIAL	N020873	001	Dec 15, 2000	Jun	CFTG

BIVALIRUDIN

>A>	AP	HOSPIRA INC	250MG/VIAL	A090811	001	Jul 14, 2015	Jun	NEWA
>A>	AP		250MG/VIAL	A090816	001	Jul 14, 2015	Jun	NEWA

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

>D>	WYETH PHARMS INC	EQ 100MG BASE	N203341	001	Sep 04, 2012	Jun	CRLD
>A>	+	EQ 100MG BASE	N203341	001	Sep 04, 2012	Jun	CRLD
>D>	+	EQ 500MG BASE	N203341	002	Sep 04, 2012	Jun	CRLD

TABLET; ORAL							
BOSULIF							
>A>		EQ 500MG BASE	N203341	002	Sep 04, 2012	Jun	CRLD
<u>BROMFENAC SODIUM</u>							
SOLUTION/DROPS; OPHTHALMIC							
BROMDAY							
AT2	+ BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	May	CTEC
BROMFENAC SODIUM							
AT2	APOTEX INC	EQ 0.09% ACID	A202620	001	Jun 23, 2014	May	CTEC
AT1	+ COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	May	CRLD
AT2	HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May	CTEC
AT1	PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jan	NEWA
<u>BUDESONIDE</u>							
AEROSOL, FOAM; RECTAL							
UCERIS							
	+ VALEANT PHARMS INTL	2MG/ACTUATION	N205613	001	Oct 07, 2014	Apr	CAHN
SPRAY, METERED; NASAL							
BUDESONIDE							
	APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Mar	CTEC
<u>BUMETANIDE</u>							
INJECTABLE; INJECTION							
BUMETANIDE							
>A> AP	EUROHLTH INTL SARL	0.25MG/ML	A079196	001	Apr 30, 2008	Jun	CAHN
>D> AP	HIKMA MAPLE	0.25MG/ML	A079196	001	Apr 30, 2008	Jun	CAHN
<u>BUPRENORPHINE HYDROCHLORIDE</u>							
TABLET; SUBLINGUAL							
BUPRENORPHINE HYDROCHLORIDE							
AB	ACTAVIS ELIZABETH	EQ 2MG BASE	A090819	001	Feb 19, 2015	Feb	NEWA
AB		EQ 8MG BASE	A090819	002	Feb 19, 2015	Feb	NEWA
AB	MYLAN PHARMS INC	EQ 2MG BASE	A201066	001	Mar 06, 2015	Feb	NEWA
AB		EQ 8MG BASE	A201066	002	Mar 06, 2015	Feb	NEWA
AB	SANDOZ INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	May	NEWA
AB		EQ 8MG BASE	A090279	002	Jun 10, 2015	May	NEWA
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE</u>							
TABLET; SUBLINGUAL							
ZUBSOLV							
>A>	OREXO AB	EQ 2.9MG BASE; EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jun	NEWA
<u>BUPROPION HYDROBROMIDE</u>							
TABLET, EXTENDED RELEASE; ORAL							
APLENZIN							
	VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008	Feb	CAHN
		348MG	N022108	002	Apr 23, 2008	Feb	CAHN
	+	522MG	N022108	003	Apr 23, 2008	Feb	CAHN
<u>BUPROPION HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE; ORAL							
BUPROPION HYDROCHLORIDE							
AB1	PRINSTON INC	100MG	A202304	001	May 26, 2015	May	NEWA
AB1		150MG	A202304	002	May 26, 2015	May	NEWA
AB1		200MG	A202304	003	May 26, 2015	May	NEWA
AB2	SANDOZ INC	150MG	A077475	001	Mar 12, 2008	Mar	CAHN
	@ WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012	May	DISC
	@	150MG	A201331	002	Aug 30, 2012	May	DISC
	@	200MG	A201331	003	Aug 30, 2012	May	DISC
<u>BUTABARBITAL SODIUM</u>							
TABLET; ORAL							
BUTISOL SODIUM							
	@ MEDA PHARMS	50MG	N000793	003		May	DISC

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

	@ ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997	May CTNA
>D>	+ PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Jun CTNA
>A>	GYNAZOLE-1					
>A>	+ PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Jun CTNA

CALCIPOTRIENE

CREAM;TOPICAL

CALCIPOTRIENE

AB	GLENMARK PHARMS LTD	0.005%	A205772	001	Jun 09, 2015	May NEWA
----	---------------------	--------	---------	-----	--------------	----------

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCITONIN-SALMON

	@ IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995	Mar CAHN
--	----------------	-----------	---------	-----	--------------	----------

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB	BANNER LIFE SCIENCES	0.25MCG	A091174	001	May 24, 2013	Jan CAHN
AB		0.5MCG	A091174	002	May 24, 2013	Jan CAHN
AB	STRIDES PHARMA	0.25MCG	A091356	001	Dec 12, 2014	Jan CAHN
AB		0.5MCG	A091356	002	Dec 12, 2014	Jan CAHN

INJECTABLE;INJECTION

CALCIJEX

>D>	AP	+ ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	Jun DISC
>A>		@	0.001MG/ML	N018874	001	Sep 25, 1986	Jun DISC
>D>	AP	+	0.002MG/ML	N018874	002	Sep 25, 1986	Jun DISC
>A>		@	0.002MG/ML	N018874	002	Sep 25, 1986	Jun DISC

CALCITRIOL

>D>	AP	AKORN	0.002MG/ML	A078066	002	Jan 29, 2008	Jun DISC
>A>		@	0.002MG/ML	A078066	002	Jan 29, 2008	Jun DISC
>D>	AP	FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002	Jun DISC
>A>		@	0.001MG/ML	A075836	001	Dec 31, 2002	Jun DISC
>D>	AP		0.002MG/ML	A075836	002	Dec 31, 2002	Jun DISC
>A>		@	0.002MG/ML	A075836	002	Dec 31, 2002	Jun DISC
>D>	AP	FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003	Jun DISC
>A>		@	0.001MG/ML	A075766	001	Feb 20, 2003	Jun DISC
>D>	AP		0.002MG/ML	A075766	002	Feb 20, 2003	Jun DISC
>A>		@	0.002MG/ML	A075766	002	Feb 20, 2003	Jun DISC
>D>	AP	LUITPOLD	0.001MG/ML	A075746	001	Sep 26, 2003	Jun DISC
>A>		@	0.001MG/ML	A075746	001	Sep 26, 2003	Jun DISC
>D>	AP		0.002MG/ML	A075746	002	Sep 26, 2003	Jun DISC
>A>		@	0.002MG/ML	A075746	002	Sep 26, 2003	Jun DISC
>D>	AP	SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006	Jun DISC
>A>		@	0.001MG/ML	A077102	001	Feb 08, 2006	Jun DISC

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

>A>	AB	LUPIN LTD	EQ 169MG CALCIUM	A202127	001	Jul 09, 2015	Jun NEWA
>A>	AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Jun NEWA

TABLET;ORAL

CALCIUM ACETATE

AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Jan NEWA
----	----------------------	------------------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jan CPOT
---	--------------------	-------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Jan CPOT
---	--------------------	----------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Jan CPOT
---	--------------------	-------------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan CPOT
---	--------------------	----------------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Jan CPOT
---	--------------------	------------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan CPOT
---	--------------------	-------------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan CPOT
---	--------------------	----------------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan CPOT
---	--------------------	-------------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan CPOT
---	--------------------	-------------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan CPOT
---	--------------------	----------------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan CPOT
---	--------------------	----------------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan CPOT
---	--------------------	--------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan CPOT
---	--------------------	--------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan CPOT
---	--------------------	-----------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan CPOT
---	--------------------	---------------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	N/A/1000ML; N/A/1000ML; N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Jan NEWA
---	---------------	--------------------------------------------------------------------------------------------------------------------------	---------	-----	--------------	----------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	3.68GM/1000ML; N/A/1000ML; N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML	N207026	001	Jan 13, 2015	Jan NEWA
---	---------------	----------------------------------------------------------------------	---------	-----	--------------	----------

INJECTABLE;INJECTION

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

GM/1000ML

;3.09GM/1000ML;6.34GM/1000ML;0.187

>D> CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

>D> SOLUTION;IRRIGATION

>D> NAVSTEL

>D> + ALCON PHARMS LTD 0.154MG/ML;0.92MG/ML;0.2MG/ML;0.18 4MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/M N022193 001 Jul 24, 2008 Jun DISC

>A> @ 0.154MG/ML;0.92MG/ML;0.2MG/ML;0.18 4MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/M N022193 001 Jul 24, 2008 Jun DISC

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE

37MG/100ML;5GM/100ML;30MG/100ML;11 9MG/100ML;161MG/100ML;94MG/100ML;1 N017390 001

Mar DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

@ BAXTER HLTHCARE

36.8MG/100ML;30.5MG/100ML;74.6MG/1 00ML;640MG/100ML;496MG/100ML;89.6M N017438 001

Mar DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+ GAMBRO LUNDIA N/A/1000ML;3.05GM/1000ML;0.314GM/1 000ML;2.21GM/1000ML;6.95GM/1000ML; N207026 002 Jan 13, 2015 Feb CAIN

0.187GM/1000ML (5000ML)

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO LUNDIA 3.68GM/1000ML;3.05GM/1000ML;0.314G M/1000ML N207026 001 Jan 13, 2015 Feb CAIN

;3.09GM/1000ML;6.34GM/1000ML;0.187

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	MACLEODS PHARMS LTD	16MG;12.5MG	A204100	001	Feb 27, 2015	Feb NEWA
AB		32MG;12.5MG	A204100	002	Feb 27, 2015	Feb NEWA
AB		32MG;25MG	A204100	003	Feb 27, 2015	Feb NEWA

>A> CANGRELOR

>A> POWDER;IV (INFUSION)

>A> KENGREAL

>A> + MEDICNES CO 50MG/VIAL N204958 001 Jun 22, 2015 Jun NEWA

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB	ACCORD HLTHCARE	150MG	A202593	001	Apr 23, 2015	Apr NEWA
AB		500MG	A202593	002	Apr 23, 2015	Apr NEWA

CAPTOPRIL

TABLET;ORAL

CAPOTEN

@ PAR PHARM

12.5MG

N018343 005 Jan 17, 1985 May DISC

@

25MG

N018343 002 May DISC

@

50MG

N018343 001 May DISC

@

100MG

N018343 003 May DISC

CAPTOPRIL

@ G AND W LABS INC

12.5MG

A074462 001 Feb 13, 1996 Apr CAHN

@

12.5MG

A074590 004 Aug 30, 1996 Apr CAHN

@

25MG

A074462 002 Feb 13, 1996 Apr CAHN

@

25MG

A074590 002 Aug 30, 1996 Apr CAHN

@

50MG

A074462 003 Feb 13, 1996 Apr CAHN

TABLET;ORAL

CAPTOPRIL

	@	50MG	A074590	001	Aug 30, 1996	Apr CAHN
	@	100MG	A074462	004	Feb 13, 1996	Apr CAHN
	@	100MG	A074590	003	Aug 30, 1996	Apr CAHN
AB	+	MYLAN 100MG	A074434	004	Feb 13, 1996	May CRLD

CAPTROPIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB	G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Apr CAHN
AB		25MG;25MG	A074827	002	Dec 29, 1997	Apr CAHN
AB		50MG;15MG	A074827	004	Dec 29, 1997	Apr CAHN
AB		50MG;25MG	A074827	003	Dec 29, 1997	Apr CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB	MYLAN PHARMS INC	100MG	A076697	001	May 20, 2011	May CAHN
AB		200MG	A076697	002	May 20, 2011	May CAHN
AB		300MG	A076697	003	May 20, 2011	May CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL

RYTARY

IMPAX LABS INC

		23.75MG;95MG	N203312	001	Jan 07, 2015	Jan NEWA
		36.25MG;145MG	N203312	002	Jan 07, 2015	Jan NEWA
		48.75MG;195MG	N203312	003	Jan 07, 2015	Jan NEWA
+		61.25MG;245MG	N203312	004	Jan 07, 2015	Jan NEWA

SUSPENSION;ENTERAL

DUOPA

+ ABBVIE INC

		4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015	Jan NEWA
--	--	-------------------	---------	-----	--------------	----------

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

AP	MYLAN PHARMS INC	50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011	May CAHN
AP		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	May CAHN
AP		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	May CAHN
AP		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	May CAHN
+		1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	May CAHN

CARISOPRODOL

TABLET;ORAL

CARISOPRODOL

>A>	AB	INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun NEWA
>A>	AA		350MG	A205126	002	Jul 08, 2015	Jun NEWA
		SOMA					
>D>	+	MEDA PHARMS	250MG	N011792	004	Sep 13, 2007	Jun CTEC
>A>	AB	+	250MG	N011792	004	Sep 13, 2007	Jun CTEC

CARVEDILOL

TABLET;ORAL

CARVEDILOL

>D>	AB	HIKMA	3.125MG	A077887	001	Sep 07, 2007	Jun DISC
>A>		@	3.125MG	A077887	001	Sep 07, 2007	Jun DISC
>D>	AB		6.25MG	A077887	002	Sep 07, 2007	Jun DISC
>A>		@	6.25MG	A077887	002	Sep 07, 2007	Jun DISC
>D>	AB		12.5MG	A077887	003	Sep 07, 2007	Jun DISC
>A>		@	12.5MG	A077887	003	Sep 07, 2007	Jun DISC
>D>	AB		25MG	A077887	004	Sep 07, 2007	Jun DISC
>A>		@	25MG	A077887	004	Sep 07, 2007	Jun DISC
AB	SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Apr CAHN	
AB		6.25MG	A076989	002	Sep 05, 2007	Apr CAHN	
AB		12.5MG	A076989	003	Sep 05, 2007	Apr CAHN	
AB		25MG	A076989	004	Sep 05, 2007	Apr CAHN	

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr CAHN
AB		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr CAHN
AB		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jan CAHN
AP		EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Jan CAHN
AP		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Jan CAHN
AP	+	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jan CAHN

CEFIXIME

FOR SUSPENSION; ORAL

CEFIXIME

AB	AUROBINDO PHARMA LTD	100MG/5ML	A204835	001	Apr 14, 2015	Apr NEWA
AB		200MG/5ML	A204835	002	Apr 14, 2015	Apr NEWA
	SUPRAX					
AB	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Apr CFTG
AB		200MG/5ML	A065355	001	Apr 10, 2007	Apr CFTG

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

@ IGI LABS INC

@

@

@

@

CEFOTAN IN PLASTIC CONTAINER

@ IGI LABS INC

@

EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	May CAHN
EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Mar CAHN
EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	May CAHN
EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Mar CAHN
EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Mar CAHN

EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar CAHN
EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr CAHN
AB		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr CAHN

TABLET; ORAL

CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr CAHN
AB		EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

>A>	AP	+	CONCORDIA PHARMS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Jun CAHN
>A>	AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Jun CAHN
>A>	AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Jun CAHN
>A>	AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Jun CAHN
>D>	AP	+	COVIS INJECTABLES	500MG/VIAL	N050578	001	Jul 19, 1985	Jun CAHN
>D>	AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Jun CAHN
>D>	AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Jun CAHN
>D>	AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Jun CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

>A>		@	CONCORDIA PHARMS INC	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Jun CAHN
>A>		+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Jun CAHN
>A>		+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Jun CAHN
>D>		@	COVIS INJECTABLES	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Jun CAHN
>D>		+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Jun CAHN
>D>		+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Jun CAHN

CEFTRIAXONE SODIUMINJECTABLE; INJECTION
CEFTRIAXONE

AP	FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan CAHN
	INJECTABLE; INTRAMUSCULAR, INTRAVENOUS					
	CEFTRIAXONE					
	@ FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Jan CAHN
	@	EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Jan CAHN

CEFUROXIME AXETILFOR SUSPENSION; ORAL
CEFUROXIME AXETIL

AB	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr CAHN
AB		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr CAHN
	TABLET; ORAL					
	CEFUROXIME AXETIL					
AB	SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr CAHN
AB		EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr CAHN
AB		EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr CAHN

CEFUROXIME SODIUMINJECTABLE; INJECTION
CEFUROXIME SODIUM

AP	FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan CAHN
AP		EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan CAHN
	ZINACEF					
>A> AP	+ CONCORDIA PHARMS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun CAHN
>A> AP	+	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun CAHN
>D> AP	+ COVIS INJECTABLES	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun CAHN
>D> AP	+	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun CAHN
	ZINACEF IN PLASTIC CONTAINER					
>A>	@ CONCORDIA PHARMS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun CAHN
>A>	+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jun CAHN
>D>	@ COVIS INJECTABLES	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun CAHN
>D>	+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jun CAHN
	INJECTABLE; INTRAMUSCULAR, INTRAVENOUS					
	CEFUROXIME SODIUM					
AB	FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan CAHN
	ZINACEF					
>A> AB	+ CONCORDIA PHARMS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun CAHN
>D> AB	+ COVIS INJECTABLES	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun CAHN

CELECOXIBCAPSULE; ORAL
CELECOXIB

AB	APOTEX INC	50MG	A204197	001	Jun 02, 2015	May NEWA
AB		100MG	A204197	002	Jun 02, 2015	May NEWA
AB		200MG	A204197	003	Jun 02, 2015	May NEWA
AB	LUPIN LTD	100MG	A202240	002	Jun 09, 2015	May NEWA
AB		200MG	A202240	003	Jun 09, 2015	May NEWA
AB		400MG	A202240	004	Jun 09, 2015	May NEWA
AB	MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan NEWA
AB		200MG	A078857	003	Feb 11, 2015	Jan NEWA
AB		400MG	A078857	004	Feb 11, 2015	Jan NEWA
AB	WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan NEWA
AB		100MG	A200562	002	Feb 11, 2015	Jan NEWA
AB		200MG	A200562	003	Feb 11, 2015	Jan NEWA
AB		400MG	A200562	004	Feb 11, 2015	Jan NEWA

CEPHALEXINCAPSULE; ORAL
CEPHALEXIN

AB	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr CAHN
AB		EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr CAHN
	FOR SUSPENSION; ORAL					
	CEPHALEXIN					
	@ SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr CAHN
	@	EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION
CHLOROTHIAZIDE SODIUM

AP SAGENT PHARMS EQ 500MG BASE/VIAL A202462 001 May 29, 2015 May NEWA

>A> CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

>A> TABLET, EXTENDED RELEASE; ORAL

>A> CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

>A> SPRIASO LLC 8MG; 54.3MG N206323 001 Jun 22, 2015 Jun NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA TRIS PHARMA INC 4MG/5ML; 5MG/5ML A206438 001 Jan 27, 2015 Jan NEWA

VITUZ

AA + CYPRESS PHARM 4MG/5ML; 5MG/5ML N204307 001 Feb 20, 2013 Jan CFTG

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

TUZISTRA XR

>D> + TRIS PHARMA INC EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML N207768 001 Apr 30, 2015 Jun CAHN

+ EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML N207768 001 Apr 30, 2015 Apr NEWA

>A> + VERNALIS R AND D LTD EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML N207768 001 Apr 30, 2015 Jun CAHN

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

>A> @ CYCLE PHARMS LTD 30MG/ML A088157 001 Apr 27, 1983 Jun CAHN

>A> @ 100MG/ML A088158 001 Apr 27, 1983 Jun CAHN

>D> @ ROXANE 30MG/ML A088157 001 Apr 27, 1983 Jun CAHN

>D> @ 100MG/ML A088158 001 Apr 27, 1983 Jun CAHN

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

+ EUROHLTH INTL SARL 25MG/ML A083329 001 Feb CAHN

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

>A> @ CYCLE PHARMS LTD 10MG A085331 001 Jun CAHN

>A> @ 25MG A085331 002 Jun CAHN

>A> @ 50MG A085331 003 Jun CAHN

>A> @ 100MG A085331 004 Jun CAHN

>A> @ 200MG A085331 005 Jun CAHN

>D> @ ROXANE 10MG A085331 001 Jun CAHN

>D> @ 25MG A085331 002 Jun CAHN

>D> @ 50MG A085331 003 Jun CAHN

>D> @ 100MG A085331 004 Jun CAHN

>D> @ 200MG A085331 005 Jun CAHN

@ SANDOZ 10MG A080439 001 May DISC

@ 25MG A080439 002 May DISC

@ 50MG A080439 003 May DISC

@ 100MG A080439 004 May DISC

@ 200MG A080439 005 May DISC

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB @ G AND W LABS INC 50MG A088651 001 May 30, 1985 Apr CAHN

MUTUAL PHARM 50MG A089286 001 Jul 21, 1986 Mar CMFD

>D> + MYLAN 50MG A086831 001 Jun CTEC

>A> AB + 50MG A086831 001 Jun CTEC

>D> THALITONE

>D> + CITRON PHARMA LLC 15MG N019574 001 Dec 20, 1988 Jun DISC

>A> @ 15MG N019574 001 Dec 20, 1988 Jun DISC

CHOLIC ACIDCAPSULE;ORAL
CHOLBAM

	ASKLEPION PHARMS LLC	50MG	N205750	001	Mar 17, 2015	Mar NEWA
+		250MG	N205750	002	Mar 17, 2015	Mar NEWA
	RTRX	50MG	N205750	001	Mar 17, 2015	Apr CAHN
+		250MG	N205750	002	Mar 17, 2015	Apr CAHN

CIDOFOVIRINJECTABLE;INJECTION
CIDOFOVIR

AP	+	MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May CRLD
		VISTIDE					
		@ GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May DISC

CIMETIDINE HYDROCHLORIDESOLUTION;ORAL
CIMETIDINE HYDROCHLORIDE

	@ G AND W LABS INC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994	Apr CAHN
--	--------------------	-------------------	---------	-----	--------------	----------

CIPROFLOXACININJECTABLE;INJECTION
CIPROFLOXACIN

AP		CLARIS PHARMASERVICE	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Apr CAHN
AP			400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Apr CAHN
		CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP		CLARIS PHARMASERVICE	200MG/100ML	A078024	001	Mar 18, 2008	Apr CAHN
AP			400MG/200ML	A078024	002	Mar 18, 2008	Apr CAHN

CIPROFLOXACIN HYDROCHLORIDETABLET;ORAL
CIPROFLOXACIN HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004	Apr CAHN
AB			EQ 500MG BASE	A075747	002	Jun 09, 2004	Apr CAHN
AB			EQ 750MG BASE	A075747	003	Jun 09, 2004	Apr CAHN

CISATRACURIUM BESYLATEINJECTABLE;INJECTION
CISATRACURIUM BESYLATE

AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A203183	001	Feb 26, 2015	Feb NEWA
		CISATRACURIUM BESYLATE PRESERVATIVE FREE					
AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A203182	001	Feb 26, 2015	Feb NEWA
AP			EQ 10MG BASE/ML	A203182	002	Feb 26, 2015	Feb NEWA

CITALOPRAM HYDROBROMIDETABLET;ORAL
CITALOPRAM HYDROBROMIDE

AB		G AND W LABS INC	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr CAHN
AB			EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr CAHN
AB			EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr CAHN

CLADRIBINEINJECTABLE;INJECTION
CLADRIBINE

AP		MYLAN PHARMS INC	1MG/ML	A200510	001	Oct 06, 2011	May CAHN
----	--	------------------	--------	---------	-----	--------------	----------

CLARITHROMYCINFOR SUSPENSION;ORAL
CLARITHROMYCIN

AB		SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007	Apr CAHN
AB			250MG/5ML	A065382	002	Aug 30, 2007	Apr CAHN

TABLET;ORAL

CLARITHROMYCIN

AB		SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004	Apr CAHN
AB			500MG	A065174	002	Sep 24, 2004	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL

BIAXIN XL

	@ ABBVIE	500MG	N050775	001	Mar 03, 2000	Jan DISC
--	----------	-------	---------	-----	--------------	----------

CLARITHROMYCIN

AB	+	TEVA	500MG	A065154	001	May 18, 2005	Jan CRLD
----	---	------	-------	---------	-----	--------------	----------

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUMINJECTABLE;INJECTION
TIMENTIN

@	GLAXOSMITHKLINE	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986	May DISC
@		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985	May DISC
@		EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985	May DISC
@		EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987	May DISC
	TIMENTIN IN PLASTIC CONTAINER					
@	GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989	May DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	G AND W LABS INC	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr CAHN
AB		EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr CAHN
AB	SUN PHARM INDS LTD	EQ 150MG BASE	A065061	001	Feb 02, 2001	Apr CAHN
AB		EQ 300MG BASE	A065061	002	Feb 02, 2001	Apr CAHN

CLINDAMYCIN PHOSPHATEINJECTABLE;INJECTION
CLINDAMYCIN PHOSPHATE

@	IGI LABS INC	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989	Mar CAHN
---	--------------	------------------	---------	-----	--------------	----------

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

@	BOCA PHARMA LLC	EQ 1% BASE	A062944	001	Jan 11, 1989	Jan CAHN
AT	VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	May NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

>A>	AB	ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564	001	Jun 12, 2015	Jun NEWA
		ZIANA					
>D>	BX	+ MEDICIS	1.2%;0.025%	N050802	001	Nov 07, 2006	Jun CTEC
>A>	AB	+	1.2%;0.025%	N050802	001	Nov 07, 2006	Jun CTEC

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

	AB2	+	FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	May	CRLD
			CORMAX						
>D>	AB1		HI TECH PHARMA	0.05%	A074220	001	May 16, 1997	Jun	CRLD
>A>	AB1	+		0.05%	A074220	001	May 16, 1997	Jun	CRLD
>D>			TEMOVATE						
>D>	AB1	+	FOUGERA PHARMS	0.05%	N019322	001	Dec 27, 1985	Jun	DISC
>A>			@	0.05%	N019322	001	Dec 27, 1985	Jun	DISC
			TEMOVATE E						
			@ FOUGERA PHARMS	0.05%	N020340	001	Jun 17, 1994	May	DISC
			GEL;TOPICAL						
			CLOBETASOL PROPIONATE						
	AB	+	FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	May	CRLD
			TEMOVATE						
			@ FOUGERA PHARMS	0.05%	N020337	001	Apr 29, 1994	May	DISC
			OINTMENT;TOPICAL						
			CLOBETASOL PROPIONATE						
	AB		G AND W LABS INC	0.05%	A074089	001	Feb 16, 1994	Feb	CAHN
			SOLUTION;TOPICAL						
			CLOBETASOL PROPIONATE						
	AT		G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995	Mar	CMFD

CLOMIPHENE CITRATE

TABLET;ORAL

SEROPHENE

>D>							
>D>	AB	EMD SERONO	50MG	N018361	001	Mar 22, 1982	Jun DISC
>A>		@	50MG	N018361	001	Mar 22, 1982	Jun DISC

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL
CLONIDINE

AB	ACTAVIS LABS UT INC	0.1MG/24HR	A090873	001	May 06, 2014	Mar CAHN
AB		0.2MG/24HR	A090873	002	May 06, 2014	Mar CAHN
AB		0.3MG/24HR	A090873	003	May 06, 2014	Mar CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

@ DAVA PHARMS INC	0.1MG	A071783	001	Apr 05, 1988	May DISC
@	0.2MG	A071784	001	Apr 05, 1988	May DISC
@	0.3MG	A071785	001	Apr 05, 1988	May DISC

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB2	ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	May NEWA
AB1		0.1MG	A203320	001	May 15, 2015	May NEWA
AB2		0.2MG	A202792	002	May 15, 2015	May NEWA
AB1		0.2MG	A203320	002	May 15, 2015	May NEWA
AB2	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	May CTEC
AB2		0.2MG	A202983	002	Apr 02, 2014	May CTEC
	CLONIDINE HYDROCHLORIDE					
AB1	ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	May CTEC
AB1		0.2MG	A202984	002	Sep 30, 2013	May CTEC
	KAPVAY					
>D> AB1	+ CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010	Jun CRLD
>A> AB1		0.1MG	N022331	003	Sep 28, 2010	Jun CRLD
AB1	+	0.1MG	N022331	003	Sep 28, 2010	May CTEC
>D> AB1		0.2MG	N022331	004	Sep 28, 2010	Jun CRLD
>A> AB1	+	0.2MG	N022331	004	Sep 28, 2010	Jun CRLD
AB1		0.2MG	N022331	004	Sep 28, 2010	May CTEC

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB	SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004	Apr CAHN
AB		7.5MG	A076911	002	Sep 29, 2004	Apr CAHN
AB		15MG	A076911	003	Sep 29, 2004	Apr CAHN

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL

PREZCOBIX

+	JANSSEN PRODS	150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015	Jan NEWA
---	---------------	---------------------	---------	-----	--------------	----------

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

@ ROXANE	30MG/5ML	N202245	001	Jun 30, 2011	Jan DISC
----------	----------	---------	-----	--------------	----------

COLCHICINE

CAPSULE;ORAL

MITIGARE

HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Jan CAHN
-------------------	-------	---------	-----	--------------	----------

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

COLISTIMETHATE SODIUM

AP	XELLIA PHARMS APS	EQ 150MG BASE/VIAL	A205356	001	May 29, 2015	May NEWA
----	-------------------	--------------------	---------	-----	--------------	----------

CYANOCOBALAMIN

INJECTABLE;INJECTION

CYANOCOBALAMIN

@ EUROHLTH INTL SARL	1MG/ML	A080515	002		Feb CAHN
----------------------	--------	---------	-----	--	----------

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

>A> AB	ORIT LABS LLC	5MG	A078218	002	Jun 19, 2015	Jun NEWA
AB	SUN PHARM INDS LTD	5MG	A078722	001	May 12, 2008	Apr CAHN
AB		7.5MG	A078722	002	May 12, 2008	Apr CAHN
AB		10MG	A078722	003	May 12, 2008	Apr CAHN

CYTARABINEINJECTABLE; INJECTION
CYTARABINE

AP	MYLAN PHARMS INC	20MG/ML	A200915	001	Dec 13, 2011	May CAHN
AP		20MG/ML	A200916	001	Dec 13, 2011	May CAHN

DABRAFENIB MESYLATECAPSULE; ORAL
TAFINLAR

	NOVARTIS PHARMS CORP	EQ 50MG BASE	N202806	001	May 29, 2013	Mar CAHN
+		EQ 75MG BASE	N202806	002	May 29, 2013	Mar CAHN

DALTEPARIN SODIUMINJECTABLE; INJECTION
FRAGMIN

>A>	@ PFIZER INC	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Jun CAHN
>D>	@ PHARMACIA AND UPJOHN	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Jun CAHN
	@	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Apr CAHN

INJECTABLE; SUBCUTANEOUS
FRAGMIN

>A>	PFIZER INC	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Jun CAHN
>A>		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Jun CAHN
>A>		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Jun CAHN
>A>	@	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Jun CAHN
>A>		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Jun CAHN
>A>		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Jun CAHN
>A>		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Jun CAHN
>A>		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Jun CAHN
>A>	+	95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Jun CAHN
>A>	@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Jun CAHN
>D>	PHARMACIA AND UPJOHN	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Jun CAHN
		2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Apr CAHN
>D>		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Jun CAHN
		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Apr CAHN
>D>		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Jun CAHN
		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Apr CAHN
>D>	@	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Jun CAHN
	@	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Apr CAHN
>D>		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Jun CAHN
		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Apr CAHN
>D>		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Jun CAHN
		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Apr CAHN
>D>		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Jun CAHN
		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Apr CAHN
>D>		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Jun CAHN
		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Apr CAHN
>D>	+	95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Jun CAHN
	+	95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Apr CAHN
>D>	@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Jun CAHN
	@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Apr CAHN

DANTROLENE SODIUMCAPSULE; ORAL
DANTROLENE SODIUM

AB	ELITE LABS INC	25MG	A076686	001	Oct 24, 2005	May CAHN
AB		50MG	A076686	002	Oct 24, 2005	May CAHN
AB		100MG	A076686	003	Oct 24, 2005	May CAHN

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL
DARIFENACIN HYDROBROMIDE

AB	ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Mar NEWA
AB		EQ 15MG BASE	A091190	002	Mar 13, 2015	Mar NEWA
	ENABLEX					
AB	WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Mar CFTG
AB	+	EQ 15MG BASE	N021513	002	Dec 22, 2004	Mar CFTG

DECITABINEINJECTABLE; INTRAVENOUS
DACOGEN

AP	+	OTSUKA PHARM CO LTD	50MG/VIAL	N021790	001	May 02, 2006	Jan CAHN
----	---	---------------------	-----------	---------	-----	--------------	----------

DEFERASIROXTABLET; ORAL
JADENU

NOVARTIS PHARMS CORP

90MG

N206910 001 Mar 30, 2015 Mar NEWA

180MG

N206910 002 Mar 30, 2015 Mar NEWA

+

360MG

N206910 003 Mar 30, 2015 Mar NEWA

DEOXYCHOLIC ACIDSOLUTION; SUBCUTANEOUS
KYBELLA

+ KYTHERA BIOPHARMS

20MG/2ML (10MG/ML)

N206333 001 Apr 29, 2015 Apr NEWA

DESIRUDIN RECOMBINANTINJECTABLE; SUBCUTANEOUS
IPRIVASK

+ VALEANT PHARMS NORTH

15MG/VIAL

N021271 001 Apr 04, 2003 May CAHN

DESLORATADINESOLUTION; ORAL
CLARINEX

>D> + MERCK SHARP DOHME

0.5MG/ML

N021300 001 Sep 01, 2004 Jun CFTG

>A> AA +

0.5MG/ML

N021300 001 Sep 01, 2004 Jun CFTG

>A> DESLORATADINE

>A> AA TARO PHARM INDS

0.5MG/ML

A202592 001 Jun 30, 2015 Jun NEWA

DESMOPRESSIN ACETATETABLET; ORAL
DDAVP

AB FERRING PHARMS INC

0.1MG

N019955 001 Sep 06, 1995 Jan CAHN

AB +

0.2MG

N019955 002 Sep 06, 1995 Jan CAHN

DESMOPRESSIN ACETATE

AB GLENMARK PHARMS LTD

0.1MG

A201831 001 May 28, 2015 May NEWA

AB

0.2MG

A201831 002 May 28, 2015 May NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

DESOGESTREL AND ETHINYL ESTRADIOL

AB FAMY CARE LTD

0.15MG; 0.03MG

A202085 001 May 20, 2015 May NEWA

KARIVA

AB + BARR

0.15MG, N/A; 0.02MG, 0.01MG

A075863 001 Apr 05, 2002 Apr CTEC

KIMIDESS

AB VINTAGE PHARMS

0.15MG, N/A; 0.02MG, 0.01MG

A076681 001 Apr 30, 2015 Apr NEWA

DESONIDECREAM; TOPICAL
DESONIDE

AB TEVA PHARMS

0.05%

A074027 001 Sep 28, 1992 May CMFD

DESOXIMETASONECREAM; TOPICAL
DESOXIMETASONE

>A> AB VERSAPHARM INC

0.25%

A203234 001 Jun 12, 2015 Jun NEWA

OINTMENT; TOPICAL

DESOXIMETASONE

AB PERRIGO NEW YORK

0.25%

A077770 001 Apr 20, 2015 Apr NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

>A> DESVENLAFAXINE SUCCINATE

>A> AB ALEMBIC PHARMS LTD

EQ 50MG BASE

A204003 001 Jun 29, 2015 Jun NEWA

>A> AB

EQ 100MG BASE

A204003 002 Jun 29, 2015 Jun NEWA

>A> AB LUPIN LTD

EQ 50MG BASE

A204172 001 Jun 29, 2015 Jun NEWA

>A> AB

EQ 100MG BASE

A204172 002 Jun 29, 2015 Jun NEWA

>A> AB MYLAN PHARMS INC

EQ 50MG BASE

A204095 001 Jun 29, 2015 Jun NEWA

>A> AB

EQ 100MG BASE

A204095 002 Jun 29, 2015 Jun NEWA

		TABLET, EXTENDED RELEASE;ORAL					
>A>		DESVENLAFAXINE SUCCINATE					
>A>	AB	SANDOZ INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Jun NEWA
>A>	AB		EQ 100MG BASE	A204028	002	Jun 29, 2015	Jun NEWA
		PRISTIQ					
>D>	+	WYETH PHARMS INC	EQ 50MG BASE	N021992	001	Feb 29, 2008	Jun CFTG
>A>	AB	+	EQ 50MG BASE	N021992	001	Feb 29, 2008	Jun CFTG
>D>	+		EQ 100MG BASE	N021992	002	Feb 29, 2008	Jun CFTG
>A>	AB	+	EQ 100MG BASE	N021992	002	Feb 29, 2008	Jun CFTG
<u>DEXAMETHASONE SODIUM PHOSPHATE</u>							
		INJECTABLE;INJECTION					
		DEXAMETHASONE SODIUM PHOSPHATE					
		@ EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282	001		Mar CAHN
AP	+		EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Feb CAHN
AP		MYLAN PHARMS INC	EQ 4MG PHOSPHATE/ML	A040803	001	Aug 29, 2008	Apr CAHN
AP			EQ 10MG PHOSPHATE/ML	A040802	001	Aug 29, 2008	Apr CAHN
<u>DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>							
		OINTMENT;OPHTHALMIC					
		MAXITROL					
AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065	002		Mar CAHN
		SUSPENSION/DROPS;OPHTHALMIC					
		MAXITROL					
AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Mar CAHN
<u>DEXMEDETOMIDINE HYDROCHLORIDE</u>							
		INJECTABLE;INJECTION					
		PRECEDEX					
		HOSPIRA					
			EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Jan NEWA
<u>DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE</u>							
		SYRUP;ORAL					
		PROMETH W/ DEXTROMETHORPHAN					
		@ G AND W LABS INC	15MG/5ML;6.25MG/5ML	A088762	001	Oct 31, 1984	May CAHN
<u>DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE</u>							
		INJECTABLE;INJECTION					
		PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER					
		@ BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;36 8MG/100ML;526MG/100ML;502MG/100ML	N017451	001		Mar DISC
<u>DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM</u>							
		INJECTABLE;INJECTION					
		MD-76R					
AP	+	LIEBEL-FLARSHEIM	66%;10%	N019292	001	Sep 29, 1989	Feb CAHN
		SOLUTION;ORAL, RECTAL					
		MD-GASTROVIEW					
AA		LIEBEL-FLARSHEIM	66%;10%	A087388	001		Jan CAHN
<u>DICLOFENAC SODIUM</u>							
		SOLUTION;TOPICAL					
		DICLOFENAC SODIUM					
>A>	AT	IGI LABS INC	1.5%	A202769	001	Jul 08, 2015	Jun NEWA
<u>DIETHYLPROPION HYDROCHLORIDE</u>							
		TABLET;ORAL					
		TENUATE					
AA	+	ACTAVIS LABS UT INC	25MG	N011722	002		Mar CAHN
		TABLET, EXTENDED RELEASE;ORAL					
		TENUATE DOSPAN					
AB	+	ACTAVIS LABS UT INC	75MG	N012546	001		Mar CAHN

DIFLUNISALTABLET;ORAL
DIFLUNISAL

AB	HERITAGE PHARMA	500MG	A202845	001	Mar 08, 2012	Mar CAHN
----	-----------------	-------	---------	-----	--------------	----------

DIGOXININJECTABLE;INJECTION
DIGOXIN

AP	EUROHLTH INTL SARL	0.25MG/ML	A083391	001		Feb CAHN
----	--------------------	-----------	---------	-----	--	----------

TABLET;ORAL
DIGOXIN

AB	MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Jan CTEC
AB		0.25MG	A040282	002	Dec 23, 1999	Jan CTEC
AB	SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	Feb CMFD
AB		0.25MG	A076363	002	Jan 31, 2003	Feb CMFD

LANOXIN

AB	CONCORDIA PHARMS INC	0.0625MG	N020405	001	Sep 30, 1997	Apr CAHN
		0.125MG	N020405	002	Sep 30, 1997	Apr CAHN
		0.1875MG	N020405	003	Sep 30, 1997	Apr CAHN
AB	+	0.25MG	N020405	004	Sep 30, 1997	Apr CAHN
	@	0.375MG	N020405	005	Sep 30, 1997	Apr CAHN
	@	0.5MG	N020405	006	Sep 30, 1997	Apr CAHN

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
DILACOR XR

	@ ACTAVIS LABS UT INC	120MG	N020092	001	May 29, 1992	Mar CAHN
	@	180MG	N020092	002	May 29, 1992	Mar CAHN
	@	240MG	N020092	003	May 29, 1992	Mar CAHN
	@ WATSON LABS	120MG	N020092	001	May 29, 1992	Feb DISC
	@	180MG	N020092	002	May 29, 1992	Feb DISC
	@	240MG	N020092	003	May 29, 1992	Feb DISC

DILTIAZEM HYDROCHLORIDE

AB2	+	MYLAN	240MG	A075124	001	Mar 18, 1998	Feb CRLD
		TIAZAC					
AB4		VALEANT PHARMS NORTH	120MG	N020401	001	Sep 11, 1995	Feb CAHN
AB4			180MG	N020401	002	Sep 11, 1995	Feb CAHN
AB4			240MG	N020401	003	Sep 11, 1995	Feb CAHN
AB4			300MG	N020401	004	Sep 11, 1995	Feb CAHN
AB4			360MG	N020401	005	Sep 11, 1995	Feb CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb CAHN

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

>A>	AP	EUROHLTH INTL SARL	5MG/ML	A078538	001	Dec 17, 2008	Jun CAHN
>D>	AP	HIKMA MAPLE	5MG/ML	A078538	001	Dec 17, 2008	Jun CAHN
		@ MYLAN PHARMS INC	5MG/ML	A075375	001	Sep 30, 1999	Apr CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

>A>	AP	+	EUROHLTH INTL SARL	50MG/ML	A080817	002	Jun CAHN
>D>	AP	+	HIKMA MAPLE	50MG/ML	A080817	002	Jun CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

>A>	AP	EUROHLTH INTL SARL	5MG/ML	A074521	001	Oct 18, 1996	Jun CAHN
>D>	AP	HIKMA MAPLE	5MG/ML	A074521	001	Oct 18, 1996	Jun CAHN
		@ MYLAN PHARMS INC	5MG/ML	A075769	001	Nov 27, 2002	Apr CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB	MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015	Feb NEWA
AB		500MG	A203916	002	Mar 04, 2015	Feb NEWA

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

AB	AMNEAL PHARMS	EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015	May NEWA
AB		EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015	May NEWA

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DOBUTAMINE HYDROCHLORIDE

@	IGI LABS INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Mar CAHN
---	--------------	-------------------	---------	-----	--------------	----------

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL
DONEPEZIL HYDROCHLORIDE

AB	HETERO LABS LTD V	5MG	A203034	001	Jan 30, 2015	Jan NEWA
AB		10MG	A203034	002	Jan 30, 2015	Jan NEWA
AB	SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010	Apr CAHN
AB		10MG	A076786	002	Nov 26, 2010	Apr CAHN
AB		23MG	A204293	001	Jun 05, 2015	May NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
NAMZARIC

	FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014	Mar CAHN
+		10MG;28MG	N206439	002	Dec 23, 2014	Mar CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DOPAMINE HYDROCHLORIDE

@	IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985	Mar CAHN
@		40MG/ML	N018656	001	Jun 28, 1983	Mar CAHN
@		80MG/ML	A070089	001	Oct 23, 1985	Mar CAHN
@		80MG/ML	A070090	001	Oct 23, 1985	Mar CAHN
@		80MG/ML	A070091	001	Oct 23, 1985	Mar CAHN
@		160MG/ML	A070092	001	Oct 23, 1985	Mar CAHN
@		160MG/ML	A070093	001	Oct 23, 1985	Mar CAHN
@		160MG/ML	A070094	001	Oct 23, 1985	Mar CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION
DOPRAM

>A>	AP	+	EUROHLTH INTL SARL	20MG/ML	N014879	001		Jun CAHN
>D>	AP	+	HIKMA MAPLE	20MG/ML	N014879	001		Jun CAHN

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL
DOXEPIIN HYDROCHLORIDE

AB	+	MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986	Jan CRLD
	+	PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987	Jan CRLD
CREAM;TOPICAL ZONALON							
	+	DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994	Mar CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION
DOXERCALCIFEROL

AP		AKORN INC	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Apr NEWA
----	--	-----------	--------------------	---------	-----	--------------	----------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION
DOXORUBICIN HYDROCHLORIDE

AP		MYLAN PHARMS INC	2MG/ML	A200901	001	Feb 14, 2012	May CAHN
AP			10MG/VIAL	A200170	001	Oct 28, 2011	May CAHN
AP			50MG/VIAL	A200170	002	Oct 28, 2011	May CAHN

DOXYCYCLINE

CAPSULE;ORAL
DOXYCYCLINE

AB		NOVEL LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	May NEWA
AB			EQ 75MG BASE	A204446	002	May 28, 2015	May NEWA
AB			EQ 100MG BASE	A204446	003	May 28, 2015	May NEWA

CAPSULE;ORAL

DOXYCYCLINE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000	Apr CAHN
AB		EQ 75MG BASE	A065053	003	Sep 10, 2003	Apr CAHN
AB		EQ 100MG BASE	A065053	002	Nov 22, 2000	Apr CAHN

TABLET;ORAL

DOXYCYCLINE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006	Apr CAHN
AB		EQ 75MG BASE	A065356	002	May 31, 2006	Apr CAHN
AB		EQ 100MG BASE	A065356	003	May 31, 2006	Apr CAHN

DOXYCYCLINE HYCLATE

INJECTABLE;INJECTION

DOXYCYCLINE

>A>	@ EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jun CAHN
>A>	@	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jun CAHN
>D>	@ HIKMA MAPLE	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jun CAHN
>D>	@	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jun CAHN

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

@	IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988	Mar CAHN
@		2.5MG/ML	A072020	001	Oct 19, 1988	Mar CAHN
@		2.5MG/ML	A072021	001	Oct 19, 1988	Mar CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	FAMY CARE LTD	3MG;0.03MG	A202131	001	May 04, 2015	Apr NEWA
----	---------------	------------	---------	-----	--------------	----------

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

AB	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar CRLD
AB	+ PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar CRLD

EDOXABAN TOSYLATE

TABLET;ORAL

SAVAYSA

DAIICHI SANKYO

		EQ 15MG BASE	N206316	001	Jan 08, 2015	Jan NEWA
		EQ 30MG BASE	N206316	002	Jan 08, 2015	Jan NEWA

+		EQ 60MG BASE	N206316	003	Jan 08, 2015	Jan NEWA
---	--	--------------	---------	-----	--------------	----------

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON

+	MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985	Mar CRLD
---	---------------------	---------	---------	-----	--------------	----------

TENSILON

@	IGI LABS INC	10MG/ML	N007959	001		Apr CAHN
---	--------------	---------	---------	-----	--	----------

@	VALEANT PHARMS	10MG/ML	N007959	001		Mar DISC
---	----------------	---------	---------	-----	--	----------

TENSILON PRESERVATIVE FREE

@	IGI LABS INC	10MG/ML	N007959	002		Apr CAHN
---	--------------	---------	---------	-----	--	----------

@	VALEANT PHARMS	10MG/ML	N007959	002		Mar DISC
---	----------------	---------	---------	-----	--	----------

ELTROMBOPAG OLAMINE

TABLET;ORAL

PROMACTA

NOVARTIS PHARMS CORP

		EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Mar CAHN
		EQ 25MG ACID	N022291	001	Nov 20, 2008	Mar CAHN
		EQ 50MG ACID	N022291	002	Nov 20, 2008	May CRLD
+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Mar CAHN
+		EQ 75MG ACID	N022291	003	Sep 08, 2009	May CRLD
		EQ 75MG ACID	N022291	003	Sep 08, 2009	Mar CAHN
+		EQ 100MG ACID	N022291	005	Nov 16, 2012	May CRLD
		EQ 100MG ACID	N022291	005	Nov 16, 2012	Mar CAHN

ELUXADOLINETABLET; ORAL
VIBERZI

FURIEX PHARMS	75MG	N206940	001	May 27, 2015	May NEWA
+	100MG	N206940	002	May 27, 2015	May NEWA

EMPAGLIFLOZIN; LINAGLIPTINTABLET; ORAL
GLYXAMBI

BOEHRINGER INGELHEIM	10MG; 5MG	N206073	001	Jan 30, 2015	Jan NEWA
+	25MG; 5MG	N206073	002	Jan 30, 2015	Jan NEWA

ENALAPRIL MALEATETABLET; ORAL
ENALAPRIL MALEATE

AB	SANDOZ INC	2.5MG	A075496	001	Aug 22, 2000	Mar CMFD
AB		5MG	A075496	002	Aug 22, 2000	Mar CMFD
AB		10MG	A075459	001	Aug 22, 2000	Mar CMFD
AB		20MG	A075459	002	Aug 22, 2000	Mar CMFD
	@ SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000	Apr CAHN
	@	5MG	A075556	002	Aug 22, 2000	Apr CAHN
	@	10MG	A075556	003	Aug 22, 2000	Apr CAHN
	@	20MG	A075556	004	Aug 22, 2000	Apr CAHN
	VASOTEC					
AB	VALEANT PHARMS NORTH	2.5MG	N018998	005	Jul 26, 1988	Apr CAHN
AB		5MG	N018998	001	Dec 24, 1985	Apr CAHN
AB		10MG	N018998	002	Dec 24, 1985	Apr CAHN
AB	+	20MG	N018998	003	Dec 24, 1985	Apr CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDETABLET; ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	G AND W LABS INC	5MG; 12.5MG	A075727	001	Sep 18, 2001	Apr CAHN
AB		10MG; 25MG	A075727	002	Sep 18, 2001	Apr CAHN

ENTACAPONETABLET; ORAL
ENTACAPONE

>A> AB	AUROBINDO PHARMA LTD	200MG	A203437	001	Jun 19, 2015	Jun NEWA
--------	----------------------	-------	---------	-----	--------------	----------

EPIRUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

AP	MYLAN PHARMS INC	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	May CAHN
AP		200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	May CAHN

>D> EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE>D> TABLET; ORAL
>D> TEVETEN HCT

>D>	ABBVIE	600MG; 12.5MG	N021268	001	Nov 01, 2001	Jun DISC
>A>	@	600MG; 12.5MG	N021268	001	Nov 01, 2001	Jun DISC
>D>	+	600MG; 25MG	N021268	002	Nov 01, 2001	Jun DISC
>A>	@	600MG; 25MG	N021268	002	Nov 01, 2001	Jun DISC

EPTIFIBATIDEINJECTABLE; INJECTION
EPTIFIBATIDE

>A> AP	TEVA PHARMS USA	2MG/ML	A090854	001	Jun 12, 2015	Jun NEWA	
AP		75MG/100ML	A091555	001	Jun 05, 2015	May NEWA	
	INTEGRILIN						
>D>	+	SCHERING	2MG/ML	N020718	001	May 18, 1998	Jun CTEC
>A> AP	+		2MG/ML	N020718	001	May 18, 1998	Jun CTEC
AP	+		75MG/100ML	N020718	002	May 18, 1998	May CFTG

ERGOCALCIFEROLCAPSULE; ORAL
VITAMIN D

AA	BANNER LIFE SCIENCES	50,000 IU	A080704	001		Jan CAHN
----	----------------------	-----------	---------	-----	--	----------

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

@ G AND W LABS INC

EQ 125MG BASE/5ML

A062169 001 Oct 17, 1990 Apr CAHN

@

EQ 250MG BASE/5ML

A062169 002 Oct 17, 1990 Apr CAHN

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA

ANTRIM PHARMS LLC

EQ 5MG BASE/5ML

A203967 001 May 26, 2015 May NEWA

TABLET;ORAL

ESCITALOPRAM OXALATE

AB

MYLAN PHARMS INC

EQ 5MG BASE

A077550 001 May 14, 2015 Apr NEWA

AB

EQ 10MG BASE

A077550 002 May 14, 2015 Apr NEWA

AB

EQ 20MG BASE

A077550 003 May 14, 2015 Apr NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP

LUITPOLD

10MG/ML

A201126 001 Feb 20, 2015 Feb NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB

IVAX SUB TEVA PHARMS

EQ 20MG BASE

A078003 001 Jan 26, 2015 Jan NEWA

AB

EQ 40MG BASE

A078003 002 Jan 26, 2015 Jan NEWA

NEXIUM

AB

ASTRAZENECA PHARMS

EQ 20MG BASE

N021153 001 Feb 20, 2001 Jan CFTG

AB

+

EQ 40MG BASE

N021153 002 Feb 20, 2001 Jan CFTG

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

ALORA

BX

ACTAVIS LABS UT INC

0.025MG/24HR

N020655 004 Apr 05, 2002 Mar CAHN

BX

0.05MG/24HR

N020655 001 Dec 20, 1996 Mar CAHN

BX

0.075MG/24HR

N020655 002 Dec 20, 1996 Mar CAHN

BX

0.1MG/24HR

N020655 003 Dec 20, 1996 Mar CAHN

MINIVELLE

NOVEN

0.025MG/24HR

N203752 005 Sep 23, 2014 Jan NEWA

TABLET;VAGINAL

ESTRADIOL

@ AMNEAL PHARMS

10MCG

A205256 001 May 29, 2015 May DISC

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB

MACLEODS PHARMS LTD

1MG

A202929 001 Jan 30, 2015 Jan NEWA

AB

2MG

A202929 002 Jan 30, 2015 Jan NEWA

AB

3MG

A202929 003 Jan 30, 2015 Jan NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE

AB

VERSAPHARM INC

100MG

A075095 001 Nov 30, 1999 Jan CMFD

AB

400MG

A075095 002 Nov 30, 1999 Jan CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

ASHLYNA

AB

GLENMARK GENERICS

0.03MG,0.01MG;0.15MG,N/A

A203163 001 Feb 23, 2015 Feb NEWA

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB

FAMY CARE LTD

0.03MG;0.15MG

A200490 001 Apr 21, 2015 Apr NEWA

AB

GLENMARK GENERICS

0.02MG;0.09MG

A202791 001 Apr 09, 2015 Mar NEWA

>A>

AB

GLENMARK PHARMS LTD

0.03MG;0.15MG

A203164 001 Jun 12, 2015 Jun NEWA

AB

+

WATSON LABS

0.02MG;0.09MG

A079218 001 Jun 06, 2011 Mar CTEC

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

>A>

AB

FAMY CARE LTD

0.02MG,0.01MG;0.1MG,N/A

A200493 001 Jun 17, 2015 Jun NEWA

AB

0.03MG,0.01MG;0.15MG,N/A

A200492 001 May 27, 2015 May NEWA

TABLET;ORAL-28
VIENVA

AB1 SANDOZ INC 0.02MG;0.1MG A201088 001 May 21, 2015 May NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL
ORTHO EVRA

@ JANSSSEN PHARMS 0.035MG/24HR;0.15MG/24HR N021180 001 Nov 20, 2001 Feb DISC
XULANE
AB + MYLAN TECHNOLOGIES 0.035MG/24HR;0.15MG/24HR A200910 001 Apr 16, 2014 Feb CRLD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BREVICON 21-DAY
@ ACTAVIS LABS UT INC 0.035MG;0.5MG N017566 001 Mar CAHN
NORINYL 1+35 21-DAY
AB ACTAVIS LABS UT INC 0.035MG;1MG N017565 001 Feb CAHN
TRI-NORINYL 21-DAY
@ ACTAVIS LABS UT INC 0.035MG,0.035MG,0.035MG;0.5MG,1MG, N018977 001 Apr 13, 1984 Feb CAHN
0.5MG

TABLET;ORAL-28

BREVICON 28-DAY
AB ACTAVIS LABS UT INC 0.035MG;0.5MG N017743 001 Mar CAHN
NORETHINDRONE AND ETHINYL ESTRADIOL
AB FAMY CARE LTD 0.035MG;0.4MG A200897 001 May 11, 2015 Apr NEWA
NORINYL 1+35 28-DAY
AB ACTAVIS LABS UT INC 0.035MG;1MG N017565 002 Feb CAHN
TRI-NORINYL 28-DAY
AB + ACTAVIS LABS UT INC 0.035MG,0.035MG,0.035MG;0.5MG,1MG, N018977 002 Apr 13, 1984 Feb CAHN
0.5MG

TABLET, CHEWABLE;ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
AB FAMY CARE LTD 0.035MG;0.4MG A202086 001 Apr 01, 2015 Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

FEMHRT
AB WARNER CHILCOTT LLC 0.0025MG;0.5MG N021065 001 Jan 14, 2005 Mar CTEC
LARIN 24 FE
AB NOVAST LABS LTD 0.02MG;1MG A202994 001 Feb 18, 2015 Feb NEWA
LOESTRIN 24 FE
@ WARNER CHILCOTT 0.02MG;1MG N021871 001 Feb 17, 2006 Jan DISC
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
AB + BARR LABS INC 0.005MG;1MG A076221 001 Nov 06, 2009 Mar CTEC
AB GLENMARK GENERICS 0.0025MG;0.5MG A203038 001 Apr 02, 2015 Mar NEWA
AB 0.005MG;1MG A203038 002 Apr 02, 2015 Mar NEWA
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
AB + AMNEAL PHARMS 0.02MG;1MG A078267 001 Sep 01, 2009 Jan CRLD
TABLET;ORAL-21
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
AB FAMY CARE LTD 0.03MG;1.5MG A202770 001 Feb 19, 2015 Feb NEWA
TABLET;ORAL-28
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL
AB FAMY CARE LTD 0.03MG;1.5MG A202741 001 Feb 20, 2015 Feb NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL
AB OC PHARMA 0.035MG;0.035MG;0.035MG;0.18MG;0.2 A200383 001 Apr 07, 2015 Mar NEWA
15MG;0.25MG
AB 0.035MG;0.25MG A200384 001 Apr 07, 2015 Mar NEWA
TRI-LO-ESTARYLLA
>A> AB SANDOZ INC 0.025MG,0.025MG,0.025MG;0.18MG,0.2 A091232 001 Jun 29, 2015 Jun NEWA
15MG,0.25MG

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

LOW-OGESTREL-28
AB WATSON LABS 0.03MG;0.3MG A075288 002 Jul 28, 1999 Feb CMFD

ETHOSUXIMIDECAPSULE;ORAL
ETHOSUXIMIDE

AB	BANNER LIFE SCIENCES	250MG	A040430	001	Oct 28, 2002	Jan CAHN
----	----------------------	-------	---------	-----	--------------	----------

ETOMIDATEINJECTABLE;INJECTION
ETOMIDATE

AP	MYLAN PHARMS INC	2MG/ML	A078289	001	Jan 02, 2009	Apr CAHN
----	------------------	--------	---------	-----	--------------	----------

ETONOGESTREL

IMPLANT;IMPLANTATION

>D>	IMPLANON					
>D>	+ ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006	Jun DISC
>A>	@	68MG/IMPLANT	N021529	001	Jul 17, 2006	Jun DISC

EZETIMIBETABLET;ORAL
EZETIMIBE

>A>	@ GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015	Jun DISC
>A>	AB	10MG	A078560	001	Jun 26, 2015	Jun NEWA
	ZETIA					
>D>	+ MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Jun CFTG
>A>	+	10MG	N021445	001	Oct 25, 2002	Jun CTEC
>A>	AB	10MG	N021445	001	Oct 25, 2002	Jun CFTG

FAMOTIDINEINJECTABLE;INJECTION
FAMOTIDINE

>A>	AP	+ EUROHLTH INTL SARL	10MG/ML	A075488	001	Apr 16, 2001	Jun CAHN
>D>	AP	+ HIKMA MAPLE	10MG/ML	A075488	001	Apr 16, 2001	Jun CAHN
		FAMOTIDINE PRESERVATIVE FREE					
>A>	AP	+ EUROHLTH INTL SARL	10MG/ML	A075486	001	Apr 16, 2001	Jun CAHN
>D>	AP	+ HIKMA MAPLE	10MG/ML	A075486	001	Apr 16, 2001	Jun CAHN

TABLET;ORAL

PEPCID

AB	VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Feb CAHN
AB	+	40MG	N019462	002	Oct 15, 1986	Feb CAHN

FELODIPINETABLET, EXTENDED RELEASE;ORAL
FELODIPINE

AB	ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015	May NEWA
AB		5MG	A203032	002	May 21, 2015	May NEWA
AB		10MG	A203032	003	May 21, 2015	May NEWA
AB	SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013	Apr CAHN
AB		5MG	A091200	002	Dec 13, 2013	Apr CAHN
AB		10MG	A091200	003	Dec 13, 2013	Apr CAHN

FENOFIBRATECAPSULE;ORAL
FENOFIBRATE

AB	SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014	Apr CAHN
AB		130MG	A201748	002	Oct 31, 2014	Apr CAHN

TABLET;ORAL

FENOFIBRATE

AB	SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005	Apr CAHN
		107MG	A076635	002	Oct 31, 2005	Apr CAHN
AB		160MG	A076635	003	Oct 31, 2005	Apr CAHN

FENOFIBRIC ACIDTABLET;ORAL
FIBRICOR

>D>	MUTUAL PHARM CO INC	35MG	N022418	001	Aug 14, 2009	Jun CAHN
>D>	+	105MG	N022418	002	Aug 14, 2009	Jun CAHN
>A>	TRIBUTE PHARMS INTL	35MG	N022418	001	Aug 14, 2009	Jun CAHN
>A>	+	105MG	N022418	002	Aug 14, 2009	Jun CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-100

AB ACTAVIS LABS UT INC 100MCG/HR A076709 004 Aug 20, 2007 Mar CAHN

FENTANYL-12

>A> AB MALLINCKRODT INC 12.5MCG/HR A077154 005 Jun 11, 2015 Jun NEWA

FENTANYL-25

AB ACTAVIS LABS UT INC 25MCG/HR A076709 001 Aug 20, 2007 Mar CAHN

FENTANYL-50

AB ACTAVIS LABS UT INC 50MCG/HR A076709 002 Aug 20, 2007 Mar CAHN

FENTANYL-75

AB ACTAVIS LABS UT INC 75MCG/HR A076709 003 Aug 20, 2007 Mar CAHN

FENTANYL CITRATE

FILM;BUCCAL
ONSOLIS

@ BIODELIVERY SCI INTL EQ 0.2MG BASE

N022266 001 Jul 16, 2009 Mar CAHN

@ EQ 0.4MG BASE

N022266 002 Jul 16, 2009 Mar CAHN

@ EQ 0.6MG BASE

N022266 003 Jul 16, 2009 Mar CAHN

@ EQ 0.8MG BASE

N022266 004 Jul 16, 2009 Mar CAHN

@ EQ 1.2MG BASE

N022266 005 Jul 16, 2009 Mar CAHN

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP + EUROHLTH INTL SARL EQ 0.05MG BASE/ML N019101 001 Jul 11, 1984 Feb CAHN

FENTANYL HYDROCHLORIDE

SYSTEM;IONTOPHORESIS, TRANSDERMAL
IONSYS

>D> @ THE MEDICINES CO 10.8MCG N021338 001 May 22, 2006 Jun CMFD

@ 10.8MCG

N021338 001 May 22, 2006 Apr CAHN

>A> + EQ 40MCG BASE/ACTIVATION N021338 001 May 22, 2006 Jun CMFD

FERRIC CITRATE

TABLET;ORAL
AURYXIA

+ KERYX BIOPHARMS EQ 210MG IRON N205874 001 Sep 05, 2014 Jan CTNA

FERRIC PYROPHOSPHATE CITRATE

SOLUTION;IV (INFUSION)
TRIFERIC

+ ROCKWELL MEDICAL INC 27.2MG IRON/5ML (5.44MG IRON/ML) N206317 001 Jan 23, 2015 Jan NEWA

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

AB ANI PHARMS INC 50MG A075882 001 Oct 28, 2002 Apr CAHN

AB 100MG A075882 002 Oct 28, 2002 Apr CAHN

AB 150MG A075882 003 Oct 28, 2002 Apr CAHN

>A> AB AUROBINDO PHARMA LTD 50MG A202821 001 Jul 08, 2015 Jun NEWA

>A> AB 100MG A202821 002 Jul 08, 2015 Jun NEWA

>A> AB 150MG A202821 003 Jul 08, 2015 Jun NEWA

AB SUN PHARM INDS LTD 50MG A076421 001 Mar 28, 2003 Apr CAHN

AB 100MG A076421 002 Mar 28, 2003 Apr CAHN

AB 150MG A076421 003 Mar 28, 2003 Apr CAHN

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

AB SUN PHARM INDS LTD 50MG/5ML A076332 001 Jul 29, 2004 Apr CAHN

AB 200MG/5ML A076332 002 Jul 29, 2004 Apr CAHN

INJECTABLE;INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP CLARIS PHARMASERVICE 200MG/100ML (2MG/ML) A077988 001 May 26, 2010 Apr CAHN

AP 400MG/200ML (2MG/ML) A077988 002 May 26, 2010 Apr CAHN

@ MYLAN PHARMS INC 200MG/100ML (2MG/ML)

A076888 001 Mar 25, 2005 Apr CAHN

@ 400MG/200ML (2MG/ML)

A076888 002 Mar 25, 2005 Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP CLARIS PHARMASERVICE 200MG/100ML (2MG/ML) A077947 001 May 26, 2010 Apr CAHN

AP 400MG/200ML (2MG/ML) A077947 002 May 26, 2010 Apr CAHN

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

		CLARIS PHARMASERVICE	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr NEWA
			100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr CAHN
AP			200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Apr CAHN
AP			400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Apr CAHN
		@ MYLAN PHARMS INC	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005	Apr CAHN
		@	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Apr CAHN

TABLET;ORAL

FLUCONAZOLE

AB		HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	May CMFD
AB			100MG	A078423	002	Mar 07, 2011	May CMFD
AB			150MG	A078423	003	Mar 07, 2011	May CMFD
AB			200MG	A078423	004	Mar 07, 2011	May CMFD

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

FLUDARABINE PHOSPHATE

AP		MYLAN PHARMS INC	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011	May CAHN
----	--	------------------	--------------------	---------	-----	--------------	----------

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F 18

AP		BIOMEDCL RES FDN	20-300mCi/ML	A203710	001	May 01, 2015	Apr NEWA
AP			20-300mCi/ML	A203837	001	May 01, 2015	Apr NEWA
>A> AP		TRIAD ISOTOPES INC	20-300mCi/ML	A203920	001	Jun 23, 2015	Jun NEWA
		UNIV NORTH DAKOTA	4-500mCi/ML	A203994	001	Feb 04, 2015	Jan NEWA
>A> AP		UNIV UTAH CYCLOTRON	20-300mCi/ML	A204498	001	Jun 23, 2015	Jun NEWA
		FLUDEOXYGLUCOSE F18					
AP		METHODIST HOSP RES	20-300mCi/ML	A203904	001	Apr 23, 2015	Apr NEWA
		PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar NEWA
		SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr NEWA

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

		@ CLARIS PHARMASERVICE	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr CAHN
		@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr CAHN
>A> AP		EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jun CAHN
>A> AP			1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jun CAHN
>D> AP		HIKMA MAPLE	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jun CAHN
>D> AP			1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jun CAHN
AP		MYLAN PHARMS INC	0.5MG/5ML (0.1MG/ML)	A078595	001	May 13, 2008	Apr CAHN
AP	+		1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Apr CAHN

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

>A> AT		VERSAPHARM INC	0.01%	A091514	001	Jun 25, 2015	Jun NEWA
--------	--	----------------	-------	---------	-----	--------------	----------

FLUOCINONIDE

GEL;TOPICAL

FLUOCINONIDE

AB		G AND W LABS INC	0.05%	A072537	001	Feb 07, 1989	Apr CAHN
----	--	------------------	-------	---------	-----	--------------	----------

FLUOROURACIL

CREAM;TOPICAL

CARAC

AB	+	VALEANT PHARMS NORTH	0.5%	N020985	001	Oct 27, 2000	Apr CFTG
	+		0.5%	N020985	001	Oct 27, 2000	Feb CAHN
		FLUOROURACIL					
AB		SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Apr NEWA
		INJECTABLE;INJECTION					
		FLUOROURACIL					
AP		MYLAN PHARMS INC	500MG/10ML (50MG/ML)	A202668	001	Jul 17, 2012	Apr CAHN
AP			1GM/20ML (50MG/ML)	A202668	002	Jul 17, 2012	Apr CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

	@ ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Mar	DISC
	@	EQ 20MG BASE	A076287	002	May 20, 2008	Mar	DISC
+	MYLAN	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CRLD
		EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CTEC
	@ SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008	Mar	DISC
	@	EQ 20MG BASE	A077469	002	Nov 17, 2008	Mar	DISC
AB1	SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015	Mar	NEWA
AB1		EQ 20MG BASE	A204597	002	Mar 16, 2015	Mar	NEWA
AB		EQ 40MG BASE	A204597	003	Mar 16, 2015	Mar	NEWA
AB	SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr	CAHN
	SARAFEM						
	@ ELI LILLY AND CO	EQ 10MG BASE	N018936	007	Jul 06, 2000	Mar	DISC
	@	EQ 20MG BASE	N018936	008	Jul 06, 2000	Mar	DISC

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

	@ MYLAN PHARMS INC	25MG/ML	A075918	001	Aug 17, 2001	Apr	CAHN
--	--------------------	---------	---------	-----	--------------	-----	------

FLURANDRENOLIDE

OINTMENT; TOPICAL

CORDRAN

>D>	AQUA PHARMS	0.05%	N012806	001		Jun	CRLD
>A>	+	0.05%	N012806	001		Jun	CRLD
		0.05%	N012806	001		May	CMFD

TAPE; TOPICAL

CORDRAN

+	ACTAVIS LABS UT INC	0.004MG/SQ CM	N016455	001		Mar	CAHN
---	---------------------	---------------	---------	-----	--	-----	------

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREO ELLIPTA

	GLAXO GRP LTD	0.2MG/INH; EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Apr	NEWA
--	---------------	--------------------------------	---------	-----	--------------	-----	------

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	10MG; 12.5MG	A076739	001	Dec 17, 2004	Apr	CAHN
AB		20MG; 12.5MG	A076739	002	Dec 17, 2004	Apr	CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

	@ IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985	Mar	CAHN
	@	10MG/ML	A070096	001	Sep 09, 1985	Mar	CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB	SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Apr	CAHN
AB		300MG	A076606	002	Oct 07, 2005	Apr	CAHN
AB		400MG	A076606	003	Oct 07, 2005	Apr	CAHN

TABLET; ORAL

GABAPENTIN

>D>	AB	HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011	Jun	DISC
>A>		@	600MG	A078782	001	Jul 21, 2011	Jun	DISC
>D>	AB		800MG	A078782	002	Jul 21, 2011	Jun	DISC
>A>		@	800MG	A078782	002	Jul 21, 2011	Jun	DISC

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+	LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999	Feb	CAHN
+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999	Feb	CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999	Feb	CAHN
+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999	Feb	CAHN
+		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999	Feb	CAHN

INJECTABLE; INJECTION
OPTIMARK IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999	Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999	Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999	Feb CAHN
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Feb CAHN

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP	MYLAN PHARMS INC	EQ 200MG BASE/VIAL	A200145	001	Jul 25, 2011	May CAHN
AP		EQ 1GM BASE/VIAL	A200145	002	Jul 25, 2011	May CAHN
AP		EQ 2GM BASE/VIAL	A200145	003	Jul 25, 2011	May CAHN

GEMIFLOXACIN MESYLATE

TABLET; ORAL
FACTIVE

>D>	+	LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jun CFTG
>A>	AB	+	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jun CFTG
>A>		GEMIFLOXACIN MESYLATE					
>A>	AB	ORCHID HLTHCARE	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jun NEWA

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS
COPAXONE

AP	+	TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Mar CFTG
		GLATOPIA					
AP		SANDOZ INC	20MG/ML	A090218	001	Apr 16, 2015	Mar NEWA

GLIMEPIRIDE

TABLET; ORAL
GLIMEPIRIDE

@	HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Apr DISC
@		2MG	A078952	002	Aug 01, 2013	Apr DISC
@		4MG	A078952	003	Aug 01, 2013	Apr DISC

>D>		<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE</u>					
>D>		TABLET; ORAL					
>D>		AVANDARYL					
>D>	+	SB PHARMC0	1MG; 4MG	N021700	001	Nov 23, 2005	Jun DISC
>A>	@		1MG; 4MG	N021700	001	Nov 23, 2005	Jun DISC
>D>			2MG; 4MG	N021700	002	Nov 23, 2005	Jun DISC
>A>	@		2MG; 4MG	N021700	002	Nov 23, 2005	Jun DISC
>D>			2MG; 8MG	N021700	004	Mar 30, 2007	Jun DISC
>A>	@		2MG; 8MG	N021700	004	Mar 30, 2007	Jun DISC
>D>			4MG; 4MG	N021700	003	Nov 23, 2005	Jun DISC
>A>	@		4MG; 4MG	N021700	003	Nov 23, 2005	Jun DISC
>D>			4MG; 8MG	N021700	005	Mar 30, 2007	Jun DISC
>A>	@		4MG; 8MG	N021700	005	Mar 30, 2007	Jun DISC

GLIPIZIDE

TABLET, EXTENDED RELEASE; ORAL
GLIPIZIDE

AB	MYLAN PHARMS INC	2.5MG	A202298	001	May 19, 2015	May NEWA
AB		5MG	A202298	002	May 19, 2015	May NEWA
AB		10MG	A202298	003	May 19, 2015	May NEWA

GLUCAGON HYDROCHLORIDE

POWDER; INTRAMUSCULAR, INTRAVENOUS
GLUCAGON

+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015	May NEWA
---	--------------------	------------------	---------	-----	--------------	----------

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL
RAVICTI

+	HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013	May CAHN
---	---------------------	----------	---------	-----	--------------	----------

GLYCOPYRROLATEINJECTABLE; INJECTION
ROBINUL

>A>	AP	+	EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Jun	CAHN
>D>	AP	+	HIKMA MAPLE	0.2MG/ML	N017558	001		Jun	CAHN

TABLET; ORAL

GLYCOPYRROLATE

AA			SUN PHARM INDS LTD	1MG	A040844	001	Aug 18, 2009	Apr	CAHN
AA				2MG	A040844	002	Aug 18, 2009	Apr	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP			BANNER LIFE SCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan	CAHN
AP				EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan	CAHN
		@	CLARIS PHARMASERVICE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr	CAHN
		@		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr	CAHN
>A>	AP		EUROHLTH INTL SARL	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jun	CAHN
>D>	AP		HIKMA MAPLE	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jun	CAHN
			GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP			BANNER LIFE SCIENCES	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan	CAHN

GUAIFENESIN; HYDROCODONE BITARTRATESOLUTION; ORAL
FLOWTUSS

			MIKART INC	200MG/5ML; 2.5MG/5ML	N022424	001	May 14, 2015	May	NEWA
--	--	--	------------	----------------------	---------	-----	--------------	-----	------

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDESOLUTION; ORAL
HYCOFENIX

+			MIKART INC	200MG/5ML; 2.5MG/5ML; 30MG/5ML	N022279	001	May 14, 2015	May	NEWA
---	--	--	------------	--------------------------------	---------	-----	--------------	-----	------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB			MYLAN PHARMS INC	EQ 1MG BASE	A202578	001	Jun 02, 2015	May	NEWA
AB				EQ 2MG BASE	A202578	002	Jun 02, 2015	May	NEWA
AB				EQ 3MG BASE	A202578	003	Jun 02, 2015	May	NEWA
AB				EQ 4MG BASE	A202578	004	Jun 02, 2015	May	NEWA
AB			SANDOZ INC	EQ 1MG BASE	A202568	001	Jun 03, 2015	May	NEWA
AB				EQ 2MG BASE	A202568	002	Jun 03, 2015	May	NEWA
AB				EQ 3MG BASE	A202568	003	Jun 03, 2015	May	NEWA
AB				EQ 4MG BASE	A202568	004	Jun 03, 2015	May	NEWA
AB			TEVA PHARMS USA	EQ 1MG BASE	A201382	001	Jun 02, 2015	May	NEWA
AB				EQ 2MG BASE	A201382	002	Jun 02, 2015	May	NEWA
AB				EQ 3MG BASE	A201382	003	Jun 02, 2015	May	NEWA
AB				EQ 4MG BASE	A201382	004	Jun 02, 2015	May	NEWA
AB			TWI PHARMS INC	EQ 1MG BASE	A201408	001	Jun 02, 2015	May	NEWA
AB				EQ 2MG BASE	A201408	002	Jun 02, 2015	May	NEWA
AB				EQ 3MG BASE	A201408	003	Jun 02, 2015	May	NEWA
AB				EQ 4MG BASE	A201408	004	Jun 02, 2015	May	NEWA

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

		@	CYCLE PHARMS LTD	0.5MG	A071128	001	Feb 17, 1987	May	CAHN
>A>		@		1MG	A071129	001	Feb 17, 1987	Jun	CAHN
>A>		@		5MG	A071131	001	Feb 17, 1987	Jun	CAHN
>A>		@		10MG	A071132	001	May 12, 1987	Jun	CAHN
		@		20MG	A071133	001	May 12, 1987	May	CAHN
>D>		@	ROXANE	1MG	A071129	001	Feb 17, 1987	Jun	CAHN
>D>		@		2MG	A071130	001	Feb 17, 1987	Jun	CAHN
>A>		@		2MG	A071130	001	Feb 17, 1987	Jun	CAHN
>D>		@		5MG	A071131	001	Feb 17, 1987	Jun	CAHN
>D>		@		10MG	A071132	001	May 12, 1987	Jun	CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL INTENSOL

@ CYCLE PHARMS LTD

EQ 2MG BASE/ML

A072045 001 Apr 12, 1988 May CAHN

INJECTABLE; INJECTION

HALOPERIDOL

@ CLARIS PHARMASERVICE

EQ 5MG BASE/ML

A076791 001 Aug 25, 2004 Apr CAHN

@

EQ 5MG BASE/ML

A076828 001 Aug 25, 2004 May CAHN

AP

MYLAN PHARMS INC

EQ 5MG BASE/ML

A078347 001 Sep 14, 2009 Apr CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

>A> AP + EUROHLTH INTL SARL

1,000 UNITS/ML

N017037 001

Jun CAHN

>A> AP

+

5,000 UNITS/ML

N017037 002

Jun CAHN

>A>

@

5,000 UNITS/0.5ML

N017037 013 Apr 07, 1986

Jun CAHN

>A> AP

+

10,000 UNITS/ML

N017037 003

Jun CAHN

>D> AP

+

HIKMA MAPLE

1,000 UNITS/ML

N017037 001

Jun CAHN

>D> AP

+

5,000 UNITS/ML

N017037 002

Jun CAHN

>D>

@

5,000 UNITS/0.5ML

N017037 013 Apr 07, 1986

Jun CAHN

>D> AP

+

10,000 UNITS/ML

N017037 003

Jun CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP

+

AKORN

20MG/ML

A040730 001 Apr 21, 2009

Feb CRLD

AP

LUITPOLD

20MG/ML

A040136 001 Jun 30, 1997

Feb CRLD

>A> AP

X-GEN PHARMS INC

20MG/ML

A203110 001 Jun 29, 2015

Jun NEWA

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

MICROZIDE

AB

+

ACTAVIS LABS UT INC

12.5MG

N020504 001 Dec 27, 1996

Feb CAHN

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB

SUN PHARM INDS LTD

12.5MG; 10MG

A076007 001 Jul 01, 2002

Apr CAHN

AB

12.5MG; 20MG

A076007 002 Jul 01, 2002

Apr CAHN

AB

25MG; 20MG

A076007 003 Jul 01, 2002

Apr CAHN

ZESTORETIC

AB

ALVOGEN IPCO SARL

12.5MG; 10MG

N019888 003 Nov 18, 1993

Feb CAHN

AB

+

12.5MG; 20MG

N019888 001 Sep 20, 1990

Feb CAHN

AB

+

25MG; 20MG

N019888 002 Jul 20, 1989

Feb CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

>A> CONCORDIA PHARMS INC

12.5MG; EQ 25MG TARTRATE

N021956 001 Aug 28, 2006

Jun CAHN

>A>

12.5MG; EQ 50MG TARTRATE

N021956 002 Aug 28, 2006

Jun CAHN

>A>

+

12.5MG; EQ 100MG TARTRATE

N021956 003 Aug 28, 2006

Jun CAHN

>D>

COVIS PHARMA SARL

12.5MG; EQ 25MG TARTRATE

N021956 001 Aug 28, 2006

Jun CAHN

>D>

12.5MG; EQ 50MG TARTRATE

N021956 002 Aug 28, 2006

Jun CAHN

>D>

+

12.5MG; EQ 100MG TARTRATE

N021956 003 Aug 28, 2006

Jun CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB

SUN PHARM INDS LTD

12.5MG; EQ 10MG BASE

A078211 001 Mar 04, 2009

Apr CAHN

AB

12.5MG; EQ 20MG BASE

A078211 002 Mar 04, 2009

Apr CAHN

AB

25MG; EQ 20MG BASE

A078211 003 Mar 04, 2009

Apr CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

>D>

+

FERRIMILL LTD

10MG

N202880 001 Oct 25, 2013

Jun CAHN

+

10MG

N202880 001 Oct 25, 2013

Apr CAHN

>D>

15MG

N202880 002 Oct 25, 2013

Jun CAHN

15MG

N202880 002 Oct 25, 2013

Apr CAHN

>D>

20MG

N202880 003 Oct 25, 2013

Jun CAHN

20MG

N202880 003 Oct 25, 2013

Apr CAHN

CAPSULE, EXTENDED RELEASE;ORAL
ZOHYDRO ER

>D>		30MG	N202880	004	Oct 25, 2013	Jun CAHN
		30MG	N202880	004	Oct 25, 2013	Apr CAHN
>D>		40MG	N202880	005	Oct 25, 2013	Jun CAHN
		40MG	N202880	005	Oct 25, 2013	Apr CAHN
>D>		50MG	N202880	006	Oct 25, 2013	Jun CAHN
		50MG	N202880	006	Oct 25, 2013	Apr CAHN
>A>	+	PERNIX IRELAND PAIN	N202880	001	Oct 25, 2013	Jun CAHN
>A>		15MG	N202880	002	Oct 25, 2013	Jun CAHN
>A>		20MG	N202880	003	Oct 25, 2013	Jun CAHN
>A>		30MG	N202880	004	Oct 25, 2013	Jun CAHN
>A>		40MG	N202880	005	Oct 25, 2013	Jun CAHN
>A>		50MG	N202880	006	Oct 25, 2013	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
HYSINGLA

	+	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Mar CRLD
--	---	------------------	------	---------	-----	--------------	----------

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

AT		RISING PHARMS INC	2.5%	A040879	001	Aug 20, 2010	Mar CAHN
		POWDER;FOR RX COMPOUNDING					
		HYDRO-RX					
		@ X GEN PHARMS	100%	A085982	001		Apr DISC
		TABLET;ORAL					
		HYDROCORTISONE					
AB		HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015	Feb NEWA
AB			10MG	A083365	003	Feb 23, 2015	Feb NEWA
AB			20MG	A083365	001		Feb CMFD

HYDROCORTISONE ACETATE

POWDER;FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

		@ X GEN PHARMS	100%	A085981	001		Apr DISC
--	--	----------------	------	---------	-----	--	----------

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

		@ G AND W LABS INC	0.2%	A074489	001	Aug 12, 1998	Apr CAHN
--	--	--------------------	------	---------	-----	--------------	----------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OTIC

CORTISPORIN

>D>	AT	+	CITRON PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A060613	001	Jun CMS2
>A>	AT	+		1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N060613	001	Jun CMS2

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB		PADDOCK LLC	8MG	A204278	001	Apr 06, 2015	Mar NEWA
AB			12MG	A204278	002	Apr 06, 2015	Mar NEWA
AB			16MG	A204278	003	Apr 06, 2015	Mar NEWA

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

CYANOKIT

		@ SERB SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Apr CAHN
		+	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

PLAQUENIL

>A>	AB	+	CONCORDIA PHARMS INC	200MG	N009768	001	Jun CAHN
>D>	AB	+	SANOFI AVENTIS US	200MG	N009768	001	Jun CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

@ ACTAVIS LABS UT INC 125MG/ML

N017439 001

Mar CAHN

@ 250MG/ML

N017439 002

Mar CAHN

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

>A> AB ELITE LABS INC 10MG

A040600 001 Dec 28, 2004 Jun CAHN

>A> AB 25MG

A040602 001 Dec 28, 2004 Jun CAHN

>A> AB 50MG

A040604 001 Dec 28, 2004 Jun CAHN

AB HERITAGE PHARMA 10MG

A204279 001 Aug 20, 2014 Mar CAHN

AB 25MG

A204279 002 Aug 20, 2014 Mar CAHN

AB 50MG

A204279 003 Aug 20, 2014 Mar CAHN

>D> AB MIKAH PHARMA 10MG

A040600 001 Dec 28, 2004 Jun CAHN

AB 10MG

A040600 001 Dec 28, 2004 Mar CMFD

>D> AB 25MG

A040602 001 Dec 28, 2004 Jun CAHN

AB 25MG

A040602 001 Dec 28, 2004 Mar CMFD

>D> AB 50MG

A040604 001 Dec 28, 2004 Jun CAHN

AB 50MG

A040604 001 Dec 28, 2004 Mar CMFD

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB HERITAGE PHARMA EQ 25MG HYDROCHLORIDE

A201507 001 Jun 03, 2013 Mar CAHN

AB EQ 50MG HYDROCHLORIDE

A201507 002 Jun 03, 2013 Mar CAHN

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

AP MYLAN PHARMS INC 1GM/20ML (50MG/ML)

A201689 001 Nov 26, 2012 May CAHN

AP 3GM/60ML (50MG/ML)

A201689 002 Nov 26, 2012 May CAHN

ILOPERIDONE

TABLET; ORAL

FANAPT

+ VANDA PHARMS INC 1MG

N022192 001 May 06, 2009 Jan CAHN

2MG

N022192 002 May 06, 2009 Jan CAHN

4MG

N022192 003 May 06, 2009 Jan CAHN

6MG

N022192 004 May 06, 2009 Jan CAHN

8MG

N022192 005 May 06, 2009 Jan CAHN

10MG

N022192 006 May 06, 2009 Jan CAHN

12MG

N022192 007 May 06, 2009 Jan CAHN

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB G AND W LABS INC 5%

A200481 001 Apr 18, 2011 Apr CAHN

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

+ LEO PHARMA AS 0.015%

N202833 001 Jan 23, 2012 May CRLD

INSULIN GLARGINE RECOMBINANT

SOLUTION; SUBCUTANEOUS

TOUJEO SOLOSTAR

+ SANOFI US SERVICES 300 UNITS/ML (300 UNITS/ML)

N206538 001 Feb 25, 2015 Feb NEWA

INSULIN LISPRO RECOMBINANT

SOLUTION; SUBCUTANEOUS

HUMALOG KWIKPEN

+ ELI LILLY AND CO 200 UNITS/ML

N205747 001 May 26, 2015 May NEWA

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION

AFREZZA

SANOFI AVENTIS 12 UNITS/INH

N022472 003 Apr 17, 2015 Apr NEWA

IOHEXOLFOR SOLUTION; ORAL
ORALTAG

INTERPHARMA PRAHA AS 9.7GM/BOT

N205383 001 Mar 26, 2015 Mar NEWA

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-250

@ FRESENIUS KABI USA 51%

A074679 001 Apr 02, 1997 Jan DISC

IOPAMIDOL-300

@ FRESENIUS KABI USA 61%

A074679 002 Apr 02, 1997 Jan DISC

IOPAMIDOL-370

@ FRESENIUS KABI USA 76%

A074679 003 Apr 02, 1997 Jan DISC

ISOVUE-200

+ BRACCO 41%

N018735 006 Jul 07, 1987 Feb CTEC

ISOVUE-250

+ BRACCO 51%

N018735 007 Jul 06, 1992 Feb CTEC

+ 51%

N020327 002 Oct 12, 1994 Feb CTEC

ISOVUE-300

+ BRACCO 61%

N020327 003 Oct 12, 1994 Feb CTEC

ISOVUE-370

+ BRACCO 76%

N020327 004 Oct 12, 1994 Feb CTEC

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION

CONRAY

+ LIEBEL-FLARSHEIM 60%

N013295 001 Feb CAHN

CONRAY 30

+ LIEBEL-FLARSHEIM 30%

N016983 001 Feb CAHN

CONRAY 43

+ LIEBEL-FLARSHEIM 43%

N013295 002 Feb CAHN

SOLUTION; INTRAVESICAL

CYSTO-CONRAY II

LIEBEL-FLARSHEIM 17.2%

N017057 002 Feb CAHN

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 160

@ LIEBEL-FLARSHEIM 34%

N019710 003 Dec 30, 1988 Feb CAHN

OPTIRAY 240

+ LIEBEL-FLARSHEIM 51%

N019710 002 Dec 30, 1988 Feb CAHN

@ 51%

N020923 001 May 28, 1998 Feb CAHN

OPTIRAY 300

+ LIEBEL-FLARSHEIM 64%

N019710 004 Jan 22, 1992 Feb CAHN

+ 64%

N020923 004 May 13, 1999 Feb CAHN

OPTIRAY 320

+ LIEBEL-FLARSHEIM 68%

N019710 001 Dec 30, 1988 Feb CAHN

@ 68%

N020923 002 May 29, 1998 Feb CAHN

OPTIRAY 350

+ LIEBEL-FLARSHEIM 74%

N019710 005 Jan 22, 1992 Feb CAHN

+ 74%

N020923 003 May 28, 1998 Feb CAHN

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION

HEXABRIX

@ GUERBET 39.3%; 19.6%

N018905 002 Jul 26, 1985 May DISC

IRBESARTAN

TABLET; ORAL

IRBESARTAN

AB JUBILANT GENERICS 75MG

A203534 001 Feb 23, 2015 Feb NEWA

AB 150MG

A203534 002 Feb 23, 2015 Feb NEWA

AB 300MG

A203534 003 Feb 23, 2015 Feb NEWA

IRON DEXTRAN

INJECTABLE; INJECTION

INFED

BP + ACTAVIS LABS UT INC EQ 50MG IRON/ML

N017441 001 Mar CAHN

ISAVUCONAZONIUM SULFATE

CAPSULE;ORAL

CRESEMBA

+	ASTELLAS	186MG	N207500	001	Mar 06, 2015	Mar NEWA
---	----------	-------	---------	-----	--------------	----------

POWDER; IV (INFUSION)

CRESEMBA

+	ASTELLAS	372MG	N207501	001	Mar 06, 2015	Mar NEWA
---	----------	-------	---------	-----	--------------	----------

ISOSORBIDE DINITRATE

TABLET;ORAL

ISORDIL

AB	VALEANT PHARMS NORTH	5MG	N012093	007	Jul 29, 1988	Feb CAHN
	@	10MG	N012093	002	Jul 29, 1988	Feb CAHN
	@	20MG	N012093	006	Jul 29, 1988	Feb CAHN
	@	30MG	N012093	005	Jul 29, 1988	Feb CAHN
+		40MG	N012093	001	Jul 29, 1988	Feb CAHN

ISOTRETINOIN

CAPSULE;ORAL

ABSORICA

RANBAXY

25MG

N021951 005 Aug 15, 2014 Feb NEWA

35MG

N021951 006 Aug 15, 2014 Feb NEWA

SOTRET

AB	SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Apr CAHN
AB		20MG	A076041	002	Dec 24, 2002	Apr CAHN
AB		30MG	A076503	001	Jun 20, 2003	Apr CAHN
AB		40MG	A076041	003	Dec 24, 2002	Apr CAHN

ZENATANE

AB	DR REDDYS LABS LTD	30MG	A202099	004	Feb 23, 2015	Feb NEWA
----	--------------------	------	---------	-----	--------------	----------

ISRADIPINE

CAPSULE;ORAL

ISRADIPINE

AB	ELITE LABS INC	2.5MG	A077169	001	Apr 24, 2006	Mar CAHN
AB		5MG	A077169	002	Apr 24, 2006	Mar CAHN

IVABRADINE HYDROCHLORIDE

TABLET;ORAL

CORLANOR

AMGEN INC

EQ 5MG BASE

N206143 001 Apr 15, 2015 Apr NEWA

+		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Apr NEWA
---	--	---------------	---------	-----	--------------	----------

IVACAFTOR

GRANULE;ORAL

KALYDECO

VERTEX PHARMS INC

50MG/PACKET

N207925 001 Mar 17, 2015 Mar NEWA

+		75MG/PACKET	N207925	002	Mar 17, 2015	Mar NEWA
---	--	-------------	---------	-----	--------------	----------

IXABEPILONE

INJECTABLE;IV (INFUSION)

IXEMPRA KIT

>D>	+	BRISTOL MYERS SQUIBB	15MG/VIAL	N022065	001	Oct 16, 2007	Jun CAHN
>D>	+		45MG/VIAL	N022065	002	Oct 16, 2007	Jun CAHN
>A>	+	R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007	Jun CAHN
>A>	+		45MG/VIAL	N022065	002	Oct 16, 2007	Jun CAHN

KANAMYCIN SULFATE

INJECTABLE;INJECTION

KANAMYCIN

>A>	@	EUROHLTH INTL SARL	EQ 75MG BASE/2ML	A062324	001		Jun CAHN
>A>	@		EQ 500MG BASE/2ML	A062324	002		Jun CAHN
>A>	@		EQ 1GM BASE/3ML	A062324	003		Jun CAHN
>D>	@	HIKMA MAPLE	EQ 75MG BASE/2ML	A062324	001		Jun CAHN
>D>	@		EQ 500MG BASE/2ML	A062324	002		Jun CAHN
>D>	@		EQ 1GM BASE/3ML	A062324	003		Jun CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

	@ CLARIS PHARMASERVICE	15MG/ML	A075631	002	Jun 29, 2001	Apr CAHN
	@	30MG/ML	A075631	001	Jun 29, 2001	Apr CAHN
>A>	@ EUROHLTH INTL SARL	15MG/ML	A075772	001	Jul 21, 2004	Jun CAHN
>A>	@	30MG/ML	A075772	002	Jul 21, 2004	Jun CAHN
>D>	@ HIKMA MAPLE	15MG/ML	A075772	001	Jul 21, 2004	Jun CAHN
>D>	@	30MG/ML	A075772	002	Jul 21, 2004	Jun CAHN
AP	MYLAN PHARMS INC	15MG/ML	A078299	001	Jul 16, 2007	Apr CAHN
AP		30MG/ML	A078299	002	Jul 16, 2007	Apr CAHN
	SPRAY, METERED; NASAL					
	SPRIX					
	+ EGALET US INC	15.75MG/SPRAY	N022382	001	May 14, 2010	Jan CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION

OMIDRIA

	+ OMEROS	EQ 4.24MG BASE/ML; EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	Feb CPOT
--	----------	--------------------------------------	---------	-----	--------------	----------

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

@ CLARIS PHARMASERVICE 5MG/ML

A076051 001 Jul 05, 2002 Apr CAHN

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	MUTUAL PHARM	100MG	A075215	001	Jul 29, 1999	Jan CMFD
AB		200MG	A075215	002	Jul 29, 1999	Jan CMFD
AB		300MG	A075215	003	Jul 29, 1999	Jan CMFD

LACTULOSE

SOLUTION; ORAL, RECTAL

LACTULOSE

AA	BIO-PHARM INC	10GM/15ML	A203762	001	Mar 27, 2015	Mar NEWA
----	---------------	-----------	---------	-----	--------------	----------

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET; ORAL

DUTREBIS

	+ MERCK SHARP DOHME	150MG; EQ 300MG BASE	N206510	001	Feb 06, 2015	Feb NEWA
--	---------------------	----------------------	---------	-----	--------------	----------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	STRIDES ARCOLAB LTD	150MG; 300MG	A079128	001	May 13, 2015	Apr NEWA
----	---------------------	--------------	---------	-----	--------------	----------

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@ HIKMA PHARMS

25MG

A078134 001 Apr 19, 2011 May DISC

@

100MG

A078134 002 Apr 19, 2011 May DISC

@

150MG

A078134 003 Apr 19, 2011 May DISC

@

200MG

A078134 004 Apr 19, 2011 May DISC

LAPATINIB DITOSYLATE

TABLET; ORAL

TYKERB

	+ NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059	001	Mar 13, 2007	Mar CAHN
--	------------------------	---------------	---------	-----	--------------	----------

LENVATINIB MESYLATE

CAPSULE; ORAL

LENNIMA

EISAI INC

EQ 4MG BASE

N206947 001 Feb 13, 2015 Feb NEWA

+

EQ 10MG BASE

N206947 002 Feb 13, 2015 Feb NEWA

LEVETIRACETAM

SOLUTION; ORAL

LEVETIRACETAM

AA	PHARM ASSOC	100MG/ML	A201157	001	Jun 04, 2015	May NEWA
----	-------------	----------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

ELEPSIA XR

	SPARC	1GM	N204417	001	Mar 02, 2015	Mar NEWA
		1.5GM	N204417	002	Mar 02, 2015	Mar NEWA
	LEVETIRACETAM					
	APOTEX INC	1GM	A202958	001	Feb 25, 2015	Feb NEWA
AB	PRINSTON INC	500MG	A203468	001	May 21, 2015	May NEWA
AB		750MG	A203468	002	May 21, 2015	May NEWA

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

	@ TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	Apr DISC
--	-------------------	----------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	APOTEX INC	5MG	A203027	001	Feb 13, 2015	Feb NEWA
>A> AB	SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015	Jun NEWA

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP	CLARIS PHARMASERVICE	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr CAHN
	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	CLARIS PHARMASERVICE	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Apr CAHN
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Apr CAHN
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Apr CAHN

TABLET;ORAL

LEVOFLOXACIN

>A> AB	JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun NEWA
>A> AB		500MG	A203613	002	Jun 19, 2015	Jun NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

	SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Feb NEWA
	SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Feb NEWA
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE

LILETTA

	MEDICINES360	52MG	N206229	001	Feb 26, 2015	Feb NEWA
--	--------------	------	---------	-----	--------------	----------

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

+	SENTYNL THERAPS INC	2MG	A074278	001	Mar 31, 2000	Apr CAHN
---	---------------------	-----	---------	-----	--------------	----------

LIDOCAINE

PATCH;TOPICAL

LIDOCAINE

AB	ACTAVIS LABS UT INC	5%	A200675	001	Aug 23, 2012	Mar CAHN
----	---------------------	----	---------	-----	--------------	----------

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

	@ EUROHLTH INTL SARL	1%	A080407	001		Mar CAHN
	@	2%	A080407	002		Mar CAHN
AP	MYLAN PHARMS INC	0.5%	A091056	001	Dec 08, 2010	May CAHN
AP		0.5%	A091058	001	Sep 30, 2010	May CAHN
AP		1%	A091056	002	Dec 08, 2010	May CAHN
AP		1%	A091058	002	Sep 30, 2010	May CAHN
	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					
	@ EUROHLTH INTL SARL	1%	A084625	001		Feb CAHN
	@	2%	A084625	002		Feb CAHN
AP	MYLAN PHARMS INC	2%	A090665	001	Sep 27, 2010	May CAHN

JELLY; TOPICAL

ANESTACON

@ BANNER LIFE SCIENCES 2%

A080429 001

Jan CAHN

LIDOCAINE HYDROCHLORIDE

@ G AND W LABS INC 2%

A081318 001 Apr 29, 1993

Apr CAHN

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

EMLA

AB + ACTAVIS LABS UT INC 2.5%; 2.5%

N019941 001 Dec 30, 1992

Feb CAHN

LINACLOTIDE

CAPSULE; ORAL

LINZESS

FOREST LABS LLC

145MCG

N202811 001 Aug 30, 2012

Mar CAHN

+

290MCG

N202811 002 Aug 30, 2012

Mar CAHN

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

AP + PHARMACIA AND UPJOHN EQ 300MG BASE/ML

N050317 001

May CFTG

LINCOMYCIN

AP X-GEN PHARMS INC EQ 300MG BASE/ML

A201746 001 Jun 04, 2015

May NEWA

LINEZOLID

FOR SUSPENSION; ORAL

LINEZOLID

AB ROXANE 100MG/5ML

A200068 001 Jun 03, 2015

May NEWA

ZYVOX

AB + PHARMACIA AND UPJOHN 100MG/5ML

N021132 001 Apr 18, 2000

May CFTG

SOLUTION; IV (INFUSION)

LINEZOLID

>A> AP HOSPIRA INC 600MG/300ML (2MG/ML)

A205442 001 Jul 07, 2015

Jun NEWA

AP TEVA PHARMS 600MG/300ML (2MG/ML)

A200222 001 Jun 27, 2012

May CDFR

>A> LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>A> + HOSPIRA INC 600MG/300ML (2MG/ML)

N206473 001 Jun 18, 2015

Jun NEWA

ZYVOX

PHARMACIA AND UPJOHN 200MG/100ML (2MG/ML)

N021131 001 Apr 18, 2000

May CDFR

400MG/200ML (2MG/ML)

N021131 002 Apr 18, 2000

May NEWA

AP + 600MG/300ML (2MG/ML)

N021131 003 Apr 18, 2000

May NEWA

TABLET; ORAL

LINEZOLID

AB TEVA PHARMS USA 600MG

A078061 001 May 18, 2015

May NEWA

ZYVOX

AB + PHARMACIA AND UPJOHN 600MG

N021130 002 Apr 18, 2000

May CFTG

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB SUN PHARM INDS LTD 2.5MG

A075944 001 Jul 01, 2002

Apr CAHN

AB 5MG

A075944 002 Jul 01, 2002

Apr CAHN

AB 10MG

A075944 003 Jul 01, 2002

Apr CAHN

AB 20MG

A075944 004 Jul 01, 2002

Apr CAHN

AB 30MG

A075944 006 Feb 11, 2003

Apr CAHN

AB 40MG

A075944 005 Jul 01, 2002

Apr CAHN

ZESTRIL

AB ALVOGEN IPCO SARL 2.5MG

N019777 005 Apr 29, 1993

Feb CAHN

AB 5MG

N019777 001 May 19, 1988

Feb CAHN

AB 10MG

N019777 002 May 19, 1988

Feb CAHN

AB 20MG

N019777 003 May 19, 1988

Feb CAHN

AB 30MG

N019777 006 Jan 20, 1999

Feb CAHN

AB + 40MG

N019777 004 May 19, 1988

Feb CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB ALEMBIC PHARMS LTD 300MG

A204445 001 Jun 10, 2015

May NEWA

@ HIKMA INTL PHARMS 450MG

A076490 001 Jun 17, 2003

Feb DISC

LOMITAPIDE MESYLATECAPSULE;ORAL
JUXTAPID

AEGERION

EQ 30MG BASE
EQ 40MG BASE
EQ 60MG BASEN203858 004 Apr 23, 2015 Apr NEWA
N203858 005 Apr 23, 2015 Apr NEWA
N203858 006 Apr 23, 2015 Apr NEWALOMUSTINECAPSULE;ORAL
GLEOSTINE

CORDEN PHARMA

5MG

N017588 004 Dec 19, 2014 Jan NEWA

LOPINAVIR; RITONAVIR>D> CAPSULE;ORAL
>D> KALETRA>D> + ABBVIE 133.3MG;33.3MG
>A> @ 133.3MG;33.3MGN021226 001 Sep 15, 2000 Jun DISC
N021226 001 Sep 15, 2000 Jun DISCLORAZEPAMINJECTABLE;INJECTION
ATIVAN>A> AP + EUROHLTH INTL SARL 2MG/ML
>A> AP + 4MG/ML
>D> AP + HIKMA MAPLE 2MG/ML
>D> AP + 4MG/MLN018140 001 Jun CAHN
N018140 002 Jun CAHN
N018140 001 Jun CAHN
N018140 002 Jun CAHNTABLET;ORAL
LORAZEPAMAB SUN PHARM INDS LTD 0.5MG
AB 1MG
AB 2MGA076045 001 Aug 29, 2001 Apr CAHN
A076045 002 Aug 29, 2001 Apr CAHN
A076045 003 Aug 29, 2001 Apr CAHNLOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB WATSON LABS 25MG
AB 50MG
AB 100MGA091129 001 Oct 06, 2010 Feb CMFD
A091129 002 Oct 06, 2010 Feb CMFD
A091129 003 Oct 06, 2010 Feb CMFDLOVASTATINTABLET, EXTENDED RELEASE;ORAL
ALTOPREV

@ COVIS PHARMA SARL

10MG
20MG
40MG
60MGN021316 001 Jun 26, 2002 May CAHN
N021316 002 Jun 26, 2002 May CAHN
N021316 003 Jun 26, 2002 May CAHN
N021316 004 Jun 26, 2002 May CAHNLOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL

LOXITANE C

@ ACTAVIS LABS UT INC

EQ 25MG BASE/ML

N017658 001 Mar CAHN

INJECTABLE;INJECTION
LOXITANE IM

@ ACTAVIS LABS UT INC

EQ 50MG BASE/ML

N018039 001 Mar CAHN

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

AB ELITE LABS INC EQ 5MG BASE
AB EQ 10MG BASE
AB EQ 25MG BASE
AB EQ 50MG BASEA076868 001 Aug 04, 2005 May CAHN
A076868 002 Aug 04, 2005 May CAHN
A076868 003 Aug 04, 2005 May CAHN
A076868 004 Aug 04, 2005 May CAHN

LOXITANE

@ ACTAVIS LABS UT INC

EQ 5MG BASE
EQ 10MG BASE
EQ 25MG BASE
EQ 50MG BASEN017525 001 Mar CAHN
N017525 002 Mar CAHN
N017525 003 Mar CAHN
N017525 004 Mar CAHN

TABLET;ORAL

LOXITANE

@ ACTAVIS LABS UT INC

EQ 10MG BASE
EQ 25MG BASE
EQ 50MG BASEN017525 006 Mar CAHN
N017525 007 Mar CAHN
N017525 008 Mar CAHN

LUCINACTANTSUSPENSION; INTRATRACHEAL
SURFAXIN

@ DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	May DISC
------------------	-------	---------	-----	--------------	----------

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDEINJECTABLE; INJECTION
PLASMA-LYTE 56 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	32MG/100ML; 128MG/100ML; 234MG/100ML	N019047	001	Jun 15, 1984	Mar DISC
-------------------	--------------------------------------	---------	-----	--------------	----------

MAGNESIUM SULFATESOLUTION; INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

AP	EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Apr CDFR
AP	+ FRESenius KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986	Apr CPOT
AP	+ HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000	Apr CDFR
	HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Apr NEWA

MAGNESIUM SULFATESOLUTION; INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

+ FRESenius KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	Apr NEWA
----------------------	--------------------	---------	-----	--------------	----------

MANNITOLINJECTABLE; INJECTION
MANNITOL 25%

@ IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987	Mar CAHN
@	12.5GM/50ML	A089240	001	May 06, 1987	Mar CAHN

MECLIZINE HYDROCHLORIDETABLET; ORAL
MECLIZINE HYDROCHLORIDE

>D> AA	VINTAGE PHARMS	12.5MG	A040179	001	Jan 30, 1997	Jun DISC
>A>	@	12.5MG	A040179	001	Jan 30, 1997	Jun DISC
>D> AA		25MG	A040179	002	Jan 30, 1997	Jun DISC
>A>	@	25MG	A040179	002	Jan 30, 1997	Jun DISC

MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
NAMENDA XR

FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Mar CAHN
	14MG	N022525	002	Jun 21, 2010	Mar CAHN
	21MG	N022525	003	Jun 21, 2010	Mar CAHN
+	28MG	N022525	004	Jun 21, 2010	Mar CAHN

SOLUTION; ORAL
NAMENDA

+ FOREST LABS LLC	2MG/ML	N021627	001	Apr 18, 2005	Mar CAHN
-------------------	--------	---------	-----	--------------	----------

TABLET; ORAL
MEMANTINE

AB	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Mar CMFD
AB		10MG	A090058	002	May 05, 2010	Mar CMFD
AB	MEMANTINE HYDROCHLORIDE					
AB	AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar NEWA
AB		10MG	A090041	002	Apr 10, 2015	Mar NEWA
>D>	@ DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jun CMFD
>A> AB		5MG	A090048	001	Apr 14, 2010	Jun CMFD
>D>	@	10MG	A090048	002	Apr 14, 2010	Jun CMFD
>A> AB		10MG	A090048	002	Apr 14, 2010	Jun CMFD
AB	LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar NEWA
AB		10MG	A090051	002	Apr 10, 2015	Mar NEWA
>D>	@ MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Jun CMFD
>A> AB		5MG	A079225	001	Jan 30, 2015	Jun CMFD
	@	5MG	A079225	001	Jan 30, 2015	Mar DISC
AB		5MG	A079225	001	Jan 30, 2015	Jan NEWA
>D>	@	10MG	A079225	002	Jan 30, 2015	Jun CMFD
>A> AB		10MG	A079225	002	Jan 30, 2015	Jun CMFD
	@	10MG	A079225	002	Jan 30, 2015	Mar DISC
AB		10MG	A079225	002	Jan 30, 2015	Jan NEWA
AB	TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	May CMFD
AB		10MG	A090052	002	Oct 25, 2011	May CMFD

TABLET; ORAL

NAMENDA

AB	FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar CAHN
AB	+	10MG	N021487	002	Oct 16, 2003	Mar CAHN

MENOTROPINS (FSH; LH)

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

REPRONEX

@ FERRING	75 IU/VIAL; 75 IU/VIAL	N021047	001	Aug 27, 1999	May DISC
-----------	------------------------	---------	-----	--------------	----------

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

AP	EUROHLTH INTL SARL	25MG/ML	A080445	001		Feb CAHN
AP		50MG/ML	A080445	002		Feb CAHN
AP		75MG/ML	A080445	003		Feb CAHN
AP		100MG/ML	A080445	004		Feb CAHN
	@ IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989	May CAHN
	@	50MG/ML	A089782	001	Mar 31, 1989	Mar CAHN
	@	50MG/ML	A089783	001	Mar 31, 1989	Mar CAHN
	@	50MG/ML	A089784	001	Mar 31, 1989	Mar CAHN
	@	75MG/ML	A089785	001	Mar 31, 1989	Mar CAHN
	@	100MG/ML	A089786	001	Mar 31, 1989	Mar CAHN
	@	100MG/ML	A089787	001	Mar 31, 1989	Mar CAHN
	@	100MG/ML	A089788	001	Mar 31, 1989	Mar CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

>D>	@ BAXTER HLTHCARE CORP	25MG/ML; 25MG/ML	N011730	001		Jun CAHN
>A>	@ EUROHLTH INTL SARL	25MG/ML; 25MG/ML	N011730	001		Jun CAHN

MEROPENEM

POWDER; IV (INFUSION)

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015	Apr NEWA
	1GM/VIAL	N202106	002	Apr 30, 2015	Apr NEWA

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

NORINYL

@ ACTAVIS LABS UT INC	0.1MG; 2MG	N013625	004		Mar CAHN
-----------------------	------------	---------	-----	--	----------

TABLET; ORAL-21

NORINYL 1+50 21-DAY

@ ACTAVIS LABS UT INC	0.05MG; 1MG	N013625	002		Mar CAHN
-----------------------	-------------	---------	-----	--	----------

TABLET; ORAL-28

NORINYL 1+50 28-DAY

+ ACTAVIS LABS UT INC	0.05MG; 1MG	N016659	001		Mar CAHN
-----------------------	-------------	---------	-----	--	----------

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

@ MYLAN SPECLT	0.4%	A071786	001	Aug 05, 1988	Apr DISC
@	0.6%	A070804	001	Aug 17, 1987	Apr DISC
@ WOCKHARDT	0.4%	A075586	001	May 30, 2002	Apr DISC
@	0.6%	A075586	002	May 30, 2002	Apr DISC

SYRUP; ORAL

METAPROTERENOL SULFATE

@ G AND W LABS INC	10MG/5ML	A072761	001	Feb 27, 1992	Apr CAHN
@	10MG/5ML	A073034	001	Aug 30, 1991	Apr CAHN

METAXALONE

TABLET; ORAL

METAXALONE

>A>	COREPHARMA	400MG	A040486	001	Feb 27, 2015	Feb NEWA
		640MG	N022503	001	Jun 01, 2015	Jun NEWA

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

+	SUN PHARM INDS LTD	500MG/5ML	N021591	001	Sep 11, 2003	Apr CAHN
---	--------------------	-----------	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET; ORAL

PRANDIMET

>D>		NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008	Jun CFTG
>A>	AB		500MG;1MG	N022386	001	Jun 23, 2008	Jun CFTG
>D>		+	500MG;2MG	N022386	002	Jun 23, 2008	Jun CFTG
>A>	AB	+	500MG;2MG	N022386	002	Jun 23, 2008	Jun CFTG
>A>		REPAGLINIDE AND METFORMIN HYDROCHLORIDE					
>A>	AB	LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015	Jun NEWA
>A>	AB		500MG;2MG	A200624	002	Jul 15, 2015	Jun NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

@ SB PHARMCO

@

@

@

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA

+

500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002	May DISC
500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002	May DISC
1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003	May DISC
1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003	May DISC
500MG;EQ 2MG BASE	A077337	001	May 07, 2014	May CTEC
500MG;EQ 4MG BASE	A077337	002	May 07, 2014	May CTEC
1GM;EQ 4MG BASE	A077337	004	May 07, 2014	May CRLD
1GM;EQ 2MG BASE	A077337	003	May 07, 2014	May CTEC

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	HERITAGE PHARMA	5MG	A040734	001	Dec 14, 2007	Mar CAHN
AB		10MG	A040734	002	Dec 14, 2007	Mar CAHN

METHOCARBAMOL

SOLUTION; IM-IV

ROBAXIN

>A>	AP	+	EUROHLTH INTL SARL	1GM/10ML (100MG/ML)	N011790	001	Jun CAHN
>D>	AP	+	HIKMA MAPLE	1GM/10ML (100MG/ML)	N011790	001	Jun CAHN

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999	May CMFD
----	--------------------	-----------------	---------	-----	--------------	----------

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	MYLAN PHARMS INC	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012	May CAHN
----	------------------	------------------------------------	---------	-----	--------------	----------

TABLET; ORAL

METHOTREXATE SODIUM

AB	ORION CORP ORION	EQ 2.5MG BASE	A201749	001	May 21, 2015	May NEWA
----	------------------	---------------	---------	-----	--------------	----------

METHOXSALLEN

CAPSULE; ORAL

METHOXSALLEN

AB	ACTAVIS INC	10MG	A202603	001	Jun 09, 2015	May NEWA
----	-------------	------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

APTENSIO XR

RHODES PHARMS

		10MG	N205831	001	Apr 17, 2015	Apr NEWA
		15MG	N205831	002	Apr 17, 2015	Apr NEWA
		20MG	N205831	003	Apr 17, 2015	Apr NEWA
		30MG	N205831	004	Apr 17, 2015	Apr NEWA
		40MG	N205831	005	Apr 17, 2015	Apr NEWA
		50MG	N205831	006	Apr 17, 2015	Apr NEWA
		60MG	N205831	007	Apr 17, 2015	Apr NEWA
	+					
		RITALIN LA				
AB1	NOVARTIS	40MG	N021284	003	Jun 05, 2002	Feb CRLD
	+	60MG	N021284	005	Oct 27, 2014	Feb CRLD

TABLET, CHEWABLE;ORAL
METHYLIN

AB	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Feb CFTG
AB		5MG	N021475	002	Apr 15, 2003	Feb CFTG
AB	+	10MG	N021475	003	Apr 15, 2003	Feb CFTG
	METHYLPHENIDATE HYDROCHLORIDE					
AB	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Feb NEWA
AB		5MG	A204115	002	Feb 25, 2015	Feb NEWA
AB		10MG	A204115	003	Feb 25, 2015	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL
METHYLIN ER

AB	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	May CTEC
	METHYLPHENIDATE HYDROCHLORIDE					
AB	ABHAI	10MG	A207488	001	Jun 09, 2015	May NEWA
AB		20MG	A207488	002	Jun 09, 2015	May NEWA

METOPROLOL TARTRATE

INJECTABLE;INJECTION
METOPROLOL TARTRATE

AP	CLARIS PHARMASERVICE	1MG/ML	A078950	001	Apr 29, 2013	Apr CAHN
	TABLET;ORAL					
	METOPROLOL TARTRATE					
	MYLAN	37.5MG	A076704	004	Mar 18, 2015	Mar NEWA
		75MG	A076704	005	Mar 18, 2015	Mar NEWA

METRONIDAZOLE

CREAM;TOPICAL
NORITATE

+	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997	Feb CAHN
---	----------------------	----	---------	-----	--------------	----------

GEL;VAGINAL

METRONIDAZOLE

+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb CAHN
	NUVESSA					
+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb CTNA

INJECTABLE;INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	500MG/100ML	A078084	001	Mar 31, 2008	Apr CAHN
----	----------------------	-------------	---------	-----	--------------	----------

TABLET;ORAL

METRONIDAZOLE

AB	AUROBINDO PHARMA LTD	250MG	A203974	001	May 29, 2015	May NEWA
AB		500MG	A203974	002	May 29, 2015	May NEWA

MICONAZOLE

TABLET;BUCCAL
ORAVIG

+	DARA BIOSCIENCES	50MG	N022404	001	Apr 16, 2010	Apr CAHN
---	------------------	------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr CAHN
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr CAHN
>A> AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jun CAHN
>A> AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jun CAHN
>D> AP	HIKMA MAPLE	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jun CAHN
>D> AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jun CAHN
	@ IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000	Apr CAHN
	@ WOCKHARDT	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Mar DISC
	@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Mar DISC
	@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Mar DISC
	@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Mar DISC

SYRUP;ORAL

MIDAZOLAM HYDROCHLORIDE

AA	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002	Apr CAHN
----	--------------------	----------------	---------	-----	--------------	----------

MIGLITOL

TABLET;ORAL
GLYSET

AB	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Mar CTEC
AA		25MG	N020682	001	Dec 18, 1996	Feb CFTG
AB		50MG	N020682	002	Dec 18, 1996	Mar CTEC

TABLET;ORAL
GLYSET

AA		50MG	N020682	002	Dec 18, 1996	Feb CFTG
AB	+	100MG	N020682	003	Dec 18, 1996	Mar CTEC
AA	+	100MG	N020682	003	Dec 18, 1996	Feb CFTG
MIGLITOL						
AB	ORIENT PHARMA CO LTD	25MG	A203965	001	Feb 24, 2015	Mar CTEC
AA		25MG	A203965	001	Feb 24, 2015	Feb NEWA
AB		50MG	A203965	002	Feb 24, 2015	Mar CTEC
AA		50MG	A203965	002	Feb 24, 2015	Feb NEWA
AB		100MG	A203965	003	Feb 24, 2015	Mar CTEC
AA		100MG	A203965	003	Feb 24, 2015	Feb NEWA

MILRINONE LACTATE

INJECTABLE;INJECTION
MILRINONE LACTATE

	AP	BEDFORD	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan	CRLD	
>A>	AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jun	CAHN	
	AP	+	HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A077966	001	Dec 03, 2010	Jan	CRLD
>D>	AP	HIKMA MAPLE	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jun	CAHN	

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL
MINOCYCLINE HYDROCHLORIDE

>D> AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun CAHN
AB		EQ 50MG BASE	A065062	001	Nov 30, 2000	Apr CAHN
>D> AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Apr CAHN
>D> AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Apr CAHN
>A> AB	TORRENT PHARMA INC	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun CAHN
>A> AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun CAHN
>A> AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun CAHN

CAPSULE, EXTENDED RELEASE;ORAL
XIMINO

@	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr CAHN
@		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Apr CAHN
@		EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr CAHN
@		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Apr CAHN
@		EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr CAHN

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

>D> AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun CAHN
AB		EQ 50MG BASE	A065156	001	Jan 06, 2004	Apr CAHN
>D> AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Apr CAHN
>D> AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Apr CAHN
>A> AB	TORRENT PHARMA INC	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun CAHN
>A> AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun CAHN
>A> AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Apr CAHN
AB		EQ 80MG BASE	A091118	004	Sep 25, 2014	Apr CAHN
AB		EQ 90MG BASE	A091118	005	Sep 25, 2014	Apr CAHN
AB		EQ 105MG BASE	A091118	006	Sep 25, 2014	Apr CAHN
AB		EQ 135MG BASE	A091118	008	Sep 25, 2014	Apr CAHN

MIVACURIUM CHLORIDE

INJECTABLE;INJECTION
MIVACURIUM CHLORIDE

@	MYLAN PHARMS INC	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009	May CAHN
---	------------------	----------------	---------	-----	--------------	----------

SOLUTION;INTRAVENOUS
MIVACRON

AB	ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jan NEWA
+		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jan NEWA

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOLINDONE HYDROCHLORIDE

	COREPHARMA	5MG	A090453	001	Mar 20, 2015	Mar NEWA
		10MG	A090453	002	Mar 20, 2015	Mar NEWA
+		25MG	A090453	003	Mar 20, 2015	Mar NEWA

MONTELUKAST SODIUM

TABLET; ORAL

MONTELUKAST SODIUM

AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A201522	001	Aug 03, 2012	Mar CAHN
----	----------------------	--------------	---------	-----	--------------	----------

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB	HETERO LABS LTD V	EQ 4MG BASE	A204093	001	May 22, 2015	May NEWA
AB		EQ 5MG BASE	A204093	002	May 22, 2015	May NEWA
AB	JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Feb NEWA
AB		EQ 5MG BASE	A203795	002	Feb 27, 2015	Feb NEWA
AB	KREMERS URBAN PHARMS	EQ 4MG BASE	A200405	001	Aug 03, 2012	Mar CAHN
AB		EQ 5MG BASE	A200405	002	Aug 03, 2012	Mar CAHN
AB	MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar 12, 2015	Feb NEWA
AB		EQ 5MG BASE	A203582	002	Mar 12, 2015	Feb NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

AB1	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Mar CAHN
AB1			20MG	N020616	001	Jul 03, 1996	Mar CAHN
AB1			30MG	N020616	004	Mar 09, 2001	Mar CAHN
AB1			40MG	N020616	009	Jul 09, 2012	May CTEC
			40MG	N020616	009	Jul 09, 2012	Mar CAHN
AB1			50MG	N020616	002	Jul 03, 1996	Mar CAHN
AB1			60MG	N020616	005	Mar 09, 2001	Mar CAHN
AB1			70MG	N020616	010	Jul 09, 2012	May CTEC
			70MG	N020616	010	Jul 09, 2012	Mar CAHN
AB1			80MG	N020616	006	Oct 27, 2006	Mar CAHN
AB1	+		100MG	N020616	003	Jul 03, 1996	Mar CAHN
			130MG	N020616	011	Jul 09, 2012	Mar CAHN
			150MG	N020616	012	Jul 09, 2012	Mar CAHN
AB1	+		200MG	N020616	007	Feb 27, 2007	Mar CAHN
		MORPHINE SULFATE					
AB1		TEVA PHARMS USA	40MG	A202718	007	Jun 03, 2015	May NEWA
AB1			70MG	A202718	008	Jun 03, 2015	May NEWA

INJECTABLE; INJECTION

DURAMORPH PF

>A>	AP	+	EUROHLTH INTL SARL	0.5MG/ML	N018565	001	Sep 18, 1984	Jun CAHN
>A>	AP	+		1MG/ML	N018565	002	Sep 18, 1984	Jun CAHN
>D>	AP	+	HIKMA MAPLE	0.5MG/ML	N018565	001	Sep 18, 1984	Jun CAHN
>D>	AP	+		1MG/ML	N018565	002	Sep 18, 1984	Jun CAHN
			INFUMORPH					
>A>		+	EUROHLTH INTL SARL	10MG/ML	N018565	003	Jul 19, 1991	Jun CAHN
>A>		+		25MG/ML	N018565	004	Jul 19, 1991	Jun CAHN
>D>		+	HIKMA MAPLE	10MG/ML	N018565	003	Jul 19, 1991	Jun CAHN
>D>		+		25MG/ML	N018565	004	Jul 19, 1991	Jun CAHN

MORPHINE SULFATE

AP		EUROHLTH INTL SARL	4MG/ML	A205758	001	May 21, 2015	May NEWA
AP			8MG/ML	A205758	002	May 21, 2015	May NEWA
AP			10MG/ML	A205758	003	May 21, 2015	May NEWA
AP	+	HOSPIRA INC	4MG/ML	N202515	002	Nov 14, 2011	May CFTG
AP	+		8MG/ML	N202515	003	Nov 14, 2011	May CFTG
AP	+		10MG/ML	N202515	004	Nov 14, 2011	May CFTG

SOLUTION; ORAL

MORPHINE SULFATE

AA		TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	May NEWA
AA			100MG/5ML	A203518	002	May 12, 2015	May NEWA

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB		ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar NEWA
AB			30MG	A203849	002	Apr 06, 2015	Mar NEWA
AB			60MG	A203849	003	Apr 06, 2015	Mar NEWA
AB			100MG	A203849	004	Apr 06, 2015	Mar NEWA
AB			200MG	A203849	005	Apr 06, 2015	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

AB	SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr CAHN
AB		30MG	A078761	002	May 11, 2012	Apr CAHN
AB		60MG	A078761	003	May 11, 2012	Apr CAHN
AB		100MG	A078761	004	May 11, 2012	Apr CAHN
AB		200MG	A078761	005	May 11, 2012	Apr CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)
MOXIFLOXACIN HYDROCHLORIDE

+	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Apr NEWA
---	--------------------	----------------------------------------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC
MOXEZA

AT2	+	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May CFTG
MOXIFLOXACIN HYDROCHLORIDE							
AT1		LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	May CTEC
AT2			EQ 0.5% BASE	A204079	001	May 28, 2015	May NEWA
AT1		WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar 06, 2015	May CTEC
AT			EQ 0.5% BASE	A202525	001	Mar 06, 2015	Feb NEWA
VIGAMOX							
AT1	+	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	May CTEC

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION
NALBUPHINE HYDROCHLORIDE

@	IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar CAHN
@		10MG/ML	A072071	001	Apr 10, 1989	Mar CAHN
@		10MG/ML	A072072	001	Apr 10, 1989	Mar CAHN
@		20MG/ML	A072073	001	Apr 10, 1989	Mar CAHN
@		20MG/ML	A072074	001	Apr 10, 1989	Mar CAHN
@		20MG/ML	A072075	001	Apr 10, 1989	Mar CAHN

NALMEFENE HYDROCHLORIDE

INJECTABLE;INJECTION
REVEX

>D>	@	BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Jun CAHN
>D>	@		EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Jun CAHN
>A>	@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Jun CAHN
>A>	@		EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Jun CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION
NALOXONE

@	EUROHLTH INTL SARL	0.4MG/ML	A070299	001	Sep 24, 1986	Mar CAHN
NALOXONE HYDROCHLORIDE						
@	IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989	Mar CAHN
@		0.02MG/ML	A072083	001	Apr 11, 1989	Mar CAHN
@		0.02MG/ML	A072084	001	Apr 11, 1989	Mar CAHN
@		0.02MG/ML	A072085	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072086	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072087	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072088	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072089	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072090	001	Apr 11, 1989	Mar CAHN
@		1MG/ML	A072091	001	Apr 11, 1989	Mar CAHN
@		1MG/ML	A072092	001	Apr 11, 1989	Mar CAHN
@		1MG/ML	A072093	001	Apr 11, 1989	Mar CAHN

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE						
AB	SUN PHARM INDS LTD	EQ 0.5MG BASE;EQ 50MG BASE	A075523	001	Mar 17, 2000	Apr CAHN

NAPROXEN

SUSPENSION;ORAL
NAPROSYN

AB	+	PEDIAPHARM INC	25MG/ML	N018965	001	Mar 23, 1987	Apr CAHN
----	---	----------------	---------	---------	-----	--------------	----------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

>A>	PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Jun NEWA
-----	--------------------	-------------------	---------	-----	--------------	----------

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

NEBIVOLOL HYDROCHLORIDE

>A>	ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun NEWA
>A>	@	EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun DISC
>A>		EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun NEWA
>A>	@	EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun DISC
>A>		EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun NEWA
>A>	@	EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun DISC
>A>		EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun NEWA
>A>	@	EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun DISC
	@ AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Apr DISC
AB		EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Mar NEWA
	@	EQ 5MG BASE	A203659	002	Apr 16, 2015	Apr DISC
AB		EQ 5MG BASE	A203659	002	Apr 16, 2015	Mar NEWA
	@	EQ 10MG BASE	A203659	003	Apr 16, 2015	Apr DISC
AB		EQ 10MG BASE	A203659	003	Apr 16, 2015	Mar NEWA
	@	EQ 20MG BASE	A203659	004	Apr 16, 2015	Apr DISC
AB		EQ 20MG BASE	A203659	004	Apr 16, 2015	Mar NEWA

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

	@ IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003	Apr CAHN
	@	100MG	A076072	002	Sep 16, 2003	Apr CAHN
	@	150MG	A076072	003	Sep 16, 2003	Apr CAHN
	@	200MG	A076072	004	Sep 16, 2003	Apr CAHN
	@	250MG	A076072	005	Sep 16, 2003	Apr CAHN
AB	SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Apr CAHN
AB		100MG	A076409	002	Sep 16, 2003	Apr CAHN
AB		150MG	A076409	003	Sep 16, 2003	Apr CAHN
AB		200MG	A076409	004	Sep 16, 2003	Apr CAHN
AB		250MG	A076409	005	Sep 16, 2003	Apr CAHN

NELARABINE

INJECTABLE; IV (INFUSION)

ARRANON

+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar CAHN
---	----------------------	---------------------	---------	-----	--------------	----------

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

	FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Jan NEWA
		10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Jan NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

>A>	AB	ALVOGEN PINE BROOK	400MG	A204621	001	Jul 10, 2015	Jun NEWA
-----	----	--------------------	-------	---------	-----	--------------	----------

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB	HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar CAHN
AB		20MG	A202644	002	Apr 25, 2013	Mar CAHN

NILUTAMIDE

TABLET; ORAL

NILANDRON

	@ CONCORDIA PHARMS INC	50MG	N020169	001	Sep 19, 1996	Apr CAHN
+		150MG	N020169	002	Apr 30, 1999	Apr CAHN

NIMODIPINE

CAPSULE;ORAL					
NIMODIPINE					
AB	+ BANNER LIFE SCIENCES	30MG	A076740	001	Jan 17, 2008 Jan CAHN

NINTEDANIB ESYLATE

CAPSULE;ORAL

OFEV

	BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014	Mar CAIN
+		EQ 150MG BASE	N205832	002	Oct 15, 2014	Mar CAIN

NITRIC OXIDE

GAS;INHALATION

INOMAX

>D>	INO	100PPM	N020845	002	Dec 23, 1999	Jun DISC
>A>	@	100PPM	N020845	002	Dec 23, 1999	Jun DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN

>D>	ALVOGEN INC	25MG	N016620	003		Jun CTEC
>A> AB		25MG	N016620	003		Jun CTEC
	NITROFURANTOIN					
>A> AB	ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Jun NEWA
>A> AB		50MG	A091095	002	Jun 18, 2015	Jun NEWA
>A> AB		100MG	A091095	003	Jun 18, 2015	Jun NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>A> AB	WATSON LABS INC	75MG;25MG	A202250	001	Jul 08, 2015	Jun NEWA
--------	-----------------	-----------	---------	-----	--------------	----------

NORETHINDRONE

TABLET;ORAL-28

NOR-QD

AB1	+ ACTAVIS LABS UT INC	0.35MG	N017060	001		Mar CAHN
-----	-----------------------	--------	---------	-----	--	----------

NORGESTREL

TABLET;ORAL

OVRETTE

>A>	@ LABORATOIRE HRA	0.075MG	N017031	001		Jun CAHN
>D>	@ WYETH PHARMS	0.075MG	N017031	001		Jun CAHN

NYSTATIN

CREAM;TOPICAL

NYSTATIN

>D>	@ G AND W LABS INC	100,000 UNITS/GM	A061966	001		Jun CMFD
>A> AT		100,000 UNITS/GM	A061966	001		Jun CMFD

SUSPENSION;ORAL

NYSTATIN

AA	G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982	Apr CAHN
	@	100,000 UNITS/ML	A062776	001	Dec 17, 1987	Apr CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Mar CMFD
----	------------------	-----------------------	---------	-----	--------------	----------

OINTMENT;TOPICAL

MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987	Mar CMFD
----	------------------	-----------------------	---------	-----	--------------	----------

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB	IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Apr NEWA
----	-----------------	------	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB	MACLEODS PHARMS LTD	5MG	A203044	001	Feb 20, 2015	Feb NEWA
AB		10MG	A203044	002	Feb 20, 2015	Feb NEWA
AB		15MG	A203044	003	Feb 20, 2015	Feb NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB		20MG	A203044	004	Feb 20, 2015	Feb NEWA
AB	ORCHID HLTHCARE	5MG	A202937	001	Mar 02, 2015	Feb NEWA
AB		10MG	A202937	002	Mar 02, 2015	Feb NEWA
AB		15MG	A202937	003	Mar 02, 2015	Feb NEWA
AB		20MG	A202937	004	Mar 02, 2015	Feb NEWA

OLAPARIB

CAPSULE;ORAL
LYNPARZA

	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Jan CTNA
--	--------------------	------	---------	-----	--------------	----------

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED; INHALATION
STIOLTO RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015	May NEWA
---	----------------------	-------------------------------------------	---------	-----	--------------	----------

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

>A>							
>A>	AT	BARR LABS INC	EQ 0.2% BASE	A090848	001	Jul 13, 2015	Jun NEWA
		PATADAY					
>D>	+	ALCON PHARMS LTD	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Jun CFTG
>A>	AT	+	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Jun CFTG
		PAZEO					
	+	ALCON RES LTD	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Jan NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

AB	SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Apr CAHN
AB		8MG	A078602	002	Feb 24, 2011	Apr CAHN
	ZOFRAN ODT					
AB	NOVARTIS PHARMS CORP	4MG	N020781	001	Jan 27, 1999	Mar CAHN
AB	+	8MG	N020781	002	Jan 27, 1999	Mar CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

>A>	AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206846	001	Jul 13, 2015	Jun NEWA	
	AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Apr CAHN	
>A>	AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun CAHN	
>D>	AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun CAHN	
	AP	MYLAN PHARMS INC	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	May CAHN	
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
	AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Apr CAHN	
>A>	AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun CAHN	
>D>	AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun CAHN	
	AP	MYLAN PHARMS INC	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	Apr CAHN	
	@	TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008	Jan DISC	
		ZOFRAN						
	AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar CAHN
		ZOFRAN PRESERVATIVE FREE						
	AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar CAHN
		SOLUTION;ORAL						
		ZOFRAN						
AA	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar CAHN	
		TABLET;ORAL						
		ZOFRAN						
AB		NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar CAHN	
AB			EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar CAHN	
AB	+		EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar CAHN	

ORPHENADRINE CITRATE

INJECTABLE;INJECTION
NORFLEX

@	IGI LABS INC	30MG/ML	N013055	001		Apr CAHN
@	MEDICIS	30MG/ML	N013055	001		Mar DISC

		INJECTABLE;INJECTION							
		ORPHENADRINE CITRATE							
AP	+	AKORN	30MG/ML	A040484	001	May 24, 2006	Mar	CRLD	
<u>OXCARBAZEPINE</u>									
		SUSPENSION;ORAL							
		OXCARBAZEPINE							
AB		SUN PHARM INDS LTD	300MG/5ML	A078734	001	Jun 26, 2009	Apr	CAHN	
<u>OXYBUTYNIN</u>									
		FILM, EXTENDED RELEASE;TRANSDERMAL							
		OXYTROL							
AB	+	ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar	CAHN	
		GEL, METERED;TRANSDERMAL							
		GELNIQUE 3%							
	+	ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Mar	CAHN	
<u>OXYBUTYNIN CHLORIDE</u>									
		GEL;TRANSDERMAL							
		GELNIQUE							
	+	ACTAVIS LABS UT INC	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Mar	CAHN	
<u>OXYCODONE HYDROCHLORIDE</u>									
		SOLUTION;ORAL							
		OXYCODONE HYDROCHLORIDE							
AA		ANI PHARMS INC	5MG/5ML	A204979	001	Jun 01, 2015	May	NEWA	
AA		NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Apr	NEWA	
>A> AA		WOCKHARDT BIO AG	5MG/5ML	A206456	001	Jun 16, 2015	Jun	NEWA	
		TABLET;ORAL							
		OXAYDO							
		ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	Mar	CTNA	
			7.5MG	N202080	002	Jun 17, 2011	Mar	CTNA	
		EGALET LTD	5MG	N202080	001	Jun 17, 2011	May	CAHN	
			7.5MG	N202080	002	Jun 17, 2011	May	CAHN	
		OXYCODONE HYDROCHLORIDE							
AB		ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015	Mar	NEWA	
AB		VINTAGE PHARMS	10MG	A077712	004	Apr 13, 2015	Mar	NEWA	
AB			20MG	A077712	005	Apr 13, 2015	Mar	NEWA	
<u>OXYMORPHONE HYDROCHLORIDE</u>									
		TABLET, EXTENDED RELEASE;ORAL							
		OXYMORPHONE HYDROCHLORIDE							
AB		SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Apr	NEWA	
AB			7.5MG	A203506	002	Apr 24, 2015	Apr	NEWA	
AB			10MG	A203506	003	Apr 24, 2015	Apr	NEWA	
AB			15MG	A203506	004	Apr 24, 2015	Apr	NEWA	
AB			20MG	A203506	005	Apr 24, 2015	Apr	NEWA	
AB			30MG	A203506	006	Apr 24, 2015	Apr	NEWA	
AB			40MG	A203506	007	Apr 24, 2015	Apr	NEWA	
<u>OXYTOCIN</u>									
		INJECTABLE;INJECTION							
		OXYTOCIN							
AP	+	EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Feb	CAHN	
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Feb	CAHN	
<u>PACLITAXEL</u>									
		INJECTABLE;INJECTION							
		PACLITAXEL							
AP		MYLAN PHARMS INC	6MG/ML	A091540	001	Sep 29, 2011	Apr	CAHN	
<u>PALBOCICLIB</u>									
		CAPSULE;ORAL							
		IBRANCE							
		PFIZER INC	75MG	N207103	001	Feb 03, 2015	Feb	NEWA	
			100MG	N207103	002	Feb 03, 2015	Feb	NEWA	
	+		125MG	N207103	003	Feb 03, 2015	Feb	NEWA	

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
INVEGA TRINZA

	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	May NEWA
		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	May NEWA
		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	May NEWA
+		819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015	May NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
PAMIDRONATE DISODIUM

AP	MYLAN PHARMS INC	30MG/10ML (3MG/ML)	A078520	001	Oct 31, 2008	Apr CAHN
AP		90MG/10ML (9MG/ML)	A078520	002	Oct 31, 2008	Apr CAHN

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE

@	IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988	Mar CAHN
@		2MG/ML	A072211	001	Mar 31, 1988	Mar CAHN
@		2MG/ML	A072212	001	Mar 31, 1988	Mar CAHN
@		2MG/ML	A072213	001	Mar 31, 1988	Mar CAHN

PANOBINOSTAT

CAPSULE; ORAL
FARYDAK

	NOVARTIS PHARMS CORP	10MG	N205353	001	Feb 23, 2015	Feb NEWA
		15MG	N205353	002	Feb 23, 2015	Feb NEWA
+		20MG	N205353	003	Feb 23, 2015	Feb NEWA

PANOBINOSTAT LACTATE

CAPSULE; ORAL
FARYDAK

	NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar CAIN
		EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar CPOT
		EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CAIN
		EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CPOT
+		EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CAIN
+		EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CPOT

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)
PANTOPRAZOLE SODIUM

>A>	AP	SANDOZ INC	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015	Jun NEWA
		TABLET, DELAYED RELEASE; ORAL					
		PANTOPRAZOLE SODIUM					
	AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar CAHN
	AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar CAHN
	AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr CAHN
	AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr CAHN

PARICALCITOL

CAPSULE; ORAL
PARICALCITOL

AB	BANNER LIFE SCIENCES	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan CAHN

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL
VOTRIENT

+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar CAHN
		EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB	VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Feb CAHN
----	----------------	-------	---------	-----	--------------	----------

PHENDIMETRAZINE TARTRATECAPSULE, EXTENDED RELEASE;ORAL
BONTRIL@ VALEANT 105MG
PHENDIMETRAZINE TARTRATE

A088021 001 Sep 21, 1982 Jan DISC

+ SANDOZ 105MG

N018074 001 Jan CTEC

PHENOXYBENZAMINE HYDROCHLORIDECAPSULE;ORAL
DIBENZYLNE

>A> AB + CONCORDIA PHARMS INC 10MG

N008708 001 Jun CAHN

>D> AB + COVIS PHARMA SARL 10MG

N008708 001 Jun CAHN

PHENTERMINE HYDROCHLORIDECAPSULE;ORAL
PHENTERMINE HYDROCHLORIDE

>D> @ MIKAH PHARMA LLC 37.5MG

A040228 001 Jun 19, 1997 Jun CMFD

>A> AA 37.5MG

A040228 001 Jun 19, 1997 Jun CMFD

PHENYLEPHRINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDEAKORN INC 2.5%
10%

N207926 001 Jan 15, 2015 Jan NEWA

N207926 002 Jan 15, 2015 Jan NEWA

PHENYTOIN SODIUMCAPSULE;ORAL
EXTENDED PHENYTOIN SODIUM

>D> AB WOCKHARDT 30MG EXTENDED

A040759 001 Dec 18, 2007 Jun DISC

>A> @ 30MG EXTENDED

A040759 001 Dec 18, 2007 Jun DISC

>D> AB WOCKHARDT USA 100MG EXTENDED

A040732 001 Jan 30, 2008 Jun DISC

>A> @ 100MG EXTENDED

A040732 001 Jan 30, 2008 Jun DISC

PHENYTOIN SODIUM

AB AUROBINDO PHARMA LTD 100MG EXTENDED

A204309 001 Jun 10, 2015 May NEWA

INJECTABLE;INJECTION

PHENYTOIN SODIUM

AP + EUROHLTH INTL SARL 50MG/ML

A084307 001 Feb CAHN

PHYTONADIONEINJECTABLE;INJECTION
AQUAMEPHYTON@ IGI LABS INC 1MG/0.5ML
@ 10MG/ML

N012223 002 Apr CAHN

N012223 001 Apr CAHN

PILOCARPINE HYDROCHLORIDETABLET;ORAL
PILOCARPINE HYDROCHLORIDE

AB ELAN PHARMA INTL LTD 5MG

A076746 001 Nov 16, 2004 Mar CAHN

PINDOLOLTABLET;ORAL
PINDOLOL

@ G AND W LABS INC 5MG

A073661 001 Oct 31, 1993 Apr CAHN

@ 5MG

A073687 001 Feb 26, 1993 Apr CAHN

@ 5MG

A074123 001 Apr 17, 1997 Apr CAHN

@ 10MG

A073661 002 Oct 31, 1993 Apr CAHN

@ 10MG

A073687 002 Feb 26, 1993 Apr CAHN

@ 10MG

A074123 002 Apr 17, 1997 Apr CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUMINJECTABLE;INJECTION
PIPERACILLIN AND TAZOBACTAMAP AGILA SPECLTS EQ 3GM BASE/VIAL;EQ 375MG
BASE/VIAL

A065458 002 Aug 15, 2014 Mar CPOT

PIRBUTEROL ACETATEAEROSOL, METERED;INHALATION
MAXAIR

@ MEDICIS EQ 0.2MG BASE/INH

N020014 001 Nov 30, 1992 Jan DISC

PIRFENIDONECAPSULE;ORAL
ESBRIET

+ GENENTECH INC 267MG N022535 001 Oct 15, 2014 Feb CAHN

PIROXICAMCAPSULE;ORAL
PIROXICAMAB MYLAN PHARMS INC 10MG A074116 001 Jun 15, 1993 May CAHN
AB 20MG A074118 001 Jun 15, 1993 May CAHNPODOFILOXGEL;TOPICAL
CONDYLOX

+ ACTAVIS LABS UT INC 0.5% N020529 001 Mar 13, 1997 Feb CAHN

SOLUTION;TOPICAL
CONDYLOX

AT + ACTAVIS LABS UT INC 0.5% N019795 001 Dec 13, 1990 Jan CAHN

PODOFILOX

AT BAUSCH AND LOMB INC 0.5% A090184 001 Jul 21, 2010 May CAHN

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT ALCON RES LTD 10,000 UNITS/ML;EQ 1MG BASE/ML A064211 001 Apr 13, 1998 Jan CAHN

PONATINIB HYDROCHLORIDETABLET;ORAL
ICLUSIG

ARIAD EQ 30MG BASE N203469 003 Apr 23, 2015 Apr NEWA

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE;ORAL
KLOR-CON>A> UPSHER SMITH 8MEQ A203106 001 Jul 10, 2015 Jun NEWA
>A> AB 10MEQ A203106 002 Jul 10, 2015 Jun NEWATABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDEAB2 MYLAN PHARMS INC 8MEQ A204662 001 Aug 21, 2014 Feb CPOT
AB2 10MEQ A204662 002 Aug 21, 2014 Feb CPOTPREDNICARBATEOINTMENT;TOPICAL
DERMATOP

AB + VALEANT PHARMS NORTH 0.1% N019568 001 Sep 23, 1991 Apr CAHN

PREGABALINCAPSULE;ORAL
LYRICAPF PRISM CV 25MG N021446 001 Dec 30, 2004 Apr CTEC
50MG N021446 002 Dec 30, 2004 Apr CTEC
75MG N021446 003 Dec 30, 2004 Apr CTEC
100MG N021446 004 Dec 30, 2004 Apr CTEC
150MG N021446 005 Dec 30, 2004 Apr CTEC
200MG N021446 006 Dec 30, 2004 Apr CTEC
225MG N021446 007 Dec 30, 2004 Apr CTEC
+ 300MG N021446 008 Dec 30, 2004 Apr CTECPROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL

PROCAINAMIDE HYDROCHLORIDE

>A> @ IDT AUSTRALIA LTD 250MG A089219 001 Jul 01, 1986 Jun CAHN
>A> @ 500MG A089221 001 Jul 01, 1986 Jun CAHN
>D> @ SANDOZ 250MG A089219 001 Jul 01, 1986 Jun CAHN
>D> @ 500MG A089221 001 Jul 01, 1986 Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

PROCAINAMIDE HYDROCHLORIDE

>A> @ IDT AUSTRALIA LTD 250MG A089369 001 Aug 14, 1987 Jun CAHN
>A> @ 500MG A089370 001 Jan 09, 1987 Jun CAHN
>A> @ 750MG A089371 001 Aug 14, 1987 Jun CAHN
>D> @ SANDOZ 250MG A089369 001 Aug 14, 1987 Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
PROCAINAMIDE HYDROCHLORIDE

>D>	@	500MG	A089370	001	Jan 09, 1987	Jun CAHN
>D>	@	750MG	A089371	001	Aug 14, 1987	Jun CAHN

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

AP	+	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Feb CAHN
----	---	--------------------	----------------	---------	-----	--------------	----------

PROGESTERONE

CAPSULE;ORAL
PROGESTERONE

AB		BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013	Jan CAHN
AB			200MG	A200900	002	Aug 16, 2013	Jan CAHN

GEL;VAGINAL
CRINONE

		ACTAVIS LABS UT INC	4%	N020701	001	Jul 31, 1997	Feb CAHN
	+		8%	N020701	002	Jul 31, 1997	Feb CAHN

INJECTABLE;INJECTION
PROGESTERONE

AO	+	ACTAVIS LABS UT INC	50MG/ML	N017362	002		Mar CAHN
----	---	---------------------	---------	---------	-----	--	----------

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
PROMETHAZINE HYDROCHLORIDE

>A>	AP	+	EUROHLTH INTL SARL	25MG/ML	A083312	001	Jun CAHN
>A>	AP	+		50MG/ML	A083312	002	Jun CAHN
>D>	AP	+	HIKMA MAPLE	25MG/ML	A083312	001	Jun CAHN
>D>	AP	+		50MG/ML	A083312	002	Jun CAHN

SUPPOSITORY;RECTAL
PHENERGAN

	@	DELCOR ASSET CORP	12.5MG	N010926	002		Apr CAHN
	@		25MG	N010926	001		Apr CAHN

TABLET;ORAL
PROMETHAZINE HYDROCHLORIDE

AB		HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008	Mar CAHN
AB			25MG	A040673	002	Mar 05, 2008	Mar CAHN
AB			50MG	A040673	003	Mar 05, 2008	Mar CAHN

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL
PYRIDOSTIGMINE BROMIDE

>A>	AB		ZYDUS PHARMS USA INC	60MG	A205650	001	Jun 22, 2015	Jun NEWA
-----	----	--	----------------------	------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL
MESTINON

>D>		+	VALEANT PHARMS LLC	180MG	N011665	001		Jun CFTG
>A>	AB	+		180MG	N011665	001		Jun CFTG

PYRIDOSTIGMINE BROMIDE

>A>	AB		ALVOGEN INC	180MG	A204737	001	Jun 26, 2015	Jun NEWA
-----	----	--	-------------	-------	---------	-----	--------------	----------

QUAZEPAM

TABLET;ORAL
DORAL

>D>		+	SCIECURE PHARMA INC	15MG	N018708	001	Dec 27, 1985	Jun DISC
>A>		@		15MG	N018708	001	Dec 27, 1985	Jun DISC

QUETIAPINE FUMARATE

TABLET;ORAL
SEROQUEL

AB	+	ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997	May CAHN
AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	May CAHN
AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	May CAHN
	@		EQ 150MG BASE	N020639	004	Dec 20, 1998	May CAHN
AB			EQ 200MG BASE	N020639	003	Sep 26, 1997	May CAHN
AB	+		EQ 300MG BASE	N020639	005	Jul 26, 2000	May CAHN
AB			EQ 400MG BASE	N020639	006	Oct 04, 2005	May CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr CAHN
AB		EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr CAHN
AB		EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr CAHN
AB		EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

>A>	@ CYCLE PHARMS LTD	324MG	A088431	001	Jan 06, 1984	Jun CAHN
>D>	@ ROXANE	324MG	A088431	001	Jan 06, 1984	Jun CAHN

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

>A>	@ CYCLE PHARMS LTD	200MG	A083640	001		Jun CAHN
>A>	@	300MG	A085632	001		Jun CAHN
>D>	@ ROXANE	200MG	A083640	001		Jun CAHN
>D>	@	300MG	A085632	001		Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE SULFATE

+	G AND W LABS INC	300MG	A040045	001	Jun 30, 1994	Apr CAHN
---	------------------	-------	---------	-----	--------------	----------

QUININE SULFATE

CAPSULE; ORAL

QUININE SULFATE

>A>	AB	AMNEAL PHARMS	324MG	A203729	001	Jul 15, 2015	Jun NEWA
	AB	LUPIN LTD	324MG	A203112	001	Apr 24, 2015	Apr NEWA

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

RALOXIFENE HYDROCHLORIDE

AB	WATSON LABS INC	60MG	A200825	001	Jan 21, 2015	Jan NEWA
----	-----------------	------	---------	-----	--------------	----------

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

>A>	AP	+	CONCORDIA PHARMS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jun CAHN
>D>	AP	+	COVIS INJECTABLES	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jun CAHN

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

@	SUN PHARM INDS LTD	EQ 150MG BASE
@		EQ 300MG BASE

A075439	001	Apr 19, 2000	Apr CAHN
A075439	002	Apr 19, 2000	Apr CAHN

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

AB	STANDARD CHEM PHARM	0.5MG	A091517	001	Apr 24, 2015	Apr NEWA
AB		1MG	A091517	002	Apr 24, 2015	Apr NEWA
AB		2MG	A091517	003	Apr 24, 2015	Apr NEWA

RIBAVIRIN

CAPSULE; ORAL

REBETOL

>D>	+	MERCK SHARP DOHME	200MG	N020903	001	Jun 03, 1998	Jun DISC
>A>	@		200MG	N020903	001	Jun 03, 1998	Jun DISC

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

AP	MYLAN PHARMS INC	600MG/VIAL	A065421	001	May 22, 2008	Apr CAHN
----	------------------	------------	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE; ORAL

ATELVIA

AB	+	WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010	May CFTG
		RISEDRONATE SODIUM					
AB		TEVA PHARMS USA	35MG	A203217	001	May 18, 2015	May NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

AB	SUN PHARM INDS LTD	0.5MG	A077542	001	Aug 06, 2010	Apr CAHN
AB		1MG	A077542	002	Aug 06, 2010	Apr CAHN
AB		2MG	A077542	003	Aug 06, 2010	Apr CAHN
AB		3MG	A078474	001	Aug 06, 2010	Apr CAHN
AB		4MG	A078474	002	Aug 06, 2010	Apr CAHN

RIVAROXABAN

TABLET;ORAL
XARELTO

	JANSSSEN PHARMS	10MG	N022406	001	Jul 01, 2011	Apr CRLD
--	-----------------	------	---------	-----	--------------	----------

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB	ORCHID HLTHCARE	EQ 1.5MG BASE	A090879	001	Jun 10, 2015	May NEWA
AB		EQ 3MG BASE	A090879	002	Jun 10, 2015	May NEWA
AB		EQ 4.5MG BASE	A090879	003	Jun 10, 2015	May NEWA
AB		EQ 6MG BASE	A090879	004	Jun 10, 2015	May NEWA

ROFLUMILAST

TABLET;ORAL
DALIRESP

+	ASTRAZENECA PHARMS	500MCG	N022522	001	Feb 28, 2011	Mar CAHN
---	--------------------	--------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB	G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Apr CAHN
AB		EQ 0.5MG BASE	A077460	002	May 05, 2008	Apr CAHN
AB		EQ 1MG BASE	A077460	003	May 05, 2008	Apr CAHN
AB		EQ 2MG BASE	A077460	004	May 05, 2008	Apr CAHN
AB		EQ 3MG BASE	A077460	005	May 05, 2008	Apr CAHN
AB		EQ 4MG BASE	A077460	006	May 05, 2008	Apr CAHN
AB		EQ 5MG BASE	A077460	007	May 19, 2008	Apr CAHN

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL
SCOPOLAMINE

AB	PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015	Mar CAHN
AB	PERRIGO R AND D	1MG/72HR	A078830	001	Jan 30, 2015	Jan NEWA
AB	TRANSDERM SCOP					
AB	+	NOVARTIS	1MG/72HR	N017874	001	Jan CFTG

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@	G AND W LABS INC	5MG	A074537	001	Aug 02, 1996	Apr CAHN
@		5MG	A074744	001	Jan 27, 1997	Apr CAHN
@		5MG	A074756	001	Nov 25, 1998	Apr CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

@	HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009	May DISC
@		EQ 50MG BASE	A077864	002	Aug 10, 2009	May DISC
@		EQ 100MG BASE	A077864	003	Aug 10, 2009	May DISC
AB	SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007	Apr CAHN
AB		EQ 50MG BASE	A077977	002	Feb 06, 2007	Apr CAHN
AB		EQ 100MG BASE	A077977	003	Feb 06, 2007	Apr CAHN
		EQ 150MG BASE	A077977	004	Feb 06, 2007	Apr CAHN
		EQ 200MG BASE	A077977	005	Feb 06, 2007	Apr CAHN

SILDENAFIL CITRATE

SOLUTION;INTRAVENOUS
REVATIO

AP	+	PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Mar CFTG
----	---	--------	----------------------------------------	---------	-----	--------------	----------

SOLUTION;INTRAVENOUS
SILDENAFIL CITRATE

AP	AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	A203988	001	Apr 01, 2015	Mar NEWA
----	----------------------	----------------------------------------	---------	-----	--------------	----------

SILODOSINCAPSULE;ORAL
RAPAFLO

+	ACTAVIS LABS UT INC	4MG	N022206	001	Oct 08, 2008	Mar CAHN
		8MG	N022206	002	Oct 08, 2008	Mar CAHN

SIMVASTATINTABLET;ORAL
SIMVASTATIN

AB	SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Apr CAHN
AB		10MG	A076285	002	Dec 20, 2006	Apr CAHN
AB		20MG	A076285	003	Dec 20, 2006	Apr CAHN
AB		40MG	A076285	004	Dec 20, 2006	Apr CAHN
AB		80MG	A076285	005	Jun 23, 2006	Apr CAHN

SODIUM CHLORIDEINJECTABLE;INJECTION
SODIUM CHLORIDE 0.9%

AP	EUROHLTH INTL SARL	9MG/ML	A201850	001	Jan 20, 2012	Feb CAHN
	SODIUM CHLORIDE 0.9%					
	EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep 24, 2013	Feb CAHN
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+	LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CAHN
		112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CAHN
+		405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb CPOT
		1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb CPOT

SODIUM FERRIC GLUCONATE COMPLEXINJECTABLE;INJECTION
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

>A>	AB	EUROHLTH INTL SARL	62.5MG/5ML	A078215	001	Mar 31, 2011	Jun CAHN
>D>	AB	HIKMA PHARMS	62.5MG/5ML	A078215	001	Mar 31, 2011	Jun CAHN

SODIUM FLUORIDE F-18INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

AP	PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015	Feb NEWA
AP	SPECTRON MRC LLC	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr NEWA
AP	UNIV UTAH CYCLOTRON	10-200mCi/ML	A204497	001	Apr 20, 2015	Apr NEWA

SODIUM IODIDE I-123CAPSULE;ORAL
SODIUM IODIDE I 123

AA	+	CARDINAL HEALTH 418	100uCi	N018671	001	May 27, 1982	Apr CAHN
AA	+		200uCi	N018671	002	May 27, 1982	Apr CAHN
	@		400uCi	N018671	003	May 27, 1982	Apr CAHN

SODIUM POLYSTYRENE SULFONATEPOWDER;ORAL, RECTAL
KALEXATE

		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015	Mar NEWA
		KAYEXALATE					
AA	+	CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Apr CAHN

SOMATROPIN RECOMBINANTINJECTABLE;INJECTION
NORDITROPIN FLEXPRO
NOVO NORDISK INC
NORDITROPIN NORDIFLEX
NOVO NORDISK INC

	@		30MG/3ML	N021148	011	Jan 23, 2015	Jan NEWA
			30MG/3ML	N021148	007	Mar 10, 2009	Mar CMFD
	@		30MG/3ML	N021148	007	Mar 10, 2009	Jan DISC

>D>		NUTROPIN					
>D>	BX	GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Jun DISC
>A>	@		5MG/VIAL	N020168	001	Nov 17, 1993	Jun DISC
>D>	BX	+	10MG/VIAL	N020168	002	Nov 17, 1993	Jun DISC
>A>	@		10MG/VIAL	N020168	002	Nov 17, 1993	Jun DISC
	BX	+	10MG/VIAL	N020168	002	Nov 17, 1993	Mar CTEC

INJECTABLE; INJECTION							
>D>	NUTROPIN AQ						
>D>	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Jun CTNA
>D>	+		10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Jun DISC
>A>	@		10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Jun DISC
>D>	+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Jun CTNA
>A>	NUTROPIN AQ NUSPIN						
>A>	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Jun CTNA
>A>	+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Jun NEWA
>A>	+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Jun CTNA
>A>	NUTROPIN AQ PEN						
>A>	+	GENENTECH	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Jun NEWA
	ZOMACTON						
BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar CTNA
BX			10MG/VIAL	N019774	003	Mar 07, 2012	Apr CRLD
BX	+		10MG/VIAL	N019774	003	Mar 07, 2012	Mar NEWA
<u>SOTALOL HYDROCHLORIDE</u>							
SOLUTION; INTRAVENOUS							
SOTALOL HYDROCHLORIDE							
	+	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009	Apr CAHN
TABLET; ORAL							
BETAPACE							
AB1		COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	Mar CAHN
AB1			120MG	N019865	005	Apr 20, 1994	Mar CAHN
AB1	+		160MG	N019865	002	Oct 30, 1992	Mar CAHN
AB1			240MG	N019865	003	Oct 30, 1992	Mar CAHN
	@		320MG	N019865	004	Oct 30, 1992	Mar CAHN
<u>SUCCINYLCHOLINE CHLORIDE</u>							
INJECTABLE; INJECTION							
QUELICIN PRESERVATIVE FREE							
>D>	+	HOSPIRA	100MG/ML	N008845	004		Jun DISC
>A>	@		100MG/ML	N008845	004		Jun DISC
<u>SUCRALFATE</u>							
TABLET; ORAL							
SUCRALFATE							
AB		MYLAN PHARMS INC	1GM	A074415	001	Jun 08, 1998	May CAHN
<u>SUFENTANIL CITRATE</u>							
INJECTABLE; INJECTION							
SUFENTANIL CITRATE							
>A>	AP	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Jun CAHN
>D>	AP	HIKMA MAPLE	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Jun CAHN
<u>SULFACETAMIDE SODIUM</u>							
LOTION; TOPICAL							
KLARON							
AB	+	VALEANT PHARMS NORTH	10%	N019931	001	Dec 23, 1996	Mar CAHN
SOLUTION/DROPS; OPHTHALMIC							
SULFACETAMIDE SODIUM							
AT		AKORN	10%	A040215	001	May 25, 1999	Mar CMFD
<u>SULFANILAMIDE</u>							
CREAM; VAGINAL							
SULFANILAMIDE							
	@	G AND W LABS INC	15%	A088718	001	Sep 19, 1985	Apr CAHN
<u>SUMATRIPTAN SUCCINATE</u>							
TABLET; ORAL							
SUMATRIPTAN SUCCINATE							
AB		SUN PHARM INDS LTD	EQ 25MG BASE	A076554	001	Aug 10, 2009	Apr CAHN
AB			EQ 50MG BASE	A076554	002	Aug 10, 2009	Apr CAHN
AB			EQ 100MG BASE	A076572	001	Feb 09, 2009	Apr CAHN

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL

NUCYNTA

+	DEPOMED INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	May CAHN
---	-------------	-----------------	---------	-----	--------------	----------

TABLET; ORAL

NUCYNTA

	DEPOMED INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	May CAHN
--	-------------	--------------	---------	-----	--------------	----------

		EQ 75MG BASE	N022304	002	Nov 20, 2008	May CAHN
--	--	--------------	---------	-----	--------------	----------

+		EQ 100MG BASE	N022304	003	Nov 20, 2008	May CAHN
---	--	---------------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

NUCYNTA ER

	DEPOMED INC	EQ 50MG BASE	N200533	001	Aug 25, 2011	May CAHN
--	-------------	--------------	---------	-----	--------------	----------

		EQ 100MG BASE	N200533	002	Aug 25, 2011	May CAHN
--	--	---------------	---------	-----	--------------	----------

		EQ 150MG BASE	N200533	003	Aug 25, 2011	May CAHN
--	--	---------------	---------	-----	--------------	----------

		EQ 200MG BASE	N200533	004	Aug 25, 2011	May CAHN
--	--	---------------	---------	-----	--------------	----------

+		EQ 250MG BASE	N200533	005	Aug 25, 2011	May CAHN
---	--	---------------	---------	-----	--------------	----------

TELAPREVIR

TABLET; ORAL

INCIVEK

@	VERTEX PHARMS	375MG	N201917	001	May 23, 2011	Jan DISC
---	---------------	-------	---------	-----	--------------	----------

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB	VINTAGE PHARMS	7.5MG	A201781	001	Jun 04, 2015	May NEWA
----	----------------	-------	---------	-----	--------------	----------

AB		15MG	A201781	002	Jun 04, 2015	May NEWA
----	--	------	---------	-----	--------------	----------

AB		22.5MG	A201781	003	Jun 04, 2015	May NEWA
----	--	--------	---------	-----	--------------	----------

AB		30MG	A201781	004	Jun 04, 2015	May NEWA
----	--	------	---------	-----	--------------	----------

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

AB	AMNEAL PHARMS	5MG	A203691	001	May 08, 2015	Apr NEWA
----	---------------	-----	---------	-----	--------------	----------

AB		20MG	A203691	002	May 08, 2015	Apr NEWA
----	--	------	---------	-----	--------------	----------

AB		100MG	A203691	003	May 08, 2015	Apr NEWA
----	--	-------	---------	-----	--------------	----------

AB		140MG	A203691	004	May 08, 2015	Apr NEWA
----	--	-------	---------	-----	--------------	----------

AB		180MG	A203691	005	May 08, 2015	Apr NEWA
----	--	-------	---------	-----	--------------	----------

AB		250MG	A203691	006	May 08, 2015	Apr NEWA
----	--	-------	---------	-----	--------------	----------

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB	TEVA PHARMS USA	300MG	A091612	001	Mar 18, 2015	Mar NEWA
----	-----------------	-------	---------	-----	--------------	----------

VIREAD

AB	+	GILEAD SCIENCES INC	300MG	N021356	001	Oct 26, 2001	Mar CFTG
----	---	---------------------	-------	---------	-----	--------------	----------

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

@	WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007	Feb DISC
---	-----------	---------------	---------	-----	--------------	----------

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

AB1	ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan CTEC
-----	--------	-------------------	---------	-----	--------------	----------

AB1	+	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan CTEC
-----	---	-----------------	---------	-----	--------------	----------

TESTIM

AB2	+	AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Jan CTEC
-----	---	-----------------	-----------------	---------	-----	--------------	----------

TESTOSTERONE

@	ACTAVIS LABS UT INC	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Mar CAHN
---	---------------------	-------------------	---------	-----	--------------	----------

@		1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Mar CAHN
---	--	-----------------	---------	-----	--------------	----------

BX	ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	May CAHN
----	----------------	-------------------	---------	-----	--------------	----------

BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	May CAHN
----	--	-----------------	---------	-----	--------------	----------

AB1	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan CTEC
-----	----------------	-------------------	---------	-----	--------------	----------

AB1		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan CTEC
-----	--	-----------------	---------	-----	--------------	----------

VOGELXO

AB2	UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jan CTEC
-----	--------------	-----------------	---------	-----	--------------	----------

TETRABENAZINETABLET; ORAL
XENAZINE

	VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug 15, 2008	Feb CAHN
+		25MG	N021894	002	Aug 15, 2008	Feb CAHN

TETRACYCLINE HYDROCHLORIDECAPSULE; ORAL
ACHROMYCIN V

AB	+	HERITAGE PHARMS INC	500MG	N050278	001		Apr CRLD
		TETRACYCLINE HYDROCHLORIDE					
	@	IVAX SUB TEVA PHARMS	250MG	A060704	001		Apr DISC
	@		500MG	A060704	002		Apr DISC

THEOPHYLLINETABLET; ORAL
THEOLAIR

	@	MEDICIS	125MG	A086399	001		Mar DISC
	@		250MG	A086399	002		Mar DISC

TABLET, EXTENDED RELEASE; ORAL
THEOPHYLLINE

AB		MYLAN PHARMS INC	400MG	A040595	001	Apr 21, 2006	May CAHN
AB	+		600MG	A040560	002	Apr 21, 2006	May CAHN

THIOTEPAINJECTABLE; INJECTION
THIOTEPA

+	EUROHLTH INTL SARL	15MG/VIAL	A075547	001	Apr 02, 2001	May CRLD
---	--------------------	-----------	---------	-----	--------------	----------

TIGECYCLINEINJECTABLE; IV (INFUSION)
TIGECYCLINE

AP		SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	May NEWA
		TYGACIL					
AP	+	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	May CFTG

TIMOLOL MALEATESOLUTION/DROPS; OPHTHALMIC
ISTALOL

AT2	+	BAUSCH AND LOMB	EQ 0.5% BASE	N021516	001	Jun 04, 2004	Apr CFTG
		TIMOLOL MALEATE					
AT1		AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Apr CTEC
AT1			EQ 0.5% BASE	A074516	001	Mar 25, 1997	Apr CTEC
AT1		ALCON RES LTD	EQ 0.5% BASE	A074262	001	Apr 28, 1995	Apr CTEC
AT2		APOTEX INC	EQ 0.5% BASE	A204936	001	Apr 17, 2015	Apr NEWA
AT1		BAUSCH AND LOMB	EQ 0.5% BASE	A074776	001	Mar 25, 1997	Apr CTEC
AT1		FDC LTD	EQ 0.5% BASE	A077259	002	Apr 30, 2008	Apr CTEC
AT1		HI TECH PHARMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002	Apr CTEC
AT1		PACIFIC PHARMA	EQ 0.5% BASE	A074747	001	Mar 25, 1997	Apr CTEC
AT1		WOCKHARDT	EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr CTEC
		TIMOPTIC					
AT1	+	ATON	EQ 0.5% BASE	N018086	002		Apr CTEC

TOBRAMYCINSOLUTION; INHALATION
KITABIS PAK

AN		PULMOFLOW INC	300MG/5ML	N205433	001	Dec 02, 2014	Feb CTEC
		TOBRAMYCIN					
>A> AN		AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	Jun NEWA
		SOLUTION/DROPS; OPHTHALMIC					
		TOBREX					
AT	+	ALCON LABS INC	0.3%	N050541	001		Mar CAHN

TOBRAMYCIN SULFATEINJECTABLE; INJECTION
TOBRAMYCIN SULFATE

	@	IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994	Mar CAHN
	@		EQ 40MG BASE/ML	A063120	001	Oct 31, 1994	Mar CAHN
	@		EQ 40MG BASE/ML	A063121	001	Oct 31, 1994	Mar CAHN
	@		EQ 40MG BASE/ML	A063122	001	Oct 31, 1994	Mar CAHN
AP		MYLAN PHARMS INC	EQ 40MG BASE/ML	A065407	001	Mar 11, 2008	Apr CAHN

TOLAZAMIDETABLET; ORAL
TOLAZAMIDE

@ G AND W LABS INC	100MG	N018894	001	Nov 02, 1984	Apr CAHN
@	250MG	N018894	002	Nov 02, 1984	Apr CAHN
@	500MG	N018894	003	Nov 02, 1984	Apr CAHN

TOLCAPONETABLET; ORAL
TASMAR

AB	+	VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar CFTG
AB		PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar NEWA

TOLMETIN SODIUMTABLET; ORAL
TOLMETIN SODIUM

@ G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996	May CAHN
@	EQ 600MG BASE	A074729	001	Feb 27, 1997	Apr CAHN

TOLTERODINE TARTRATETABLET; ORAL
TOLTERODINE TARTRATE

AB		IVAX SUB TEVA PHARMS	1MG	A077006	001	Feb 23, 2015	Feb NEWA
AB			2MG	A077006	002	Feb 23, 2015	Feb NEWA

TOPIRAMATETABLET; ORAL
TOPIRAMATE

AB		SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Apr CAHN
AB			100MG	A076327	002	Mar 27, 2009	Apr CAHN
AB			200MG	A076327	003	Mar 27, 2009	Apr CAHN
	@	WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010	Apr DISC
	@		50MG	A090353	002	Sep 01, 2010	Apr DISC
	@		100MG	A090353	003	Sep 01, 2010	Apr DISC
	@		200MG	A090353	004	Sep 01, 2010	Apr DISC
		TOPIRAMATE					
	@	HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013	May DISC
	@		50MG	A091185	002	Nov 25, 2013	May DISC
	@		100MG	A091185	003	Nov 25, 2013	May DISC
	@		200MG	A091185	004	Nov 25, 2013	May DISC

TOPOTECAN HYDROCHLORIDECAPSULE; ORAL
HYCANTIN

NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Mar CAHN
+	EQ 1MG BASE	N020981	002	Oct 11, 2007	Mar CAHN

INJECTABLE; INJECTION
HYCANTIN

AP	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar CAHN
AP		TOPOTECAN HYDROCHLORIDE					
		CHEM WERTH INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May CAHN

TORSEMIDEINJECTABLE; INJECTION
TORSEMIDE

@ EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Jan DISC
@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Jan DISC
@ LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jan DISC
@	50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jan DISC

TRAMETINIB DIMETHYL SULFOXIDETABLET; ORAL
MEKINIST

NOVARTIS PHARMS CORP	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Mar CAHN
	EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Mar CAHN
+	EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Mar CAHN

TRANEXAMIC ACIDINJECTABLE; INJECTION
TRANEXAMIC ACID

AP		FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Apr	CMFD
----	--	--------------------	----------	---------	-----	--------------	-----	------

TRANLYCYPROMINE SULFATETABLET; ORAL
PARNATE

>A>	AB	+	CONCORDIA PHARMS INC	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jun	CAHN
>D>	AB	+	COVIS PHARMA	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jun	CAHN

TRAVOPROSTSOLUTION/DROPS; OPHTHALMIC
TRAVATAN Z

>D>		+	ALCON PHARMS LTD	0.004%	N021994	001	Sep 21, 2006	Jun	CTEC
>A>	AT	+		0.004%	N021994	001	Sep 21, 2006	Jun	CTEC
			TRAVOPROST						
>A>	AT		APOTEX INC	0.004%	A203431	001	Jul 10, 2015	Jun	NEWA

TRAZODONE HYDROCHLORIDETABLET; ORAL
DESYREL

@	PRAGMA PHARMS LLC	50MG	N018207	001			May	CAHN
@		100MG	N018207	002			May	CAHN
@		150MG	N018207	003	Mar 25, 1985		May	CAHN
@		300MG	N018207	004	Nov 07, 1988		May	CAHN

TABLET, EXTENDED RELEASE; ORAL
OLEPTRO

@	ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010		Mar	DISC
@		300MG	N022411	002	Feb 02, 2010		Mar	DISC

TRETINOINCREAM; TOPICAL
RENOVA

		+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	Apr	CAHN
AB2		+		0.05%	N019963	001	Dec 29, 1995	Apr	CAHN
			RETIN-A						
AB		+	VALEANT PHARMS NORTH	0.1%	N017340	001		Apr	CAHN

TRIAMCINOLONE ACETONIDECREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

AT			G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr	CMFD
AT				0.1%	A089798	001	May 31, 1991	Apr	CMFD
			TRIDERM						
AT			CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar	NEWA
AT				0.5%	A088042	003	Mar 25, 2015	Mar	NEWA

LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE

AT			G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Mar	CMFD
----	--	--	------------------	------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL
KENALOG

AT			DELCOR ASSET CORP	0.025%	N011600	003		Mar	CMFD
AT				0.1%	N011600	001		Mar	CMFD

SPRAY; TOPICAL
KENALOG

AT		+	RANBAXY	0.147MG/GM	N012104	001		Mar	CFTG
			TRIAMCINOLONE ACETONIDE						
AT			PERRIGO UK FINCO	0.147MG/GM	A205782	001	Apr 13, 2015	Mar	NEWA

TRIAMTERENECAPSULE; ORAL
DYRENIUM

			CONCORDIA PHARMS INC	50MG	N013174	001		Apr	CAHN
		+		100MG	N013174	002		Apr	CAHN

TRIMIPRAMINE MALEATECAPSULE;ORAL
SURMONTIL

>D>	AB	ODYSSEY PHARMS	EQ 50MG BASE	N016792	002		Jun	CRLD
>A>	AB	+	EQ 50MG BASE	N016792	002		Jun	CRLD
>D>	AB	+	EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun	CRLD
>A>	AB		EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun	CRLD

TRIPTORELIN PAMOATEINJECTABLE;INTRAMUSCULAR
TRELSTAR

+	ACTAVIS LABS UT INC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Jan	CAHN
+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Jan	CAHN
+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Jan	CAHN

TROSPIUM CHLORIDECAPSULE, EXTENDED RELEASE;ORAL
SANCTURA XR

		@ ALLERGAN	60MG	N022103	001	Aug 03, 2007	May	DISC	
		TROSPIUM CHLORIDE							
>D>	AB	+	ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012	Jun	CRLD
>A>	AB			60MG	A091289	001	Oct 12, 2012	Jun	CRLD
	AB	+		60MG	A091289	001	Oct 12, 2012	May	CRLD
	AB		SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr	NEWA
		TABLET;ORAL							
		SANCTURA							
		@ ALLERGAN	20MG	N021595	001	May 28, 2004	May	DISC	
		TROSPIUM CHLORIDE							
>D>	AB	+	GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010	Jun	CRLD
>A>	AB			20MG	A091575	001	Aug 13, 2010	Jun	CRLD
	AB	+		20MG	A091575	001	Aug 13, 2010	May	CRLD

UNOPROSTONE ISOPROPYLSOLUTION/DROPS;OPHTHALMIC
RESCULA

+	R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	May	CAHN
+	SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Jan	CAHN

URSODIOLCAPSULE;ORAL
ACTIGALL

		@ ACTAVIS LABS UT INC	150MG	N019594	001	Dec 31, 1987	Mar	CAHN
AB	+		300MG	N019594	002	Dec 31, 1987	Mar	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

		VALACYCLOVIR HYDROCHLORIDE						
AB		HETERO LABS LTD V	EQ 500MG BASE	A203047	001	Apr 08, 2015	Mar	NEWA
AB			EQ 1GM BASE	A203047	002	Apr 08, 2015	Mar	NEWA
AB		SUN PHARM INDS LTD	EQ 500MG BASE	A076588	001	Jan 31, 2007	Apr	CAHN
AB			EQ 1GM BASE	A076588	002	Jan 31, 2007	Apr	CAHN

VALPROIC ACIDCAPSULE;ORAL
VALPROIC ACID

AB		BANNER LIFE SCIENCES	250MG	A073484	001	Jun 29, 1993	Jan	CAHN
		CAPSULE, DELAYED RELEASE;ORAL						
		STAVZOR						
		@ BANNER LIFE SCIENCES	125MG	N022152	001	Jul 29, 2008	Jan	CAHN
		@	250MG	N022152	002	Jul 29, 2008	Jan	CAHN
		@	500MG	N022152	003	Jul 29, 2008	Jan	CAHN

VALSARTANTABLET;ORAL
VALSARTAN

AB		PRINSTON INC	40MG	A204821	001	Jun 09, 2015	May	NEWA
AB			80MG	A204821	002	Jun 09, 2015	May	NEWA
AB			160MG	A204821	003	Jun 09, 2015	May	NEWA
AB			320MG	A204821	004	Jun 09, 2015	May	NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

AB	LUPIN LTD	EQ 125MG BASE	A090439	001	Jan 28, 2015	Jan NEWA
AB		EQ 250MG BASE	A090439	002	Jan 28, 2015	Jan NEWA

INJECTABLE; INJECTION

VANCOLED

>A>	@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Jun CAHN
>A>	@	EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Jun CAHN
>A>	@	EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Jun CAHN
>A>	@	EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Jun CAHN
>A>	@	EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Jun CAHN
>D>	@ HIKMA MAPLE	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Jun CAHN
>D>	@	EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Jun CAHN
>D>	@	EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Jun CAHN
>D>	@	EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Jun CAHN
>D>	@	EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Jun CAHN

VANCOMYCIN HYDROCHLORIDE

AP	MYLAN PHARMS INC	EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	Apr CAHN
AP		EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	Apr CAHN
AP		EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	May CAHN

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

STAXYN

AB	+ BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Apr CFTG
	VARDENAFIL HYDROCHLORIDE					
AB	WATSON LABS INC	10MG	A203689	001	Apr 22, 2015	Apr NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	MYLAN PHARMS INC	10MG/VIAL	A090243	001	May 11, 2010	Apr CAHN
AP		20MG/VIAL	A090243	002	May 11, 2010	Apr CAHN

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Feb CAHN
AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Feb CAHN
AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Feb CAHN

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	YAOPHARMA CO LTD	EQ 25MG BASE	A202036	001	May 28, 2015	May NEWA
AB		EQ 37.5MG BASE	A202036	002	May 28, 2015	May NEWA
AB		EQ 50MG BASE	A202036	003	May 28, 2015	May NEWA
AB		EQ 75MG BASE	A202036	004	May 28, 2015	May NEWA
AB		EQ 100MG BASE	A202036	005	May 28, 2015	May NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERELAN

AB	RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr CAHN
AB		180MG	N019614	003	Jan 09, 1992	Apr CAHN
AB		240MG	N019614	002	May 29, 1990	Apr CAHN
	+	360MG	N019614	004	May 10, 1996	Apr CAHN

VERELAN PM

AB	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr CAHN
AB		200MG	N020943	002	Nov 25, 1998	Apr CAHN
AB	+	300MG	N020943	003	Nov 25, 1998	Apr CAHN

INJECTABLE; INJECTION

ISOPTIN

@ MT ADAMS

2.5MG/ML

N018485	001		Apr CAHN
---------	-----	--	----------

TABLET; ORAL

ISOPTIN

@ MT ADAMS

40MG

N018593	003	Nov 23, 1987	Apr CAHN
---------	-----	--------------	----------

@

80MG

N018593	001	Mar 08, 1982	Apr CAHN
---------	-----	--------------	----------

@

120MG

N018593	002	Mar 08, 1982	Apr CAHN
---------	-----	--------------	----------

VERTEPORFININJECTABLE;INJECTION
VISUDYNE

+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Mar CAHN
---	--------------------	-----------	---------	-----	--------------	----------

VILAZODONE HYDROCHLORIDETABLET;ORAL
VIIBRYD

+	FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011	Mar CAHN
		20MG	N022567	002	Jan 21, 2011	Mar CAHN
		40MG	N022567	003	Jan 21, 2011	Mar CAHN

ZAFIRLUKASTTABLET;ORAL
ACCOLATE

AB	PAR PHARM INC	10MG	N020547	003	Sep 17, 1999	Feb CAHN
AB	+	20MG	N020547	001	Sep 26, 1996	Feb CAHN

ZOLEDRONIC ACIDINJECTABLE;IV (INFUSION)
ZOLEDRONIC ACID

AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Apr NEWA
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar NEWA
AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar CPOT

ZOLPIDEM TARTRATETABLET;ORAL
ZOLPIDEM TARTRATE

	@ HIKMA	5MG	A078129	001	Apr 30, 2008	Mar DISC
	@	10MG	A078129	002	Apr 30, 2008	Mar DISC
AB	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr CAHN
AB		10MG	A078055	002	Apr 23, 2007	Apr CAHN

TABLET;SUBLINGUAL
INTERMEZZO

AB	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011	May CFTG
AB	+	3.5MG	N022328	002	Nov 23, 2011	May CFTG
	ZOLPIDEM TARTRATE					
AB	NOVEL LABS INC	1.75MG	A204299	001	Jun 03, 2015	May NEWA
AB		3.5MG	A204299	002	Jun 03, 2015	May NEWA

ZONISAMIDECAPSULE;ORAL
ZONISAMIDE

AB	BANNER LIFE SCIENCES	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL
ACETAMINOPHEN

SUN PHARM INDS LTD 650MG
@ 650MG

A078569 001 Dec 14, 2011 Apr CAHN
A090205 001 Nov 18, 2009 Apr CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL
SHADE UVAGUARD

+ BAYER HEALTHCARE LLC 3%;7.5%;3%

N020045 001 Dec 07, 1992 Mar CAHN

BUDESONIDE

SPRAY, METERED;NASAL
RHINOCORT ALLERGY

+ ASTRAZENECA PHARMS 0.032MG/SPRAY

N020746 003 Mar 23, 2015 Mar NEWA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL
LOTRIMIN ULTRA

+ BAYER HEALTHCARE LLC 1%

N021307 001 Dec 07, 2001 Mar CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BANNER LIFE SCIENCES 5MG

N022429 001 Jul 23, 2009 Jan CAHN

+ 10MG

N022429 004 Jul 23, 2009 Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BANNER LIFE SCIENCES 5MG

N022429 003 Jul 23, 2009 Jan CAHN

+ 10MG

N022429 002 Jul 23, 2009 Jan CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS LTD 5MG

A077498 001 Dec 27, 2007 Apr CAHN

10MG

A077498 002 Dec 27, 2007 Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS LTD 5MG

A077498 003 Dec 27, 2007 Apr CAHN

10MG

A077498 004 Dec 27, 2007 Apr CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS 5MG

A091116 001 Feb 19, 2015 Feb NEWA

10MG

A091116 002 Feb 19, 2015 Feb NEWA

SANDOZ 5MG

A078692 001 Feb 14, 2008 Feb CTNA

+ 10MG

A078692 002 Feb 14, 2008 Feb CTNA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

JUBILANT GENERICS 5MG

A091116 003 Feb 19, 2015 Feb NEWA

10MG

A091116 004 Feb 19, 2015 Feb NEWA

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL
CHLOR-TRIMETON

@ BAYER HEALTHCARE LLC 8MG

N007638 001 Mar CAHN

+ 12MG

N007638 002 Mar CAHN

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
CHLOR-TRIMETON

+ BAYER HEALTHCARE LLC 8MG;120MG

N018397 001 Mar CAHN

CLOTRIMAZOLE

CREAM;VAGINAL
GYNE-LOTRIMIN

+ BAYER HEALTHCARE LLC 1%

N018052 002 Nov 30, 1990 Mar CAHN

GYNE-LOTRIMIN 3

+ BAYER HEALTHCARE LLC 2%

N020574 001 Nov 24, 1998 Mar CAHN

CREAM, TABLET;TOPICAL, VAGINAL

GYNE-LOTRIMIN COMBINATION PACK

+ BAYER HEALTHCARE LLC 1%,100MG

N020289 002 Apr 26, 1993 Mar CAHN

TABLET;VAGINAL

GYNE-LOTRIMIN

+ BAYER HEALTHCARE LLC 100MG

N017717 002 Nov 30, 1990 Mar CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BANNER LIFE SCIENCES 25MG;EQ 200MG FREE ACID AND
POTASSIUM SALT

A090397 001 Nov 22, 2010 Jan CAHN

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

SUN PHARM INDS LTD 10MG
20MG

A090283 001 Nov 17, 2009 Apr CAHN

A090283 002 Nov 17, 2009 Apr CAHN

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUN PHARMA GLOBAL 60MG;120MG

A090818 001 Jan 29, 2015 Jan NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL INC 600MG;60MG
1.2GM;120MG

A091071 001 May 27, 2015 May NEWA

A091071 002 May 27, 2015 May NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BANNER LIFE SCIENCES EQ 200MG FREE ACID AND POTASSIUM
SALT

A078682 001 Mar 24, 2009 Jan CAHN

MIDOL LIQUID GELS

+ BANNER LIFE SCIENCES 200MG

N021472 001 Oct 18, 2002 Jan CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

BAUSCH AND LOMB EQ 0.035% BASE

N021996 002 Feb 11, 2015 Feb NEWA

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

LOTUS PHARM CO LTD 1.5MG
OC PHARMA 1.5MG

A202246 001 Jun 05, 2015 May NEWA

A202380 001 May 29, 2015 May NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER LIFE SCIENCES 1MG
+ 2MG

N021855 001 Aug 04, 2005 Jan CAHN

N021855 002 Aug 04, 2005 Jan CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

SUN PHARM INDS LTD 2MG;125MG

A077500 001 Sep 06, 2006 Apr CAHN

LORATADINE

CAPSULE;ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 10MG

N021952 001 Jun 16, 2008 Mar CAHN

SYRUP;ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 1MG/ML

N020641 002 Nov 27, 2002 Mar CAHN

CLARITIN HIVES RELIEF

@ BAYER HEALTHCARE LLC 1MG/ML

N020641 003 Nov 19, 2003 Mar CAHN

TABLET;ORAL

LORATADINE

SUN PHARM INDS LTD 10MG

A076134 001 Aug 18, 2003 Apr CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+ BAYER HEALTHCARE LLC 5MG

N021891 001 Aug 23, 2006 Mar CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
CLARITIN REDITABS

+ BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006	Mar CAHN
LORATADINE REDIDOSE					
SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007	Apr CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
CLARITIN-D

+ BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002	Mar CAHN
CLARITIN-D 24 HOUR					
+ BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002	Mar CAHN
LORATADINE AND PSEUDOEPHEDRINE SULFATE					
SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004	Apr CAHN

NAPROXEN SODIUM

CAPSULE;ORAL
NAPROXEN SODIUM

>D>	+ BANNER LIFE SCIENCES	EQ 200MG BASE	N021920	001	Feb 17, 2006	Jan CAHN
	CATALENT	EQ 200MG BASE	A202807	001	Feb 13, 2015	Jun CAHN
		EQ 200MG BASE	A202807	001	Feb 13, 2015	Feb NEWA
>A>	OHM LABS INC	EQ 200MG BASE	A202807	001	Feb 13, 2015	Jun CAHN

TABLET;ORAL

NAPROXEN SODIUM

SUN PHARM INDS LTD	EQ 200MG BASE	A091183	001	May 20, 2011	Apr CAHN
--------------------	---------------	---------	-----	--------------	----------

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX

@ IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009	Mar DISC
@	EQ 4MG BASE	A077850	001	Feb 18, 2009	Mar DISC

OMEPRazole; SODIUM BICARBONATE

CAPSULE;ORAL
ZEGERID OTC

+ BAYER HEALTHCARE LLC	20MG;1.1GM	N022281	001	Dec 01, 2009	Mar CAHN
------------------------	------------	---------	-----	--------------	----------

FOR SUSPENSION;ORAL
ZEGERID OTC

+ BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013	Mar CAHN
------------------------	---------------------------	---------	-----	--------------	----------

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OCUCLEAR

BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986	Mar CAHN
----------------------	--------	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL
MIRALAX

+ BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006	Mar CAHN
POLYETHYLENE GLYCOL 3350					
RARITAN PHARMS INC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Jan CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PSEUDOEPHEDRINE HYDROCHLORIDE
SUN PHARM INDS LTD

120MG	A077442	001	Sep 28, 2005	Apr CAHN
-------	---------	-----	--------------	----------

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ SUN PHARM INDS LTD	EQ 75MG BASE	A075132	001	Jan 14, 2000	Apr CAHN
@ WOCKHARDT	EQ 75MG BASE	A078884	001	Jul 31, 2008	Jan DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 6 JUNE 2015

NO JUNE 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551 001	6417191	Mar 28, 2016	DP U-1572			
	6417191*PED	Sep 28, 2016				
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652 001	6417191	Mar 28, 2016	DP U-257			
	6417191*PED	Sep 28, 2016				
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
>A>	9050335	May 16, 2032	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	>A> 9056100	Jul 07, 2020	DP U-1263			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	7223387	Jul 24, 2021	DP U-1006			
	7223387	Jul 24, 2021	DP U-1484			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8936800	Dec 23, 2022	DP U-1078			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8946262	Feb 12, 2030	U-1655			
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	>A> 8778924	Dec 08, 2026	DS DP U-897			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 001					ODE	Dec 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 002					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 003					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 004					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 005					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 006					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021713 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-761			
	5006528*PED	Apr 20, 2015				
	6977257	Apr 24, 2022	DP			
	6977257*PED	Oct 24, 2022				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 002					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 003					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021866 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-763			
	5006528*PED	Apr 20, 2015				
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 0202971 001	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 0202971 002	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 001	>A> 5849911	Jun 20, 2017	DS DP U-167			
	>A> 5849911*PED	Dec 20, 2017				
	>A> 6087383	Dec 21, 2018	DS DP			
	>A> 6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 002	>A> 5849911	Jun 20, 2017	DS DP U-167			
	>A> 5849911*PED	Dec 20, 2017				
	>A> 6087383	Dec 21, 2018	DS DP			
	>A> 6087383*PED	Jun 21, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 003	>A> 5849911	Jun 20, 2017	DS DP U-167			
	>A> 5849911*PED	Dec 20, 2017				
	>A> 6087383	Dec 21, 2018	DS DP			
	>A> 6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 004	>A> 5849911	Jun 20, 2017	DS DP U-167			
	>A> 5849911*PED	Dec 20, 2017				
	>A> 6087383	Dec 21, 2018	DS DP			
	>A> 6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	>A> 5849911	Jun 20, 2017	DS DP U-167		>A> NP	Jun 02, 2017
	>A> 5849911*PED	Dec 20, 2017			>A> PED	Dec 02, 2017
	>A> 6087383	Dec 21, 2018	DS DP			
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	>A> 5849911	Jun 20, 2017	DS DP U-167			
	>A> 5849911*PED	Dec 20, 2017				
	>A> 6087383	Dec 21, 2018	DS DP			
	>A> 6087383*PED	Jun 21, 2019				
	8148374	Sep 03, 2029	DS DP U-1279			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001					NPP	Feb 20, 2018
					NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-81			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8895070	Jun 03, 2029	U-124			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8937062	Nov 13, 2029	U-80			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8933120	Mar 16, 2025	DP			
	8933127	Mar 16, 2025	DP			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	7351404	May 25, 2024	U-939	Y		
	7388029	Jan 21, 2022	U-938	Y		
	8541466	Jan 31, 2021	U-1217			
	8986715	Jan 15, 2023	U-1217			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	9044484	Oct 30, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	>A> 8877708	Jun 07, 2030	DP U-1706			
<u>BUDESONIDE - UCERIS</u>						
N 205613 001	5914122	Dec 19, 2015	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8470361	May 22, 2030	DP U-1425			
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	>A> 8454996	Sep 24, 2019	U-1421			
	>A> 8470361	May 22, 2030	DP U-1425			
	>A> 8658198	Dec 03, 2027	DP U-1494			
	>A> 8940330	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	8916195	Feb 02, 2030	U-1639			
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003	6875445	Jul 30, 2021	DP			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001				>A> NCE		Jun 22, 2020
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952 001					NP ODE	Jan 09, 2018 Jan 09, 2022
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
<u>CELECOXIB - CELECOXIB</u>						
A 076898 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 003					PC	Jun 02, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELECOXIB</u>						
A 200562 004					PC	Jun 02, 2015
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768 001	8062667	Mar 29, 2029	DP			
	8790700	Mar 15, 2027	DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					ODE	Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					ODE	Mar 17, 2022
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Feb 01, 2028	U-1356			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Feb 01, 2028	U-1357			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 090898 001					PC	Jul 01, 2015
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	8962000	Aug 31, 2025	DP U-1410			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8981103	Oct 26, 2026	DS DP		I-704	Dec 17, 2017
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	8927607	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Aug 26, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Aug 26, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CROFELEMER - FULYZAQ</u>						
N 202292 001	8962680	Oct 31, 2031	U-1319			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001 >A>	8703781	Oct 15, 2030	DS DP U-1713			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002 >A>	8703781	Oct 15, 2030	DS DP U-1713			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001					ODE	Jul 22, 2021
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001					M-157	Mar 11, 2018
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002					M-157	Mar 11, 2018
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	6037157	Jun 26, 2016	U-1635			
	6703403	Jun 26, 2016	U-1635			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1637			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1637			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
>A>	9044480	Apr 10, 2031	U-1638			
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 001	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
<u>DEFERASIROX - JADENU</u>						
N 206910 002	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - JADENU</u>						
N 206910 003	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	7622130	Dec 10, 2027			U-1690	
	7754230	Dec 10, 2027			U-1690	
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025			U-1690	
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP U-1690			
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025			U-1690	
	8883770	Feb 21, 2028	DP			
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 001					PC	May 16, 2015
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 002					PC	May 16, 2015
<u>DESONIDE - VERDESO</u>						
N 021978 001	8962000	Aug 31, 2025	DP U-1412			
<u>DESVENLAFAXINE SUCCINATE - PRISTIO</u>						
N 021992 003	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8043628	Oct 20, 2020			U-1205	
	8088407	Oct 20, 2020			U-1205	
	9012437	Oct 20, 2020			U-1205	
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9011926	Feb 24, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	9011926	Feb 24, 2026	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019			U-1472	
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032			U-421	
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 002					PC	Aug 01, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 003					>A> PC	Dec 19, 2015
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	8927604	Jun 16, 2026	U-436			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396 001	6407079	Jun 18, 2019	DP			
	8946292	Mar 22, 2027	U-1659			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	>A> 9066913	Oct 17, 2027	DP U-1488			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DOXYCYCLINE HYCLATE - DOXTERIC</u>						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>EDOXYBAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	9018192	Jun 13, 2026	U-750			
	9018192	Jun 13, 2026	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	>A> 6280959	Aug 01, 2027	DS DP U-930		>A> D-149	Jun 11, 2018
	>A> 6280959	Aug 01, 2027	DS DP U-1306		>A> I-711	Jun 11, 2018
	>A> 6280959	Aug 01, 2027	DS DP U-1575			
	>A> 6280959	Aug 01, 2027	DS DP U-1714			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1575			
	>A> 7160870	Nov 20, 2022	DS DP U-1714			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1575			
	>A> 7473686	May 24, 2021	DS DP U-1714			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-1714			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1575			
	>A> 7790704	May 24, 2021	U-1714			
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1575			
	>A> 7795293	May 21, 2023	U-1714			
	>A> 8052993	Aug 01, 2027	DP U-930			
	>A> 8052993	Aug 01, 2027	DP U-1306			
	>A> 8052993	Aug 01, 2027	DP U-1575			
	>A> 8052993	Aug 01, 2027	DP U-1714			
	>A> 8052994	Aug 01, 2027	DP U-1714			
	>A> 8062665	Aug 01, 2027	DP U-1714			
	>A> 8071129	Aug 01, 2027	DP U-1714			
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-1619			
	>A> 8828430	Aug 01, 2027	DP U-1714			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	>A> 6280959	Aug 01, 2027	DS DP U-930		>A> D-149	Jun 11, 2018
	>A> 6280959	Aug 01, 2027	DS DP U-1306		>A> I-711	Jun 11, 2018
	>A> 6280959	Aug 01, 2027	DS DP U-1575			
	>A> 6280959	Aug 01, 2027	DS DP U-1714			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1575			
	>A> 7160870	Nov 20, 2022	DS DP U-1714			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1575			
	>A> 7473686	May 24, 2021	DS DP U-1714			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-1714			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1575			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	>A> 7790704	May 24, 2021	U-1714			
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1575			
	>A> 7795293	May 21, 2023	U-1714			
	>A> 8052993	Aug 01, 2027	DP U-1714			
	>A> 8052994	Aug 01, 2027	DP U-930			
	>A> 8052994	Aug 01, 2027	DP U-1306			
	>A> 8052994	Aug 01, 2027	DP U-1575			
	>A> 8052994	Aug 01, 2027	DP U-1714			
	>A> 8062665	Aug 01, 2027	DP U-1714			
	>A> 8071129	Aug 01, 2027	DP U-1714			
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-1619			
	>A> 8828430	Aug 01, 2027	DP U-1714			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	>A> 6280959	Aug 01, 2027	DS DP U-930		>A> D-149	Jun 11, 2018
	>A> 6280959	Aug 01, 2027	DS DP U-1306		>A> I-711	Jun 11, 2018
	>A> 6280959	Aug 01, 2027	DS DP U-1575			
	>A> 6280959	Aug 01, 2027	DS DP U-1714			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1575			
	>A> 7160870	Nov 20, 2022	DS DP U-1714			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1575			
	>A> 7473686	May 24, 2021	DS DP U-1714			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-1714			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1575			
	>A> 7790704	May 24, 2021	U-1714			
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1575			
	>A> 7795293	May 21, 2023	U-1714			
	>A> 8052993	Aug 01, 2027	DP U-1714			
	>A> 8052994	Aug 01, 2027	DP U-1714			
	>A> 8062665	Aug 01, 2027	DP U-714			
	>A> 8062665	Aug 01, 2027	DP U-930			
	>A> 8062665	Aug 01, 2027	DP U-1306			
	>A> 8062665	Aug 01, 2027	DP U-1575			
	>A> 8071129	Aug 01, 2027	DP U-1714			
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-1619			
	>A> 8828430	Aug 01, 2027	DP U-1714			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	>A> 6280959	Aug 01, 2027	DS DP U-930		>A> D-149	Jun 11, 2018
	>A> 6280959	Aug 01, 2027	DS DP U-1306		>A> I-711	Jun 11, 2018
	>A> 6280959	Aug 01, 2027	DS DP U-1575			
	>A> 6280959	Aug 01, 2027	DS DP U-1714			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1575			
	>A> 7160870	Nov 20, 2022	DS DP U-1714			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1575			
	>A> 7473686	May 24, 2021	DS DP U-1714			
	>A> 7547719	Jul 13, 2025	DS DP U-930			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-1714			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1575			
	>A> 7790704	May 24, 2021	U-1714			
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1575			
	>A> 7795293	May 21, 2023	U-1714			
	>A> 8052993	Aug 01, 2027	DP U-1714			
	>A> 8052994	Aug 01, 2027	DP U-1714			
	>A> 8062665	Aug 01, 2027	DP U-1714			
	>A> 8071129	Aug 01, 2027	DP U-930			
	>A> 8071129	Aug 01, 2027	DP U-1306			
	>A> 8071129	Aug 01, 2027	DP U-1575			
	>A> 8071129	Aug 01, 2027	DP U-1714			
	>A> 8828430	Aug 01, 2027	DP U-1306			
	>A> 8828430	Aug 01, 2027	DP U-1619			
	>A> 8828430	Aug 01, 2027	DP U-1714			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005					>A> D-149	Jun 11, 2018
					>A> I-711	Jun 11, 2018
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	>A> 7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	>A> 7786158	Mar 14, 2025	DS			
	>A> 8344011	Mar 14, 2025	U-1709			
	>A> 8609709	Mar 14, 2025	DS			
	>A> 8691860	Jul 07, 2028	DS U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	>A> 7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	>A> 7786158	Mar 14, 2025	DS			
	>A> 8344011	Mar 14, 2025	U-1709			
	>A> 8609709	Mar 14, 2025	DS			
	>A> 8691860	Jul 07, 2028	DS U-1709			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	8981103	Oct 26, 2026	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001					>A> M-159	Jun 26, 2018
					>A> M-160	Jun 26, 2018
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002					>A> M-159	Jun 26, 2018
					>A> M-160	Jun 26, 2018
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2024	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1509			
	5714504*PED	Aug 03, 2015				
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1509			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1509			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810*PED	May 03, 2020				
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8945621	Oct 17, 2031	U-1661			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8945621	Oct 17, 2031	U-1661			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	>A> 8410131	Nov 01, 2025	DS DP U-1368			
	>A> 8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	>A> 8410131	Nov 01, 2025	DS DP U-1368			
	>A> 8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	>A> 8410131	Nov 01, 2025	DS DP U-1368			
	>A> 8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	>A> 8410131	Nov 01, 2025	DS DP U-1368			
	>A> 8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	>A> 6169920	Jan 02, 2018	DP U-736			
	>A> 6181963	Nov 02, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	>A> 8301238	Sep 30, 2031	DP			
	>A> 8428708	May 21, 2032	U-736			
	>A> 8428709	Jun 11, 2032	DP U-736			
	>A> 8781571	Mar 31, 2032	DP U-736			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	8901349	Feb 18, 2024	U-1577			
	>A> 9050316	Feb 18, 2024	U-1577			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			
	7816404	Apr 17, 2029	DP U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	8933097	Aug 16, 2032	DP			
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001	6133260	Apr 12, 2017	DS DP			
	6432948	Apr 12, 2017	DS DP			
	8536167	Aug 08, 2031	U-1679			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1691			
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	5873360	Feb 23, 2016	DP		NP	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1691			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1691			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001					NPP	Jan 16, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 001					M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					M-155	Mar 27, 2018
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8969302	Aug 19, 2030	U-441			
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 001					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 002					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 003					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 004					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 004					M-154	Mar 18, 2018
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9023401	Oct 30, 2021	DP			
	>A> 9056052	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9023401	Oct 30, 2021	DP			
	>A> 9056052	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9023401	Oct 30, 2021	DP			
	>A> 9056052	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9023401	Oct 30, 2021	DP			
	>A> 9056052	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	>A> 9056052	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	>A> 9056052	Oct 30, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007 >A>	9056052	Oct 30, 2021	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8497277	Dec 28, 2026	U-1456		I-702	Jan 29, 2018
	8497277	Dec 28, 2026	U-1491		ODE	Jan 29, 2022
	8497277	Dec 28, 2026	U-1650			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8871810	Sep 30, 2029	U-1599			
	9012508	Sep 14, 2030	U-981			
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001 >A>	5648333	Jul 15, 2019	DS DP U-1187			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001 >A>	8138195	Apr 24, 2021	DS DP U-1549			
	>A> 8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	>A> RE44599	Jul 21, 2025	U-1558			
	>A> RE44599	Jul 21, 2025	U-1615			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002 >A>	8138195	Apr 24, 2021	DS DP U-1549			
	>A> 8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	>A> RE44599	Jul 21, 2025	U-1558			
	>A> RE44599	Jul 21, 2025	U-1615			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8992982	Apr 23, 2030	DP			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8992982	Apr 23, 2030	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	8920383	Jul 17, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	8920383	Jul 17, 2026	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 205747 001	>A> 6034054	Jun 11, 2018	DP U-1707			
	>A> 6034054	Jun 11, 2018	DP U-1708			
	>A> 6551992	Jun 11, 2018	DP U-1707			
	>A> 6551992	Jun 11, 2018	DP U-1708			
	>A> 7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1697			
	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	8474447	Jan 17, 2030	DP			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		>A> ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					>A> GAIN	Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		>A> ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					>A> GAIN	Mar 06, 2027
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027		U-1311		
	8354427	Jul 06, 2026		U-1311		
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	5952372	Sep 18, 2018		U-1631		
	6133310	Apr 26, 2019		U-1631		
	7550440	Apr 22, 2024	DP	U-1631		
	8080530	Apr 22, 2024	DP	U-1631		
	8093219	Apr 22, 2024	DP	U-1631		
	8415311	Apr 22, 2024	DP	U-1631		
	8470788	Apr 22, 2024	DP	U-1631		
	8815816	Apr 22, 2024	DP	U-1631		
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8946281	May 28, 2024		U-1662		
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8992952	Aug 05, 2024	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA</u>						
N 205388 001 >A>	9066856	Oct 23, 2033	DP			
<u>LAMIVUDINE - LAMIVUDINE</u>						
A 203564 001					PC	Sep 01, 2015
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	6004968	Mar 20, 2018	DP	U-248		
	6004968*PED	Sep 20, 2018				
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022		U-1663		
	7435734	Oct 21, 2022		U-1663		
	7754731	Mar 11, 2029	DS DP	U-1663		
	7820660	Apr 25, 2023	DS			
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 001					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 002					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 003					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 004					PC	Sep 28, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 005					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 006					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004					M-159	May 18, 2018
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	8980327	Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	8980327	Dec 01, 2030	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	>A> 8821927	Sep 18, 2029	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	>A> 9056120	Apr 11, 2023	U-1215		I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	>A> 9056120	Apr 11, 2023	U-1215		I-706 ODE	Feb 17, 2018 Feb 17, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003 >A>	9056120	Apr 11, 2023	U-1215		I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004 >A>	9056120	Apr 11, 2023	U-1215		I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005 >A>	9056120	Apr 11, 2023	U-1215		I-706 ODE	Feb 17, 2018 Feb 17, 2022
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS	U-1211	I-706	Feb 17, 2018
>A>	9056120	Apr 11, 2023		U-1215	ODE	Feb 17, 2022
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027		U-1695		
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027		U-1695		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	7429559	Jan 13, 2019	DP			
	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP	U-1666		
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 001					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 002					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 003					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 004					M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001					M-156	Mar 12, 2018
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 001	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Jun 30, 2024	DP			
	8535717	Feb 22, 2026	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 002	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Jun 30, 2024	DP			
	8535717	Feb 22, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 001					PC	Oct 20, 2015
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 002					PC	Oct 20, 2015
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001					NP	Feb 26, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 001	9006289	Oct 03, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 002	9006289	Oct 03, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 003	9006289	Oct 03, 2032	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8933030	Feb 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8933030	Feb 17, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027	U-1503			
	8853156	Mar 05, 2031	U-1642			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503			
<u>LINEZOLID - LINEZOLID</u>						
A 078061 001					>A> PC	Dec 19, 2015
<u>LINEZOLID - LINEZOLID</u>						
A 200222 001					PC	Jul 04, 2015
<u>LINEZOLID - ZYVOX</u>						
N 021131 002	>A> 6559305	Jan 29, 2021	DS			
	>A> 6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021131 003	>A> 6559305	Jan 29, 2021	DS			
	>A> 6559305*PED	Jul 29, 2021				
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	8846618	Jun 27, 2022	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6268343	Aug 22, 2022	DS DP	U-1255		
	6458924	Aug 22, 2017	DS DP	U-1255		
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			
	8114833	Aug 13, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006					I-703	Jan 30, 2018
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007					I-703	Jan 30, 2018
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LORATADINE - CLARITIN</u>						
N 020641 002	6132758	Jun 01, 2018	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001 >A>	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002 >A>	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003 >A>	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004 >A>	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005 >A>	RE45573	Jun 23, 2025	DS			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778 001 >A>	9040088	Apr 22, 2024	U-755			
<u>MESALAMINE - APRISO</u>						
N 022301 001	8940328	Apr 20, 2018	DP			
	8956647	Apr 20, 2018	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	8945063	Mar 19, 2030	DP U-1442			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	9034370	Oct 07, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8956649	Feb 15, 2031	DP U-1665			
	9040083	Feb 15, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Apr 12, 2022	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028		U-1682		
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032		U-1664		
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	8921348	Aug 27, 2028		U-1643		
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001	7699609	Mar 29, 2022	DP			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002	6946120	Apr 20, 2019	DP	U-702		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	>A> 9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	>A> 9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	>A> 9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	>A> 9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	>A> 9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	8623418	Nov 07, 2029		U-1640		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	8623418	Nov 07, 2029		U-1640		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	8623418	Nov 07, 2029	U-1640			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	>A> 9056170	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	8969369	May 10, 2022	DP U-1556			
	>A> 9056051	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	8969369	May 10, 2022	DP U-1556			
	>A> 9056051	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	8969369	May 10, 2022	DP U-1556			
	>A> 9056051	May 10, 2022	DP U-1556			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	6060499	Aug 14, 2017	DP U-867			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-867			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				
	8022095	Aug 14, 2017	DP U-867			
	8022095*PED	Feb 14, 2018				
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 002				>A> NP		May 14, 2018
				>A> PED		Nov 14, 2018
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	8921337	Mar 31, 2032	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8951969	Nov 18, 2030	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8999379	Feb 13, 2020	U-1686			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8940772	Apr 30, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8940772	Apr 30, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	7989474	Apr 06, 2024	U-1677			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	7989474	Apr 06, 2024	U-1677			
<u>OLAPARIB - LYNPARZA</u>						
N 206162 001	7151102	Apr 29, 2022	DS DP		ODE	Dec 19, 2021
	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027	U-1634			
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031	U-1634			
	8912187	Mar 12, 2024	U-1634			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	>A> 5964416	Oct 04, 2016	DP		NC	May 21, 2018
	>A> 6149054	Dec 19, 2016	DP		NCE	Jul 31, 2019
	>A> 6176442	Oct 04, 2016	DP			
	>A> 6453795	Dec 05, 2016	DP			
	>A> 6726124	Oct 04, 2016	DP			
	>A> 6846413	Aug 28, 2018	DP			
	>A> 6977042	Aug 28, 2018	DP			
	>A> 6988496	Feb 23, 2020	DP			
	>A> 7056916	Dec 07, 2023	DS DP			
	>A> 7104470	Oct 04, 2016	DP			
	>A> 7220742	May 12, 2025	DS DP U-1703			
	>A> 7246615	May 31, 2016	DP			
	>A> 7284474	Aug 26, 2024	DP			
	>A> 7396341	Oct 10, 2026	DP			
	>A> 7491719	Nov 10, 2023	DS DP			
	>A> 7727984	Nov 10, 2023	DS			
	>A> 7786111	Nov 10, 2023	DP			
	>A> 7802568	Feb 26, 2019	DP			
	>A> 7837235	Mar 13, 2028	DP			
	>A> 7896264	May 26, 2025	DP			
	>A> 7988001	Aug 04, 2021	DP			
	>A> 8034809	May 12, 2025	U-1702			
	>A> 8044046	Nov 10, 2023	U-1702			
	>A> 8733341	Dec 16, 2029	DP			
	>A> 9027967	Mar 31, 2027	DP			
	>A> RE39820	Jan 30, 2018	DS DP U-1702			
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	8791154	May 19, 2032	DP U-1680		NP PED	Jan 30, 2018 Jul 30, 2018
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	9012501	Feb 07, 2025	DP U-1511			
	>A> 9050308	Jan 04, 2033	U-1511			
	>A> 9050309	Jan 04, 2033	DS			
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 022032 001	9023391	Aug 16, 2025	DP			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	8642079	Jul 09, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	8920392	Mar 26, 2031	U-1644			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001 >A>	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002 >A>	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003 >A>	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004 >A>	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005 >A>	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006 >A>	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007 >A>	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 001	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 002	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 003	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 004	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP	U-1669	ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8946251	Aug 04, 2026	DS DP U-904			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001					>A> I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002					>A> I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003					>A> I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004					>A> I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005					>A> I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006					>A> I-710	Jun 19, 2018
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7696236	Dec 18, 2027	U-1601			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698			
<u>PREDNISONE - RAYOS</u>						
N 202020 001 >A>	9040085	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002 >A>	9040085	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 003 >A>	9040085	Apr 23, 2024	U-1362			
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001 >A>	9045519	Jun 22, 2019	DP			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001 >A>	8637553	Feb 16, 2031	DS DP			
	>A> 8680124	Jun 02, 2030	U-1506			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001 >A>	6861053	Aug 11, 2019	U-1707		I-709	May 27, 2018
	>A> 6861053	Aug 11, 2019	U-1708			
	>A> 7452857	Aug 11, 2019	U-1707			
	>A> 7452857	Aug 11, 2019	U-1708			
	>A> 7605240	Aug 11, 2019	U-1707			
	>A> 7605240	Aug 11, 2019	U-1708			
	>A> 7718608	Aug 11, 2019	U-1707			
	>A> 7718608	Aug 11, 2019	U-1708			
	>A> 7915275	Feb 23, 2025	U-1707			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	>A> 7915275	Feb 23, 2025	U-1708			
	>A> 7935799	Aug 11, 2019	U-1707			
	>A> 7935799	Aug 11, 2019	U-1708			
	>A> 8193196	Sep 02, 2027	DS DP U-1707			
	>A> 8193196	Sep 02, 2027	DS DP U-1708			
	>A> 8309569	Jul 18, 2029	U-1707			
	>A> 8309569	Jul 18, 2029	U-1708			
	>A> 8741904	Feb 27, 2026	DS U-1526			
	>A> 8741904	Feb 27, 2026	DS U-1707			
	>A> 8741904	Feb 27, 2026	DS U-1708			
	8946252	Jul 24, 2029	U-1481			
	8969398	Oct 02, 2029	U-1481			
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 001					PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 002					PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 003					PC	Nov 28, 2015
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	5712298	Jan 27, 2016	DS DP U-1115			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	>A> 9040562	Jul 28, 2026	DS DP U-1467			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8952062	Dec 22, 2019	U-1101			
	8952062	Dec 22, 2019	U-1102			
	>A> 9050302	Mar 15, 2033	U-1532			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 008	8920383	Jul 17, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 009	8920383	Jul 17, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 010	8920383	Jul 17, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXP</u>						
N 021148 011	>A> 5849700	Dec 15, 2015	U-1041			
	>A> 5849704	Dec 15, 2015	DS DP U-1041			
	>A> 6899699	Jan 02, 2022	DP			
	>A> 7686786	Aug 03, 2026	DP			
	>A> 8672898	Jan 02, 2022	DP			
	>A> 8684969	Oct 20, 2025	DP			
	>A> 8841252	Dec 26, 2017	DP			
	>A> 8920383	Jul 17, 2026	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	8841330	Jan 12, 2020	U-1696			
<u>SPINOSAD - NATROBA</u>						
N 022408 001	6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	8983594	Nov 19, 2030	DP U-1328			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	>A> 9060995	Jan 25, 2033	U-1710			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2016	DS DP U-1320			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8435944	Sep 27, 2027	U-1390			
	8993520	Jun 02, 2026	U-1390			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8975242	Oct 24, 2028	DP			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8992989	Nov 16, 2027	DP U-1675			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	>A> 8703781	Oct 15, 2030	DS DP U-1712			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	>A> 8703781	Oct 15, 2030	DS DP U-1712			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	>A> 8703781	Oct 15, 2030	DS DP U-1712			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8957113	Mar 04, 2025	DP U-1182			
	>A> 9060939	Mar 04, 2025	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	7417070	Jul 30, 2026	DS			
	>A> 9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	7417070	Jul 30, 2026	DS			
	>A> 9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	7417070	Jul 30, 2026	DS			
	>A> 9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	7417070	Jul 30, 2026	DS			
	>A> 9050311	May 24, 2024	DS DP			
<u>TRETINOIN - RETIN-A-MICRO</u>						
N 020475 003	5955109	Sep 21, 2016	DP U-134			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8962603	Jun 12, 2030	U-1657			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8511304	Jun 14, 2027	DP U-1476			
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003					D-146	Mar 16, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8722684 8969355	Jun 30, 2031 Jun 15, 2027	DS DP U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>